

RESEARCH REPORT 2015-2018

DEPARTMENT OF PEDIATRICS AND ADOLESCENT MEDICINE



DEPARTMENT OF
PEDIATRICS AND ADOLESCENT MEDICINE

Contents

Preface.....	4
Research Profile – Summary.....	5
Research Groups	7
Externally Funded Research Projects and Studies.....	19
Scientific Events.....	33
Prizes and Awards	37
Guest Scientists	39
International Cooperation Partners.....	39
Doctorates Conferred	40
Habilitations Conferred	42
Publications in Scientific Journals.....	43
Sources of Funding	67

Imprint

Publisher

Prof. Dr. Klaus-Michael Debatin, Director
Department of Pediatrics and Adolescent Medicine, Ulm University

Editor and Design

Nicolas Marschall, Research Management

Photos

Stock pictures: Nicolas Marschall; Research profile: Heiko Grandel;
Other photos and illustrations: the respective researchers.

Revised and updated edition 2015-2018
Previous editions published: 2006-2010, 2011-2014

© 2019 - No form of reproduction, either in whole or in part, is permitted without the prior authorization of the publisher.

Preface

University-based medicine provides optimal patient-care within the framework of state-of-the-art knowledge and aims at the same time to continuously develop this medical knowledge for its application in the future.

Innovation requires research and in particular the translation of scientific findings into clinical application as well as the analysis of clinical questions by employing methods and models of basic research.

Especially in Pediatric Oncology, the pioneer of interdisciplinary and multimodal treatment of leukemias and tumors on the whole, further progress in the already relatively successful therapy of our patients is only possible through further research.

Also, the analysis and characterization of the fundamentals of rare diseases, the adaption of medical care to age-dependent factors like premature birth, and the prevention of metabolic and endocrinologic diseases require the combination of basic research, clinical research and innovative treatment strategies.

Research at our department is dedicated to these goals. With the establishment and successful conclusion of the DFG-funded clinical research unit “Regulation of Apoptosis and its Dysfunction in Human Diseases” our department has developed a profile in its field and within the Medical Faculty.

Currently, our department participates in two Collaborative Research Centers (SFB) of the German Research Foundation (DFG) at Ulm University, SFB 1074 “Experimental Models and Clinical Translation in Leukemia” (Prof. Debatin co-chair) and SFB 1149 “Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma”. Our department also participates in a research consortium funded by the state of Baden-Württemberg and Boehringer Ingelheim (BIU; coordinator Prof. Debatin).

With this report, we inform you about the focuses and developments during the last four years. Special thanks go to all employees that have contributed to this top-class research in a clinical setting.



Prof. Dr. Klaus-Michael Debatin
Director

Research Profile – Summary

Our research in [Hematology and Oncology](#) is dedicated to understanding the role of cell death (apoptosis) and cell death signaling in diseases, such as cancer, with the aim of developing new therapies from this knowledge. Our lab was involved in the early discovery of one of the key apoptosis signaling pathways (CD95/APO/Fas in 1989 and 1990), while identifying and initially describing its role in cancer therapy in 1996. A particular focus lies on strategies to



overcome treatment resistance in leukemia, neuroblastoma and brain tumors. In doing so, we have addressed several issues dealing with apoptosis regulators and apoptosis signaling as prognostic factors and therapeutic targets, and have thereby contributed to the development of new drugs for cancer therapy. By using models of primary leukemias, we are in the process of analyzing aspects of leukemia stem cell function and apoptosis sensitivity of leukemia-initiating cells as well as parameters for treatment response and outcome in patients. The expertise of our work group has been introduced into the international study group (I-BMF) for the treatment of childhood leukemia. In the area of solid tumors, we investigate the molecular pathways which may provide novel therapeutic targets in glioblastoma by utilizing patient-derived tumor cells.



The [Experimental Pediatric Oncology](#) Section investigates the molecular pathogenesis and diagnosis of neuroblastoma and develops experimental therapy for neuroblastoma and acute lymphoblastic leukemia.

In the field of [Non-malignant Hematological Diseases](#), we also investigate pathological processes and the underlying molecular alterations as a basis for the development of specific treatment strategies, especially in the area of congenital and acquired erythrocytoses/polycythemia, as well as rare metabolic defects associated with the disruption of hematopoiesis.

In the area of [Stem cell transplantation and Immunology](#), our work groups have significantly contributed to the development of blood stem cell and bone marrow transplantations and have characterized the genetic origins of several forms of severe combined immune defects (SCID). In the early seventies one of the first ever bone marrow transplants


in children in Europe was performed at our hospital. Novel therapies, such as haploidentical stem cell transplantations, cell-based immunotherapies and, most recently, radioimmunotherapy-based conditioning for reduced toxicity during treatment of severe combined immune defects, congenital hematological disorders and leukemias, have since been developed. The work group at Ulm University is part of the federal network on primary immunodeficiencies.



The research areas of the Division of [Pediatric Endocrinology](#) include development and disturbances of the endocrine system, endocrine regulation of body weight and diabetes mellitus type 1 and type 2. The main focus of research projects lays in diseases going along with alterations in adipose tissue mass and function such as obesity and lipodystrophies and their comorbidities. On one hand the aim is to identify the underlying pathophysiology on the genetic, molecular, cellular, organ and systemic level. On the other hand, in clinical studies novel treatment options are evaluated.

The research of the [Neonatology and Pediatric Intensive Care](#) Section is dedicated to clinical studies related to primary care of neonates and preterm infants. Our center participates in a number of multicenter randomized trials, including the coordination of a European multicenter study on the use of inhalative NO treatment, and has initiated a study on permissive hypercapnia in very immature preterm infants.

In the [Social Pediatrics and Child Neurology](#) Section, we study the developmental prognosis of neonates after severe perinatal asphyxia and the long-term prognosis of premature babies of very low birth weight. We are assessing the influence of longchain polyunsaturated fatty acids on characteristics and cognition in attention-deficit/hyperactivity disorder (ADHD). Finally, we study the long term development and outpatient care of children with ADHD.



Photos by
Heiko Grandel

Research Groups

Glioblastoma Research


Heads:	Prof. Klaus-Michael Debatin, Dr. Mike-Andrew Westhoff
Staff:	Martina Maushart, Dr. Lisa Nonnenmacher, Christel Payer, Andrea Schuster
Students:	Tim Baisch, Helène von Bandemer, Lara Barteczko, Valerie Bezler, Christine Ebeid, Lea Edrich, Fernando Tavares Fedumenti, Rahel Fitzel, Simon Freisinger, Dorothea Gebauer, Amina Hadzalic, Verena Herbener, Patricia Kattner, Franz Ketzer, Antti Kiviniemi, Julia Langhans, Florian Mohr, Julian Riedel, Karthika Devi Selvasaravanan, Akshaya Srikanth, Hannah Strobel, Nancy Trenkler, Nicole Wiederspohn, Katharina Zeiler, Marco Zimmer, Julia Zimmermann, Tamara Zimmermann

The main focus of our cancer therapy and apoptosis research lies with Glioblastoma which is among the most lethal tumours encountered in the clinic. It is the most frequent primary brain tumour in adults and is also not uncommon in children. Successful therapy, consisting of maximal safe surgical resection, radio- and chemotherapy, only extends life expectancy to 15 months.

Our research group focuses on three areas of interest:

■ The molecular features of Glioblastoma

Unusual for such an aggressive disease Glioblastoma has relatively few distinct mutations and other genetic alterations, presenting the researcher with few druggable targets. Among those is the PI3K signalling cascade that is activated in ~90% of all Glioblastoma. Understanding the role of this signalling network in different cell populations of the tumour and elucidating the therapeutic potential of pathway inhibition has led new therapeutic avenues implemented in our clinic. [1]



Actin was stained with TRIC-phalloidin. The left glioblastoma cell clearly exhibits a well-structured cytoskeleton. In the right cell, a signalling pathway has been blocked, which hitherto had not been considered to be connected with cell organization and motility. The destruction of F-actin fibres can clearly be seen. Photos by Claudia Jennewein [4]

■ Therapeutic approaches

Due to the unique features of Glioblastoma (see below) it is not sufficient to target the tumour bulk as malignant cells will have already spread throughout the brain. Therapeutic approaches to target those cells are rather limited due to the blood-brain-barrier which prevents the free distribution of drugs throughout the brain. Hence novel approaches, drug combinations or treatment regimens are needed to overcome these limitations. Such as the RIST therapy, which was developed in this clinic and is used in a compassionate use setting. [2]

■ Patho-clinical features of Glioblastoma

Glioblastoma only rarely metastasises outside the CNS but seems to not exist in a pre-invasive form. Understanding the underlying molecular mechanisms will help us to modulate the invasive nature of the Glioblastoma cells and transform it into a more localised, i.e. easier to treat disease. We have formulated the so-called Alcatraz Strategy that aims to prevent the interaction/communication of cancer cells with their environment. [3]

Taking these three aspects together gives us a clear aim of our research: By combining basic research and bidirectional translational research to improve our understanding how to a) target the unique features of Glioblastoma and b) adapt novel treatment approaches for their implementation in Glioblastoma treatment.

To answer these questions we have created a collection of ~300 case files with ~100 stored tumour samples and ~50 patient-derived cell populations.


■ References

1. Langhans J, Schnee L, Trenkler N, von Bandemer H, Nonnenmacher L, Karpel-Massler G, Siegelin MD, Zhou S, Halatsch M-E, Debatin K-M, Westhoff M-A (2017). The effects of PI3K-mediated signalling on glioblastoma cell behaviour. *Oncogenesis* 6 (11):398. doi:10.1038/s41389-017-0004-8
2. Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM (2015). RIST: A potent new combination therapy for glioblastoma. *Int J Cancer* 136 (4):E173-187. doi:10.1002/ijc.29138
3. Mettang M, Meyer-Pannwitt V, Karpel-Massler G, Zhou S, Carragher NO, Föhr KJ, Baumann B, Nonnenmacher L, Enzenmüller S, Dahlhaus M, Siegelin MD, Stroh S, Mertens D, Fischer-Posovszky P, Schneider EM, Halatsch M-E, Debatin K-M, Westhoff M-A (2018). Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. *Scientific Reports* 8 (1):5527. doi:10.1038/s41598-018-23592-z
4. Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM (2013). Inhibition of NF- κ B signaling ablates the invasive phenotype of glioblastoma. *Mol Cancer Res* 11(12):1611-23. doi: 10.1158/1541-7786.MCR-13-0435-T

Experimental Pediatric Oncology Section

Head: Prof. Dr. Christian Beltinger

Staff: Dr. Carmen Dorneburg, Dr. Célimène Galiger, Annika V. Goß, Nicole Heymann, Helgard Knauß, Astrid Laut, Lara M. Riehl, Ning Wei



In our focus “Molecular pathogenesis and diagnosis of neuroblastoma” we investigate the interaction of oncogenes with tumor suppressors in the genesis of neuroblastoma and we explore the feasibility of liquid biopsy in neuroblastoma patients. In our second focus “Experimental therapy of neuroblastoma and acute lymphoblastic leukemia” we develop novel preclinical strategies utilizing small molecules or oncolytic viruses against neuroblastoma and acute lymphoblastic leukemia (ALL).

Figure: A neuroblastoma that developed in a MYCN-transgenic mouse haploid for BIRC5 avidly takes up ^{18}F -FDG (magenta) because of its strong Warburg effect. Shown is a MRI/PET fusion image.

■ Focus “Molecular pathogenesis and diagnosis of neuroblastoma”

Neuroblastoma is the most common extracranial solid tumor in childhood. The aggressiveness of neuroblastoma is determined by tumor-promoting and tumor-suppressive mechanisms that are inactivated or activated, respectively. We therefore investigate the interaction of oncogenes such as MYCN, BIRC5 and LDHA/B with dysfunctional tumor suppressors in the genesis, progression and aerobic glycolysis (Warburg effect) of neuroblastoma. To this end, we use cellular and molecular biology methods, transgenic and xenotransplant mouse models, and bioinformatic tools. We are translating the results of this preclinical work into establishing prognostic markers and liquid biopsy for neuroblastoma patients.

■ Focus “Experimental therapy of neuroblastoma and acute lymphoblastic leukemia”

Specificity and efficacy are major challenges in targeted tumor therapy. We develop novel approaches to address these challenges in neuroblastoma and acute lymphoblastic leukemia. To this end, we investigate small molecules that interfere specifically in signaling pathways crucial for neuroblastoma. In addition, we explore oncolytic measles virus against ALL. Our aim is to translate these novel preclinical therapies to the patient with neuroblastoma or ALL.

Leukemia

Heads: apl. Prof. Dr. Lüder-Hinrich Meyer, Prof. Dr. Klaus-Michael Debatin
Staff: Dr. Stefanie Enzenmüller, Sevil Essig, Dr. Vera Münch, Alexandra Niedermayer, Dr. Felix Seyfried, Dr. Helen Sun, Dr. Julia Zinngrebe
Students: Elena Boldrin, Salih Demir, Malcom Meyer, Felix Stirnweiß

Among all pediatric cancers, acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood and adolescence. Over the past decades, substantial achievements have been made resulting in successful treatment of pediatric ALL and cure rates of more than 80%. Despite this success in pediatric oncology, therapy fails in about 20% of the patients leading to reoccurrence




Figure: Central nervous system (CNS) leukemia modeled in the NOD/SCID/huALL system: (A) Massive meningeal infiltration with human ALL cells in NMRI scan analysis (left panel, white arrows indicate enlarged meninges) and immunohistochemistry (right panel, purple: human B-cell precursor cells, anti-human CD10 staining; and (B) absence of meningeal manifestation in a CNS negative ALL sample. [see Münch et al., Blood 2017; 130(5):643-654]

of the disease associated with clearly reduced prognosis and outcome. However, the majority of patients encountering relapse are not identified using the currently available risk markers and extramedullary leukemia manifestation outside the hematopoietic system as for example in the central nervous system remains a diagnostic and therapeutic challenge. Moreover, although generally well tolerated, anti-leukemia therapies bear the risk of late sequelae and side effects, in particular for intensified treatment in relapse situations. These problems and limitations clearly highlight the need for less toxic treatment modalities including directed therapies acting on identified targets and improved risk stratification.

In our Leukemia Research Group, the main interests focus on acute lymphoblastic leukemia (ALL). In our work, we want to better understand leukemia biology and to analyze and characterize molecular mechanisms of disease initiation, development and manifestation. Based on our findings, we aim to investigate and develop novel therapeutic approaches like evaluation of new risk markers and new therapeutic agents including preclinical validation in corresponding model systems. By combining comprehensive molecular and functional analyses, we characterize leukemia-specific biological mechanisms and try to identify possible starting points for new therapy strategies for leukemia. Moreover, we have established and refined a leukemia model that mimics the disease seen in patients thus allowing to investigate different aspects of disease biology but also evaluate new treatment modalities pre-clinically and have provided evidence for a good efficacy of several substances alone and in combination with conventional chemotherapy against different subgroups and manifestations of ALL.

Immunoregulation and GvHD

Head: apl. Prof. Dr. Gudrun Strauß

Staff: Ingrid Knape, Dr. Yvonne Hüsecken, Malena Klingspor (medical student),
Dr. Monika Kustermann, Silvia Muche, Tanja Reisser, Jasmin Scheurer, Linda Wolf

A functional immune system protects from disease development and autoimmunity. The immune response therefore requires a tight control to ensure that immune cells eliminate invading pathogens but do not attack the body's own cells. Various molecular processes and cell types are involved in the regulation of the immune response.

The main focus of our research group deals with the regulation of the T cell immune response and the development of new treatment strategies for graft-versus-host disease (GvHD) prevention. GvHD is the major complication after allogeneic bone marrow transplantation leading to increased morbidity and mortality. T cells in the donor transplant, which are activated by antigens of the recipient, expand and subsequently attack and destroy recipient tissues thereby inducing GvHD. During the last years we have established several murine models of GvHD mimicking the human transplantation situation. Currently we are working on the following projects:

■ Modulation of the T cell immune response by death receptors

Death receptors were initially characterized to induce apoptosis after ligation with their cognate death ligand. Nowadays, however, it is clear that death receptors have additional functions. We have recently investigated the influence of death receptor CD95 and TRAIL on T cell activation and define for the first time, that CD95 and TRAIL-receptors suppress T cell activation when stimulated by death ligands during T cell priming. This mechanism might contribute to immune evasion of viruses or other pathogens, which induce death ligand expression in target cells after infection.

■ Development of new treatment strategies for GvHD prevention

GvHD is characterized by recipient organ destruction induced by activated T cells. Since activated T cells strongly up-regulate death ligands we are exploring whether blocking of death ligand functions might serve as a possible treatment option in GvHD prevention. Destructive functions of activated T cells, however, can also be abrogated by suppressor cells. Myeloid-derived suppressor cells (MDSCs) are an immature population of myeloid cells inhibiting T cell activation, proliferation and function and are therefore under investigation for GvHD-prophylaxis. T cells do not represent a uniform population of cells but are subdivided in different subpopulations due to their phenotype and function. The impact of different T cell subpopulations especially Th9 cells on GvHD development is studied.

■ Function of myeloid-derived suppressor cells (MDSCs) in trauma

The immune response after traumatic injuries is predominated in the beginning by an overwhelming pro-inflammatory response of the innate immune system, followed by a suppression of the adaptive immunity leading to immunosuppression and an enhanced risk for all types of infections. At present, the impact of MDSCs on the course of disease and the immune response after trauma is not well defined. Using murine trauma models we determine the influence of trauma on the induction of MDSCs, define their potential to modulate T cell-mediated immune responses in order to clarify whether interference with MDSC development might be a therapeutic option after trauma.


Division of Paediatric Endocrinology and Diabetes

Head: Prof. Dr. Martin Wabitsch

Principal Investigators: Prof. Dr. Martin Wabitsch, Prof. Dr. Pamela Fischer-Posovszky, PD Dr. Christian Denzer, Dr. Stephanie Brandt, Dr. Julia von Schnurbein, Dr. Daniel Tews, Dr. Anja Moss

Staff: Dr. Patricia Cardenas de Bäuerle, Dr. Meike Dahlhaus, Dr. Friederike Denzer, Malaika Fuchs, Dr. Jan-Bernd Funcke, Daniel Halbgebauer, Dr. Gloria Herrmann, Alexandra Killian, Dr. Katja Kohlsdorf, Stephanie Laviani, Adriana Nunziata, Julian Roos, Dr. Heike Vollbach, Dr. Helmut Weyhreter

Our research areas include development and disturbances of the endocrine system, endocrine regulation of body weight and diabetes mellitus type 1 and type 2. The main focus of the research projects lays on diseases going along with alterations in adipose tissue mass and function such as obesity and lipodystrophies and their comorbidities. On the one hand (see Experimental Endocrinology and Metabolism Research) we aim to identify the underlying pathophysiology at the genetic, molecular, cellular, organ and systemic level. On the other hand, we are involved in clinical studies evaluating novel treatment options (see Externally Funded Research Projects and Studies).



Our objectives include not only the further development of a pure science of endocrino-

logy, but also the evolution of an applied science of endocrinology and the improvement of the medical art in endocrine domains. We believe that the promise of basic science is that tomorrow's patients will be treated better than today's.

■ Monogenic obesity

Monogenic forms of early onset obesity are very rare. Severe early-onset obesity is often caused by genetic defects. Most of these genes are involved in the central nervous regulation of hunger and satiety. Herein, the leptin-melanocortin system plays a pivotal role. Patients with congenital leptin deficiency can be treated with a hormone replacement therapy with metreleptin, a recombinant analogue of the human leptin. Leptin is a highly important hormone stimulating the MC4 pathway with pleiotropic functions mostly elicited via specific leptin receptors. Apart from regulating satiety, some of the most important aspects of leptin function include its influence on energy homeostasis, on glucose homeostasis, on the sympathetic nervous system and on immune function. Our department is one of a few centers worldwide offering leptin replacement therapy to patients. Furthermore, we have identified and treated the first known patients with severe early onset obesity due to a mutation in the leptin gene that renders the hormone biologically inactive (Wabitsch et al., *New Engl J Med* 2015). Our laboratory investigates the biological functions of leptin and aims to better understand the clinical picture of congenital leptin deficiency. Recently, the MC4R agonist Setmelanotide has been introduced as a new treatment option for patients with POMC and LPR deficiency (please see below - clinical study with Setmelanotide).

■ In vitro model systems to study human adipocyte biology

In recent years we have developed model systems to study human adipocyte biology. We have established a cell line derived from an adipose tissue specimen of a patient with Simpson-Golabi-Behmel syndrome (SGBS). The cells are close to primary human adipocytes as they are neither transformed nor immortalized. SGBS adipocytes exhibit the typical characteristics of human white fat cells, including synthesis and storage of triglycerides and insulin sensitivity, as well as sensitivity to beta-adrenergic agents. Therefore, the cells represent a unique and versatile research tool for examining human adipose tissue biology. We share SGBS cells for scientific purposes. So far, the cells have been spread to more the 250 international research labs.

Experimental Endocrinology and Metabolism Research (Heisenberg Professorship)

Head: Prof. Dr. Pamela Fischer-Posovszky
Staff: Dr. Meike Dahlhaus, Jan-Bernd Funcke, Daniel Halbgebauer, Alexandra Killian, Adriana Nunziata, Julian Roos, Dr. Daniel Tews
Students: Elena Brenner, Taner Pula

Obesity is a worldwide epidemic. The excessive accumulation of adipose tissue leads to the development of severe comorbidities such as insulin resistance, type 2 diabetes mellitus, hepatic steatosis, cardiovascular diseases including hypertension and atherosclerosis, and an increased risk of developing certain types of cancer. Conventional therapy concepts involving e.g. diet, physical exercise, or behavior therapy often fail. Thus, there is an urgent need to develop innovative pharmacological treatment strategies. In our group we aim to understand the physiology and pathophysiology of adipose tissue.

■ Death receptors in adipose tissue

Adipose tissue is a dynamic organ with ~10% of fat cells being renewed annually. Our group investigates the role of death receptors in this remodeling process.

We found out that preadipocytes and adipocytes express death receptors, among them CD95, TNF receptors, and TRAIL receptors. Interestingly, both cell types are protected from apoptosis induced by their respective ligands. Apoptosis of adipocytes can only be induced under certain conditions, e.g. by inhibition of protein biosynthesis (Fischer-Posovszky et al., *Endocrinology* 2004).

In our current projects we study non-apoptotic function of death receptors in adipose tissue. We have elucidated that TRAIL stimulates the proliferation of preadipocytes and inhibits their adipogenic differentiation (Funcke et al., *FASEB J* 2015; Zoller et al., *Cell Death Dis* 2016).

■ MicroRNAs in adipose tissue

MicroRNAs (miRNAs) are small, 18-25 nucleotide long, non-coding RNA molecules. They are central regulators of gene expression and influence a variety of biological processes including cellular differentiation and metabolism.

Obese adipose tissue is characterized by pathological alterations such as hypertrophy of adipocytes, inflammation, hypoxia, and fibrosis. We showed that miRNAs are differentially regulated by inflammatory stimuli in adipocytes (Roos et al., *Sci Rep* 2016). We now aim at identifying the function of specific miRNAs. miR-146a, for example, was identified as a negative regulator of the inflammatory response in adipocytes (Roos et al., *Sci Rep* 2016).

miRNAs can be released to the circulation. We also seek to find out if these small RNA molecules might constitute novel biomarkers of adipose tissue health.

■ Brown adipose tissue

The discovery of active brown adipose tissue in adult humans and its negative association with fat mass and body weight gave rise to the idea, that this special tissue could be utilized for the treatment of obesity and metabolic disease.

Brown adipocytes are characterized by the expression of uncoupling protein-1 (UCP1). This mitochondrial protein is capable of uncoupling cellular respiration from ATP synthesis. The proton gradient, which is built up by the electron transport chain is not used for the production of ATP. Instead, energy is dissipated as heat. UCP1 is activated by cold or β -adrenergic agents, which stimulate lipolysis and result in the metabolism of free fatty acids. Therefore, brown adipocytes can consume stored energy. White adipocytes do not express UCP1 and are thus not capable of thermogenesis. They are responsible for the storage of excess energy, which can be mobilized as needed. A third, intermediate phenotype of fat cells was named beige adipocyte. Beige adipocytes express UCP1 and are thermogenic. They can form within white adipose tissue depots, e.g. upon prolonged cold exposure, in a process called “browning”.

Our laboratory investigates white and beige/brown adipose tissue in humans. From surgical operations in the neck region we collected paired samples of subcutaneous, white adipose tissue and brown adipose tissue from the deep neck region (Tews et al., *Mol Cell Endocrinol* 2014). Progenitor cells isolated from both depots showed a distinct gene expression profile. We currently study whether the differentially expressed genes play a role in white or brown adipogenesis.

Non-malignant hematological diseases

Head: apl. Prof. Dr. Holger Cario

Cooperations: Molecular Diagnostics and Therapy Group at IKT Ulm (Dr. K. Schwarz), European Congenital Erythrocytosis Consortium (ECE) and MPN&MPNr Euronet (COST)

■ Congenital erythrocytoses

In patients without underlying cardiac or pulmonary diseases, erythrocytoses are a very rare, heterogenic group of diseases. There is only few systematically collected data on basic principles, presentation and therapy of these etiologically in many cases unclear disease patterns, neither on polycythemia vera in pediatric patients. On these grounds, a register for these diseases was established in Germany, in which patients from other European countries are included as well. It now forms the basis for a European register (www.erythrocytosis.org).

In the recent years we identified several hitherto unknown mutations which, occasionally in connection with other genetic or epigenetic alterations, contribute to primary and secondary congenital erythrocytosis. These efforts are currently continued with a focus on secondary congenital erythrocytosis. In cooperation with the MPN&MPNr Euronet (B. Gardie, Nantes), there are furthermore functional analyses of the potential pathogenetic role of the identified mutations.

■ Hemoglobin diseases

The department is a center for the treatment of patients with hemoglobin disorders, in particular thalassemia and sickle-cell disease. It has laid important foundations for clinical scientific and epidemiological works on thalassemia and sickle-cell disease in Germany. The German Society for Pediatric Oncology and Haematology established a consortium coordinating a new register study on sickle-cell disease in which Ulm is participating.

Immunodeficiency and Stem Cell Transplantation

Head: apl. Prof. Dr. Ansgar Schulz

Investigators: PD Dr. Manfred Hönig, Dr. Catharina Schütz, Dr. Eva Jacobsen, Andrea Hänsler

■ Primary Immunodeficiencies

Through our long lasting experience with diagnosis and therapy of primary immunodeficiencies – particularly stem cell transplantations in severe combined immunodeficiencies (SCID) – a unique cohort of patients has grown. Our scientific points of interest are 1. Individualized therapy through an as exact as possible characterization of the clinical phenotype; 2. Identification of the underlying genetic causes of the disease; 3. Long-term course of disease after successful stem cell transplantation under consideration of non-immunological symptoms of the disease. Our work in all three areas cumulated in successful publications.

Our group closely cooperates with Dr. Schwarz (Molecular Diagnostics and Therapy at IKT Ulm). We are part of a BMBF-funded nationwide research network (PID-NET) on phenotypic and genetic characterization of inborn immunodeficiencies. Currently, we are collecting data from worldwide sources on clinical presentation and therapy of patients with reticular dysgenesis, a rare subgroup of the severe combined immunodeficiency and granulopenia.


■ Osteopetrosis

The Department of Pediatrics and Adolescent Medicine of Ulm University has long standing experience with diagnosis and therapy of the various forms of osteopetrosis. Our group contributed to the identification of additional genetic variants. In addition, we were able to further optimize various therapeutic approaches in the field of hematopoietic stem cell transplantation. Our hospital is now one of the leading contacts in the area of osteopetrosis.



above: Characteristic x-ray of a baby with infantile osteopetrosis (TCIRG1 mutation)

right: Bone marrow biopsy from an infant with LAD-III syndrome and osteopetrosis



In order to further pursue the goal of improving diagnosis and therapy of this rare disease, a network of basic scientists and clinicians from many European countries was established by the E-RARE initiative of the European Union. The following goals of the sub-project from Ulm were reached and are now widened: a) the registration of European patients with infantile osteopetrosis in a central register and b) the development of recommendations for diagnosis, therapy and clinical monitoring of patients with osteopetrosis.

Neonatology and Pediatric Intensive Care

Acting Head: Dr. Wolfgang Lindner

■ Clinical Research

The Division of Neonatology is actively participating in scientific clinical studies to improve patient care. We participated in multicenter studies on the effects of automated adjustment of the inspired oxygen on fluctuations of oxygen saturation together with University Hospital Tübingen (Investigators: Dr. Mendler and Dr. Essers).

Currently we participate in two large international studies (SAIL-Trial, Premod-Trial) with special focus on delivery room care (investigators: Dr. Essers and Dr. Mendler). Furthermore, we are working together with Stephan Medizintechnik GmbH with the aim to improve non-invasive respiratory support of newborns and participate in the German Neonatal Network (GNN, investigators: Dr. Essers and Dr. Schiefele). These studies are funded by the Federal Ministry of Economic Affairs and Energy.

■ Experimental Neonatology

In close collaboration with several physicians and guest scientists, we perform studies with laboratory animals on resuscitation of newborns. The animal lab is supervised by Dr. Mendler

who conducts studies on resuscitation after circulatory collapse due to asphyxia together with his team of physicians and students. One focus is on the respiratory support during cardiac massage. These studies are funded by the German Research Foundation (DFG).

Pediatric Gastroenterology

Head: PD Dr. Carsten Posovszky

Staff: Kirsten Lang, MD; Lena Wölfle, MD; Susanne Stephan, MD; Doris Gülke, MD; Andrea Kresz, MD; Monika Kriechbaum, dietician; Sigrid Räkel-Rehner, dietician; Maria Zernickel, study nurse

Funding: German Research Foundation (DFG), industry




The Division of Pediatric Gastroenterology, Hepatology and Nutrition advances the treatment of pediatric gastrointestinal and liver diseases through the coordinated efforts of its patient care, research and educational activities. As part of an academic medical centre, researchers and clinicians work continually together to improve the standard of care. Our research includes both basic and clinical investigations and involves other disciplines. Exploring the molecular and genetic origin of chronic gastrointestinal diseases,

transform pathogenesis findings into most advanced diagnostics, drug therapies and procedures available today. There are ongoing multicentre interventional trials for children with chronic functional abdominal pain, chronic inflammatory bowel disease and paediatric endoscopy.

■ Clinical Research

Our research interests include single- and multi-center clinical studies in inflammatory bowel disease, vaccination of immunosuppressed patients, pediatric endoscopy and pediatric functional abdominal pain.

Currently we participate in several prospective randomized trials and long-term-safety observations regarding therapeutic agents in inflammatory bowel disease. Our group is a member of the German inflammatory bowel disease register (CEDATA). A randomized controlled trial evaluating carbon dioxide insufflation during colonoscopy was performed at our center. Currently, we recruit patients for a randomized controlled trial evaluating safety and efficacy of a new bowel cleansing preparation in pediatric patients (Easykid). We also initiated multicenter observational studies on life vaccination in immunosuppressed patients founded by the German Crohn and Colitis Organization (DCCV). Furthermore, we have just recently finished a multi-center study funded by the German Research Foundation (DFG), which aimed to improve the treatment of children with functional abdominal pain (STOP-FAP).



Mislocated PAS-positive granula in the intestinal epithelium of a Patient with FHL Typ5 due to STXBP2 Mutation on the right.

■ Experimental Gastroenterology

Our basic research focuses on the cellular and molecular pathogenesis of congenital enteropathies and inflammatory bowel diseases. We contributed to the identification of the gastrointestinal pathomechanisms involved in Autoimmune-Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) and Familial Hemophagocytic Lymphohistiocytosis (FHL) Type 5.

In order to further pursue the goal of improving the genetic and pathophysiological understanding of congenital gastrointestinal diseases we investigate cellular trafficking and inflammatory pathways in the gut. We perform these studies in a network of European collaborators.

Pediatric Cardiology

Head: apl. Prof. Dr. Christian Apitz

Investigators: Dr. Peter Bride, cand. med. Miriam Heinzelmann, Dr. Michael Kaestner, cand. med. Verena Kiesler, Dr. Johannes Krämer, Dr. Fabian von Scheidt, Dr. Jannos Siaplaouras

The research focus of the Division of Pediatric Cardiology is on diagnosis and treatment of pulmonary hypertension and heart failure. In this regard, we are actively participating in scientific national and international clinical studies to investigate innovative therapies for the care of patients with pulmonary hypertension (Riociguat, Tadalafil) and heart failure (Sacubitril/Valsartan). To collect data on etiology, prevalence and treatment strategies, we participate in several national and international registries for pulmonary hypertension and heart failure/myocarditis (CompERA, TOPP, Mykke).

A further research topic of interest of the Division of Pediatric Cardiology is modern imaging techniques for the early detection of myocardial dysfunction potentially resulting in heart failure due to different causes. These studies are funded by a research grant of the German Association for Pediatric Cardiology. In addition, we are participating in an international multi-center study to investigate factors leading to the development of protein-losing enteropathy, a life-threatening complication in patients with failing single-ventricle hemodynamics, as for example with the hypoplastic left heart syndrome.

Another thematic focus of the Division of Pediatric Cardiology is the systematic assessment of physical activity in children and adolescents with congenital heart disease in collaboration with the German Competence Network Congenital Heart Defects and the Karlsruhe Institute of Technology. We are further evaluating home based training programs to allow patients with congenital heart disease active sports participation.

DNA Damage Response in Human Lymphocytes

Head: Dr. Kerstin Felgentreff

Staff: Jasmin Sprissler, Dilek Dayanakli

Cooperation: Institute for Clinical Transfusion Medicine and Immunogenetics (IKT) Ulm, Dr. K. Schwarz Group

Funding: German Research Foundation (DFG), Else-Kroener-Fresenius Foundation

DNA damage occurs ubiquitously in every cell and is triggered by endogenous factors of metabolism, or exogenous influences such as ionizing radiation or intercalating chemical drugs. The cellular integrity relies on a complex repair system that ensures immediate sensing and efficient

repair to protect the DNA from any persisting damage, known as DNA damage response. If this system fails, apoptosis, senescence, or introduction of chromosomal breaks and mutations potentially leading to neoplastic transformation are the consequences. Furthermore, DNA double strand breaks are physiologically induced, such as in the process of V(D)J recombination in lymphocyte development for generation of diversified T cell and immunoglobulin receptors. Recombination activating genes RAG1 and RAG2 target specific signal sequences to cleave adjacent DNA. Subsequently, DNA ends are processed and joined by factors of the non-homologous end-joining (NHEJ) DNA repair pathway.

■ Analysis of DNA Damage Response


Genetic defects in genes coding for DNA repair proteins can cause various immunodeficiencies due to impaired lymphocyte development and survival. The only treatment option for many of these diseases is the allogeneic hematopoietic stem cell transplantation, although associated with increased toxicity to conditioning regimens. Early diagnosis of increased radio- and chemosensitivity, for example in severe combined immunodeficiency, has a tremendous impact on treatment decisions regarding use of chemotherapy and diagnostic medical radiation.

We are working on diagnostic assays to rule out radio- and chemosensitivity that allows an early diagnosis of DNA repair deficiencies using biomarkers on peripheral blood mononuclear cells.

■ Recombination-induced DNA damage response

Although transient, RAG-induced DNA double strand breaks launch a DNA damage response that impacts on transcriptional regulation for cellular-processes beyond canonical DNA repair.

There is evidence in mice that RAG proteins are already expressed in early lymphoid progenitors and also target sequences in developing NK cells with important DDR-related effects on maturation, cytotoxic function and cellular fitness. We are using induced pluripotent stem cells (iPSC) as a platform to study DNA damage response after RAG-cleavage in lymphocyte differentiation.



Externally Funded Research Projects and Studies

Consortium “Adolescents with Extreme Obesity” (Competence Network Obesity, CNO)

Speaker:	Prof. Dr. Martin Wabitsch
Funding:	Federal Ministry for Education and Research (BMBF)
Duration:	2012 - 2018
Partners:	University Children's Hospitals at Essen, Witten-Herdecke, Berlin and Leipzig; Institute for Epidemiology and Medical Biometry of Ulm University, Helmholtz Center Munich
Registry IDs:	DRKS00004172, DRKS00004198, DRKS00004195, DRKS00009437, DRKS00004196, DRKS00004197 (Deutsches Register Klin. Studien)

Extremely obese adolescents are at a strongly elevated risk of early death, somatic comorbidities, psychiatric disorders, and social isolation, including unemployment, due to both functional impairment and stigmatization. Despite the dire implications of extreme obesity in adolescents and the frequently overt (e.g. orthopaedic disorders) and non-overt (e.g. hypertension) comorbidity, these adolescents are difficult to reach and treat in medical terms. Thus, only a small percentage actively seeks treatment.

The underlying reasons are poorly understood and may presumably be attributed to the young age, a predominantly low educational and socioeconomic status, as well as to functional impairment due to inactivity and psychiatric comorbidity. Unsuccessful attempts to lose weight on their own and/or within the medical system may have led to frustration with respect to their behaviour in seeking treatment.

In acknowledgement of this, we have developed the “Medical and psychosocial implications of extreme obesity in adolescents - acceptance and effects of structured care study”, which is known by its abbreviated title as: “Youth with Extreme obesity Study (YES)”. YES aims at improving the medical care and social support structures for this so far widely ignored patient group. Results of this study will improve the medical care and social support structures for youths with extreme obesity in Germany.



Collaborative Research Center SFB 1074: Experimental Models and Clinical Translation in Leukemia

Speaker:	Prof. Dr. Hartmut Döhner, Department of Internal Medicine III
Vice Speaker:	Prof. Dr. Klaus-Michael Debatin
Funding:	German Research Foundation (DFG)
Duration:	2016 - 2020 (second funding period)
Partners:	Additional Departments and Institutes of Ulm University

■ **Subproject *Genomic and signalomic characterization of pre- and post-therapy ALL modeled in vivo***

Investigator: apl. Prof. Dr. Lüder H. Meyer, Prof. Dr. Klaus-Michael Debatin

Despite the great success in treating pediatric acute lymphoblastic leukemia (ALL) with elaborated risk-stratifying protocols, resulting in cure rates of more than 80%, 20% of the patients will relapse resulting mostly in poor outcome. The majority of relapses occurs in the standard-risk group.

Over the last years, molecular and functional analyses of ALL have identified mechanisms and characteristics of leukemia biology such as activating mutations, dysregulated pathways, and clonal selection at relapse opening the avenue for pathway-directed therapies. However, translational studies in patient-derived ALL are limited by the restricted availability of cells and the inability to culture primary ALL cells in vitro. Thus, preclinical xenograft models, using primary patient-derived ALL cells transplanted into immunodeficient mice, are used to overcome these restrictions.

We have established a NOD/SCID/hu-ALL xenograft model for pediatric ALL and have built up a large biobank of ALL xenografts derived from more than 130 individual pediatric ALL patients. In this model, we have identified a specific gene expression signature, which characterizes ALL samples with rapid engraftment, i.e., a short-time to leukemia development (TTLshort) and poor prognosis. This TTLshort phenotype is characterized by a hyperactivated mTOR signaling pathway and in vivo treatment using combinations of mTOR-directed therapies with chemotherapy was highly effective. By genomic profiling, we have characterized mutation frequencies upon repeated transplantation and diagnostic ALL samples and obtained miRNA signatures. Using candidate genes of the TTL signature, we identified novel targets by RNA interference and obtained first evidence for an anti-CD70-directed immunotherapy as novel treatment strategy in B-cell precursor ALL. Lastly, we identified defective apoptosis signaling as an additional feature associated with the TTL signature which could be restored by Smac-mimetics such as BV6.

Taking further advantage of this xenograft model, we will perform an in-depth analysis with a particular focus on genomic alterations, functional status and clonal evolution of ALL between diagnosis and relapse. To this aim, we will characterize genomic signatures in primary ALL and at the time of relapse occurring after conventional short term treatment in the NOD/SCID/hu-ALL system. This will include clonal analysis to address issues of heterogeneity and drug resistance of individual clones. Furthermore, this analysis will be extended to paired samples from patients analyzed at diagnosis and relapse. The genomic analysis will be complemented by multicolor-phosphoflow and phosphoproteomic analyses of individual leukemia cells. To this aim, we will also make use of the newly established CyTOF technology, allowing multimarker analysis of surface and cytoplasmic molecules at the single cell level. Furthermore, we will analyze sensitivity and resistance for targeting of specific pathways involved in differentiation, survival and apoptosis such as PI3K, mTOR, pre-B-cell receptor, B-cell receptor, IL7 receptor, Bcl-2 and IAP. This approach can also be used for novel compound screening in the appropriate setting.

Taken together, given the fact that we have established one of the largest cohorts of pediatric ALL in the NOD/SCID/hu-ALL model, we expect that our studies will not only give a more detailed insight into leukemia biology and possible prognostic markers, but will also help identifying rational targets for novel therapeutic interventions.

Collaborative Research Center SFB 1149: Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma

Speaker: Prof. Dr. Florian Gebhard (Department of Orthopaedic Trauma, Hand, Plastic, and Reconstruction Surgery)
Funding: German Research Foundation (DFG)
Duration: 2015 - 2018 (first funding period; continuation granted)
Partners: Additional Departments and Institutes of Ulm University

■ Subproject *Role of myeloid-derived suppressor cells (MDSCs) in trauma*

Investigator: apl. Prof. Dr. Gudrun Strauß

The clinical course after trauma depends on the balance or imbalance of pro- and anti-inflammatory responses. While predominance of a pro-inflammatory response leads to “systemic inflammatory response syndrome” (SIRS) and overwhelming immune reactions, inhibition of the immune response induces the “compensatory anti-inflammatory response syndrome” (CARS) connected with immunosuppression and an enhanced risk for all types of infections. Traumatic injuries are associated with the release of pro-inflammatory factors such as TNF- α , IL-6 or glucocorticoids, which shape the immune response. Several types of inflammation such as tumors, autoimmunity, and bacterial infections are known to induce a population of immature myeloid cells, which suppress T cell-mediated immune responses such as T cell activation, proliferation, and cytotoxicity. These heterogeneous populations of immature myeloid cells are defined as myeloid-derived suppressor cells (MDSCs) and are characterised by the co-expression of surface molecules CD11b and Gr-1. At present, the impact of MDSCs on the course of disease and the innate and adaptive immune responses after traumatic injuries are not well defined. A few studies point to a beneficial effect of MDSC appearance for the injured host, however, their precise effects on innate and cellular immunity are unclear. Therefore, we will use different trauma models – preferentially blunt chest trauma and blunt chest trauma in combination with femur osteotomy – to define the kinetics of MDSC induction after injury and determine their influence on innate immunity and T cell functions. Using MDSC-depleting antibodies or the injection of in vitro-generated MDSCs will show at which time point after trauma, MDSCs interfere with the trauma-induced immune response and whether induction of MDSCs is detrimental or advantageous for the injured host. A major focus of the studies will be the modulation of T cell functions by trauma-induced MDSCs. Immune suppression and susceptibility for opportunistic infections after trauma is often associated with a skewing towards Th2 immunity and the loss of Th1-specific cytotoxicity. Whether and how MDSCs influence the Th1/Th2 balance after traumatic injuries will be analysed. Since pro-inflammatory factors such as IL-6 and glucocorticoids are strongly induced after blunt chest trauma and are known to be required for the expansion and maturation of MDSCs, we will delineate the role of IL-6 and GC for MDSCs induction and T cell immune responses. Analysis of MDSCs induction and function and their influence on T cell-mediated immune responses in other trauma models will further clarify whether MDSCs have a general impact on the course of traumatic injuries and how they influence SIRS and CARS. The anticipated results will define the role of MDSCs after traumatic injury and might help to clarify whether interference with MDSC development is a possible therapeutic option after trauma induction.

■ Subproject *Role of severe obesity in healing of muscle injuries*

Investigators: Prof. Dr. Uwe Knippschild (Department of General and Visceral Surgery), Prof. Dr. Martin Wabitsch

In obesity, adipose tissue functions are dysregulated leading to changes in the release of growth factors, adipocytokines, cytokines, chemokines, hormones, and fatty acids, which are secreted from adipocytes and macrophages resident in white adipose tissue. These changes affect lipid metabolism, glucose homeostasis, inflammation, angiogenesis, haemostasis, and blood pressure. In addition, the ectopic lipid accumulation in organs and tissues can lead to severe co-morbidities including heart disease, diabetes, metabolic syndrome, hypertension, sleep apnoea, and cancer. Furthermore, there is increasing evidence that obesity impairs tissue regeneration processes after trauma. For example, obesity negatively affects regeneration of skeletal muscle injuries, yet the underlying mechanisms have not been elucidated. Muscle regeneration can be divided into an initial response, i.e. the peak inflammation and degenerative response, and the structural and functional recovery phase. It is a highly synchronised process demanding the timely coordinated activation of different cellular responses by many different signalling molecules. There is evidence that toxic lipid metabolites and pro-inflammatory adipocytokines and chemokines as well as leptin and insulin resistance impair these processes, especially muscle satellite activation and functions, finally resulting in decreased regenerative ability. The aim of our project is to investigate (i) the role of lipid metabolites and fatty acids on muscle regeneration, (ii) the consequences of an altered interplay between macrophages and stem cells on muscle regeneration, and (iii) how changes in signal transduction pathways affect satellite cell physiology. The results of our project will lead to the identification of new obesity-related factors with prognostic and therapeutic relevance in regard to muscle regeneration after injury.

Boehringer Ingelheim Ulm University BioCenter (BIU)


Speaker:	Prof. Dr. Klaus-Michael Debatin (on behalf of the Medical Faculty)
Funding:	State of Baden-Württemberg, Boehringer Ingelheim, Medical Faculty
Duration:	2016 - 2019 (second funding period)
Partners:	Groups from Ulm University and from Boehringer Ingelheim, Biberach
Topics:	Cardio-metabolic and lung diseases, neuropsychiatric diseases and immunomodulation

■ Subproject *Role of secreted factors for white and brown adipocyte differentiation*

Investigators: Dr. Daniel Tews, Prof. Dr. Pamela Fischer-Posovszky,
Dr. Bradford Hamilton (Boehringer Ingelheim Pharma GmbH & Co. KG,
Cardiometabolic Diseases Research)

In this project, we concentrate on preadipocyte-secreted factors and their impact on brown adipocyte differentiation using our state-of-the-art model of ex vivo differentiated primary human deep neck preadipocytes.

Secreted factors and their respective receptors are promising targets to develop novel drugs for obesity treatment by promoting brown adipocyte differentiation. We hypothesize that the progenitor pool within the adipose tissue releases factors, which modulate either white or brown adipocyte differentiation in an auto-/paracrine manner.



UCP1 (UCP1/DAPI) immunostaining of differentiated adipocytes from brown adipocyte progenitor cells ex vivo.

■ Subproject *Influence of inflammation on the differentiation and function of MDSCs and T cell-mediated immune responses*

Investigators: apl. Prof. Dr. Gudrun Strauß, Prof. Dr. Klaus-Michael Debatin

This project aims to clarify how the disease-specific inflammatory environment influences the outcome of a MDSC therapy. By using three different murine disease models (graft-versus-host disease (GvHD), adipositas and trauma) the differentiation and immunosuppressive capacity of MDSCs and their subsequent effect on the adaptive immune response will be determined. This work will help to estimate the therapeutic success of MDSC treatment dependent on the disease entity.

RECOMB: Stem-cell based gene therapy for recombination deficient SCID

Coordinator: Prof. Dr. Frank Staal, Leiden, The Netherlands

Our Investigator: apl. Prof. Dr. Ansgar Schulz

Funding: European Union – Horizon 2020

Duration: 2018 - 2022

Partners: 17 partners in Europe and Israel

Recomb is a multi-stakeholder research consortium aiming to create a novel treatment for severe combined immunodeficiency (SCID) by conducting clinical trials using gene therapy for one of the most common type of SCID: RAG-SCID. The consortium, started in 2018, brings together clinical and research professionals from 16 European and 1 Israeli institutes with expertise in the management of primary immunodeficiencies, such as SCID. The project received funding from the European Union Horizon 2020 programme.

SCID comprises a group of rare diseases in which cells in the adaptive immune system fail to develop properly. The specific SCID phenotype depends on the underlying genetic defect, and more than 20 SCID-associated genes have been identified to date. SCID affects around 1:35,000 infants, with approximately 145 affected babies born each year in the EU.

These infants are born without a functional immune system, thus typically experience a wide range of serious, eventually life-threatening infections, including pneumonia, meningitis, and sepsis, and die within the first year of life unless effective treatment is given.

Source: Recomb leaflet; www.recomb.eu

International Registry for the Therapy of Patients with Severe Combined ImmunoDeficiency, SCID

Speaker: PD Dr. Manfred Hönig

Funding: Deutsche Kinderkrebsstiftung

Duration: 2018 - 2020

Partners: University Children's Hospitals in Munich (LMU), Vienna, Freiburg, Zürich, Leipzig and Hannover

The term "Severe combined Immunodeficiency, SCID" describes a heterogeneous group of rare diseases which are clinically defined by the lack of specific immune function. Without cellular therapies such as allogeneic Hematopoietic Stem Cell Transplantation (HSCT) or gene therapy, affected children die within their first year of life from recurrent and abnormal and

severe infections. As patients are treated in multiple centers all over Austria, Switzerland and Germany it is crucial to gather data in a central registry for scientific evaluation.

The intention of this international registry is to collect prospective data on all patients treated in participating countries with the diagnosis of Severe Combined Immunodeficiency (SCID). Information on the clinical presentation, immunophenotype, genotype, transplantation and follow up (cGVHD, chimerism, immunological reconstitution, frequency of infections and quality of life) will be gathered in a central database. With the inclusion in the registry and after transplantation patient samples will be cryopreserved in a biobank for future scientific projects. Counselling on therapeutic options and strategies is offered by the members of the board.

Scientific work up of registry data, clinical counselling and accompanying studies with the samples stored in the biobank will contribute to improving the standard of medical care for patients with SCID.

Preclinical Comprehensive Cancer Center (PCCC)

Coordinator: Prof. Dr. Hellmut Augustin, German Cancer Research Center, Heidelberg
Our Investigators: Prof. Dr. Klaus-Michael Debatin, apl. Prof. Dr. Lüder H. Meyer, Dr. Stefanie Enzenmüller
Funding: Helmholtz Association
Duration: 2013 - 2016
Partners: Additional Departments and Institutes of Ulm University; Helmholtz Centers DKFZ, HMGU, MDC; EMBL, Max-Planck Institute for Brain Research, and the Universities of Heidelberg, Munich (TU) and Cologne

The availability of advanced preclinical tumor models has emerged as one of the most rate-limiting factors for both, the advancement of basic tumor biology and translational oncology research. Therefore, the Helmholtz Association has established the Helmholtz Alliance Preclinical Comprehensive Cancer Center (PCCC) as a nationwide network for the development and validation of established and novel preclinical cancer models of superior quality, which truly mimic the natural course of human tumor initiation, growth and metastasis. Our mission is to translate discoveries into the clinic: from bench to bedside. Focusing on key issues of contemporary oncology research, such concerted effort holds great prospect to revolutionize current cancer research.

Source: Helmholtz Association; www.dkfz.de

German Mass Cytometry Network

Speaker: Dr. Henrik Mei, German Rheumatism Research Centre Berlin
Our Investigator: PD Dr. Manfred Hönig (on behalf of the Cytometry Core Facility)
Funding: German Research Foundation (DFG)
Duration: 2017 - 2020
Partners: DRFZ, Deutsches Rheumaforschungszentrum Berlin; CRTD, Center for Regenerative Therapies TU Dresden; BCRT, Berlin-Brandenburger Centrum für Regenerative Therapien

The detection of fluorochromes as markers of specific antibodies in flow cytometry is currently limited to 12-16 colors due to technical reasons. This limitation can be overcome by the use

of metal tags conjugated to specific antibodies in single cell mass cytometry. With this technology, currently more than 35 epitopes can be stained on a single cell. A detailed characterization of cell surface proteins combined with the staining of intracellular (phosphorylated) proteins opens new fields and perspectives for phenotypic and functional studies in hematology, oncology and immunology.

The establishment of staining protocols for intra- and extracellular antigens and the management of the huge amount of data pose major challenges in the use of this emerging technology.

To accelerate and facilitate the use of Mass Cytometry five centers gathered in a national network to exchange experience, data and protocols. The Core Facility Cytometry of the Medical Faculty of Ulm University was a founding member of this network and started the service in Mass Cytometry in March 2017.

Identification and enrichment of beige/brown adipocyte progenitors from white adipose tissue for the generation of functional brown fat in humans

Investigator: Prof. Dr. Pamela Fischer-Posovszky
Funding: German Research Foundation (DFG)
Duration: 2016 - 2020

The existence of functional relevant brown adipose tissue (BAT) in human adults has been accepted in the scientific community since 2009. In contrast to the energy storing white adipose tissue (WAT), BAT utilizes energy to generate heat. Recent data demonstrated that BAT activity is reduced in obese patients. Therefore it became an attractive pharmacological target for the treatment of overweight and obesity. Besides white and brown adipocytes a third adipocyte type has been recently described – the so-called “beige” adipocyte. In mice, this cell type emerges under certain circumstances within the WAT depot. The cellular and molecular basis for the recruitment of beige adipocytes in humans is only poorly understood. However, both brown and beige adipocytes are thermogenic and can contribute to an increase in energy expenditure.

Our group demonstrated recently that human progenitor cells of white and brown adipocytes have distinct gene expression signatures. Among the differentially expressed genes were many surface proteins, which could potentially be used to enrich brown adipocytes.

The fundamental hypothesis within this project is that specific progenitor cells, which are able to differentiate into functional brown or beige adipocytes reside in the stromal-vascular fraction of white adipose tissue depots. Specific aims are: 1. We want to identify surface markers of human white and beige/brown adipocyte progenitors. 2. We want to use these markers to enrich beige/brown adipocyte progenitor cells from white adipose tissue. 3. We will investigate if the identified markers play a causal role for the generation of beige/brown adipocytes. 4. Taking advantage of transplantation experiments, we want to test if progenitor cells enriched from WAT which display a beige/brown gene signature *in vitro* can give rise to functional beige/brown adipocyte tissue *in vivo*. In mice, transplantation of BAT can prevent or revert diet-induced obesity and its associated comorbidities. Our vision is to develop such a strategy for humans. The planned experiments provide a scientific basis for this approach.

Healthy Fat for a Healthy Life - Targeting Adipocyte Adipose Tissue Function to Maintain and Improve Systemic Metabolism (Heisenberg Professorship)

Investigator: Prof. Dr. Pamela Fischer-Posovszky
Funding: German Research Foundation (DFG)
Duration: since 2017

Overweight and obesity have reached epidemic proportions worldwide. The excessive accumulation of white adipose tissue leads to the development of severe comorbidities including insulin resistance, type 2 diabetes mellitus, hepatic steatosis, cardiovascular problems, and to an increased risk of developing certain types of cancer. Conventional therapy such as dietary and exercise intervention often fail in the long run. Therefore, there is an urgent need to develop innovative treatment strategies.

This research project aims at developing strategies to maintain and/or restore adipose tissue health to provide a basis for systemic metabolic health.

Role of microRNAs for obesity-associated adipose tissue inflammation

Investigator: Prof. Dr. Pamela Fischer-Posovszky
Funding: Baden-Württemberg Stiftung
Duration: 2015 - 2018

Obesity leads to an accumulation of white adipose tissue. Obese adipose tissue is characterized by local inflammation, hypoxia, and fibrosis. These pathological alterations play a causative role in the pathogenesis in associated diseases. We hypothesize that microRNAs play an important role in obesity-associated inflammation of white adipose tissue. This project aimed at the identification of microRNAs involved in inflammatory processes in adipose tissue, the elucidation of their functional role, and their suitability as biomarker to estimate adipose tissue inflammation.

The role of transcription factors in human brown adipocyte development

Investigator: Dr. Daniel Tews (Division of Pediatric Endocrinology and Diabetes)
Funding: German Research Foundation (DFG)
Duration: 2018 - 2020
Partners: Picower Institute for Learning and Memory, MIT, Cambridge, USA (Prof. Elly Nedivi)
 Department of Nuclear Medicine, Ulm University Medical Center (Prof. Ambros Beer)

Brown adipose tissue (BAT) is the key thermogenic tissue in hibernating and newborn animals and has recently been shown to be present and active in adult humans. It is involved in body weight regulation and is currently discussed as a promising therapeutic tool to combat obesity and insulin resistance in humans. Upon cold exposure or pharmacological treatment, brown-like adipocytes can also emerge in white adipose tissue (WAT), representing another phenotype of adipocytes differentiating from a certain subtype of progenitor cells. Using gene array analyses, we recently identified a list of transcription factors differentially expressed in progenitor cells isolated from human brown and white adipose tissue. In this project, we aim

to elucidate the function of these factors concerning brown adipocyte identity using gain- and loss of function experiments and functional assays. Knock-out mouse models are used to assess the role of the respective genes on the systemic level. Characterization of these genes will thus provide potential targets for therapeutic intervention of obesity.

An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation

Investigator: Prof. Dr. Martin Wabitsch
Sponsor: Rhythm Pharmaceuticals, Boston, USA
Duration: 2017 - 2020
Partners: Dr. Erica van den Akker (Obesity Center CGG, Rotterdam),
 Prof. Dr. Sadaf Farooqi (University of Cambridge), Prof. Dr. Karine Clément (Sorbonne Université, Paris)
Trial ID: RM-493-015

Patients with mutations in the leptin receptor (LEPR) gene suffer from severe hyperphagia and obesity caused by the lack of activation of the MC4 pathway, which prevents control of appetite and weight. LEPR deficiency represents a very rare genetic disorder of obesity.

Unfortunately, these patients cannot benefit from treatment with metreleptin. The investigational medicinal product setmelanotide is undergoing clinical trials in patients with loss-of-function mutations in the LEPR gene. Representing a new-generation melanocortin-4 receptor (MC4R) agonist, setmelanotide is thought to activate the melanocortin 4 receptor (MC4R), part of a key biological pathway in humans that regulates appetite, caloric intake and energy expenditure. Setmelanotide is expected to become a potential replacement therapy that may restore lost activity in the MC4 pathway, resulting in substantial reductions in hyperphagia and body weight, re-establishing weight and appetite control. Our Division of Paediatric Endocrinology and Diabetes is one of four study centres in Europe enrolling patients in a Phase 3 clinical trial evaluating long-term (one year) safety and efficacy of setmelanotide in LEPR deficiency obesity.



A randomised, multinational, active-controlled, open-labelled, dose finding, double-blinded, parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency REAL3 Study (Novo Nordisk)

Investigator: Prof. Dr. Martin Wabitsch
Sponsor: Novo Nordisk A/S
Duration: 2016 - 2020
Partners: multiple partners (multinational study)
Trial ID: NN8640-4172

Growth hormone is crucial for physical development. Growth hormone is needed for normal growth in children. In adults, growth hormone is needed to maintain the proper amounts of body fat, muscle, and bone. Growth hormone deficiency (GHD) is caused by an inadequate secretion of growth hormone from the pituitary gland and leads to diverse physically and psychologically impairments. GHD negatively affects growth and body composition in childhood and adulthood.

Somapacitan or “NNC0195-0092” is a novel long-acting derivative of human growth hormone for treatment of children and adults with GHD. The children need to be pre-pubertal to avoid interference with the growth spurt during puberty with the treatment effect. The aim of the trial is to investigate efficacy and safety of Somapacitan treatment compared to the treatment with Norditropin® FlexPro® which is administered daily. Daily injections for years or lifetime can be inconvenient and distressing for patients. Somapacitan is designed to be administered only once weekly to improve convenience and compliance. The clinical trial is conducted multinationally in different sites around the world, one of which is our Division of Paediatric Endocrinology and Diabetes at Ulm University Hospital.

Non-interventional, post-marketing surveillance “Saizen®-online”

Investigator: Prof. Dr. Martin Wabitsch
Sponsor: Merck Serono
Duration: since 2015 (15 years follow-up period)
Partners: global partners (international phase IV study)
Trial ID: EMR200104_544

Saizen®, a recombinant human growth hormone (somatropin), is indicated for the treatment of growth hormone deficiency in children and adults, Turner Syndrome, chronic renal failure and children born short for gestational age (SGA). An observational, longitudinal, non-interventional, post-marketing surveillance programme has been initiated to assess the level of adherence under every day conditions and long-term safety and efficacy of therapy with Saizen® in a large number of patients. Our Division Division of Paediatric Endocrinology and Diabetes is one of the study centres involved in the global study.

Post-marketing surveillance to monitor the long-term safety and efficacy of Omnitrope® in infants, children and adolescents (PATRO Children)

Investigator: Prof. Dr. Martin Wabitsch
Sponsor: Sandoz Pharmaceuticals / Hexal AG
Duration: since 2016
Partners: global partners (international phase IV study)
Trial ID: EP00-501

Omnitrope®, a recombinant human growth hormone (somatropin) is used to treat children with growth disorders or genetic disorders like Turner syndrome and Prader-Willi syndrome. It is also used to treat adults with pronounced growth hormone deficiency. Omnitrope® has been used for over a decade since it has been marketed in Europe in 2006. However, some concerns remain about the long-term safety of Omnitrope®, which is administered to the patients on a daily basis. PATRO Children, an observational, longitudinal, non-interventional, post-marketing surveillance programme, investigates the long-term safety and effectiveness assessing the diabetogenic potential of Omnitrope and the risk of malignancies. Our Division of Paediatric Endocrinology and Diabetes is one of the study centres involved in the global study.

European Consortium of Lipodystrophies (ECLip) Registry

Speaker: Prof. Dr. Martin Wabitsch
Duration: since 2012
Partners: European Consortium of Lipodystrophies (ECLip)

Lipodystrophy syndromes are rare diseases characterised by selective deficiency of adipose tissue. They are categorised in different types based on aetiology (genetic or acquired) and distribution of lost adipose tissue affecting the entire body (generalised) or only regions (partial). Lipodystrophy is frequently associated high morbidity and mortality. Patients suffer from hormonal and metabolic disorders resulting in severe comorbidities. Lipodystrophy syndromes occur very rarely and the different types vary widely in their associated comorbidities, complications and courses. Even very experienced experts in this field do not see more than 50-100 patients in their lives. Due to the rarity of lipodystrophy syndromes and the lack of knowledge about these, physicians are unfamiliar with their diagnosis and management. Sensible clinical and basic research into rare diseases such as lipodystrophy syndromes is only possible in multi-location networks with sufficient case numbers. The European Consortium of Lipodystrophies (ECLip) is a network of European clinical and basic-science research groups working in the field of lipodystrophy syndromes. The network aims to increase the basic understanding of this rare disease and to develop ways to better diagnose, prevent and take in charge patients suffering from lipodystrophy syndromes. ECLip has launched a registry intended to improve the research conditions by consolidating information about lipodystrophy syndromes and collecting patient data on an international level. Upon informed consent, data obtained from patients during their clinical visits in participating centres (registry members) are being entered in a web-based registry platform. In our Centre for Rare Diseases (ZSE Ulm) at Ulm University Medical Center, we are treating patients with lipodystrophy syndromes. Our Division of Paediatric Endocrinology and Diabetes is the leading clinical centre coordinating the ECLip Registry. Ulm University is the governing body, the legal institution, where all data entered in the registry is stored. The ECLip Registry will enable the exchange of patient data for scientific evaluations and will help to recruit suitable subjects for clinical studies.

Ulm Birth Cohort Study (UBCS) (“Ulmer Kinderstudie”)

Investigators: Prof. Dr. Hermann Brenner (German Cancer Research Center, Heidelberg), Prof. Dr. Dietrich Rothenbacher (Ulm University), Prof. Dr. Martin Wabitsch
Funding: Federal Ministry for Education and Research (BMBF), German Research Foundation (DFG)
Duration: since 2000

The Ulm Birth Cohort Study (UBCS) was initiated in 2001/2002 at the Department of Gynecology and Obstetrics of Ulm University Medical Center in order to investigate the impact of perinatal and neonatal factors on growth and metabolic diseases in adulthood (for example cardiovascular diseases, allergies, asthma and oncologic diseases). In total, over 1,000 mothers (including mothers with 22 pairs of twins) have agreed to participate in the study. At the time of the birth of the child, basic data have been collected using a questionnaire and biological samples have been obtained. Since then, the children and their parents have been followed up in regular, defined intervals for over 18 years.

One example of the meaningful results recently obtained from our studies: Circulating insulin concentrations reflect the metabolic cardiovascular risk and may trigger weight gain. The UBCS study showed that fasting plasma insulin concentrations of children are significantly correlated with the BMI values that mothers exhibit before pregnancy, and fasting plasma insulin concentrations of children are significantly correlated with maternal, but not with paternal fasting plasma insulin concentrations. Furthermore, the development of the BMI of a child with high fasting plasma insulin concentrations is altered compared to a child with low concentrations. These findings are in line with the concept of perinatal programming of insulin concentrations and BMI development by maternal factors.

Diabetes and Social Jet Lag

Speaker: Dr. Julia von Schnurbein
Funding: German Paediatric Diabetes Association (AGPD), Dr.-Herbert-Schiffers-Stiftung
Duration: 2013 - 2019
Partners: Dr. Claudia Boettcher (Justus Liebig University Giessen), Prof. Dr. Beate Karges (Bethlehem Gesundheitszentrum Stolberg gGmbH, RWTH Aachen University), Dr. Desiree Dunstheimer (Klinikum Augsburg), Dr. Angela Galler (Charité - Universitätsmedizin Berlin), Prof. Till Roenneberg (Ludwig-Maximilians-University Munich), Dr. Celine Vetter (Brigham and Women’s Hospital and Harvard Medical School Boston)

It is well known that lack of sleep increases the risk for development and deterioration of type 2 diabetes. The multicentre prospective study “Diabetes and Social Jet Lag” investigated the impact of lack of sleep, poor sleep quality and of a sleep timing unsuited to the patients natural sleep timing on blood sugar levels in patients with type 1 diabetes. The study showed that reduced sleep quality has a negative impact on HbA1c levels in patients with type 1 diabetes indicating that advice for a better sleep hygiene should maybe be integrated into the counseling of patients with diabetes.

Evidence-based harmonization of follow-up recommendations for endocrine late-effects of TOS and registries of the German Society for Pediatric Oncology and Hematology and development of a database module for the prospective evaluation of the follow-up guideline AWMF-no. 025-030

Speaker: PD Dr. Christian Denzer
Funding: Deutsche Kinderkrebsstiftung e.V. (DKS 2015.11)
Duration: 2015 - 2018
Partners: Prof. Dr. T. Langer, Universität zu Lübeck, Kinder- und Jugendmedizin

New treatment strategies have significantly improved the 5-year survival rate for childhood cancers in the past 40 years. Unfortunately, these treatments are associated with a markedly increased risk for late complications. Endocrine disorders are among the most common late effects, affecting 20 to 50% of survivors. In a preceding project funded by Deutsche Kinderkrebsstiftung (Project-Nr. DKS 2010/16), evidence-based guidelines for long-term endocrine follow-up have been developed by our group (S3 guideline “Endokrinologische Nachsorge nach onkologischen Erkrankungen im Kindes- und Jugendalter”, AWMF registry Nr. 025-030). In our current project, we are revising follow-up recommendations for endocrine late-effects of all currently active as well as all closed therapy studies and registries for pediatric cancers of the GPOH e.V. using an exposure- and risk-centered approach. Harmonization of follow-up recommendations will have a major impact on the implementation of evidence-based clinical care and will furthermore provide the basis for standardized prospective documentation of endocrine late-effects using the well-established database structure of the ‘Late Effects Surveillance System’ (LESS, coordinator: Prof. T. Langer). Prospectively, this dataset will allow for systematic evaluation of current follow-up recommendations and will therefore contribute to continuous improvement of follow-up care.

Optimizing the RIST protocol for the treatment of Glioblastoma patients

Investigators: Dr. Mike-Andrew Westhoff, Dr. Lisa Nonnenmacher, Dr. Stephan Bartholomä, Prof. Dr. Klaus-Michael Debatin
Funding: Förderkreis für tumor- und leukämiekranken Kinder Ulm e.V.
Duration: ongoing

The multimodal RIST Protocol is a cyclic treatment approach where repeated treatment with two pharmacological inhibitors Rapamycin (Sirolimus) and Sprycel (Dasatinib) is followed by several doses of the two chemotherapeutic agents Irinotecan and Temozolomide (TMZ) in a metronomic, low-dose setting. It was initially considered for the treatment of patients with recurrent or refractory Neuroblastoma (Corbacioglu et al., 2013), but has also been applied in a compassionate use setting for other paediatric tumours, such as Glioblastoma (Nonnenmacher et al., 2015). Importantly, the RIST treatment is associated with few side effects and, thus, a good quality of life is often associated with the treatment. Clinically, it significantly improves the life expectancy of approximately a third of the patients whose malignancy had been previously deemed untreatable.

Using our collection of over 100 patient-derived stem cell-like glioblastoma cells we are currently screening cell populations as to whether they respond to the RIST Protocol. Importantly, unlike those tumours presented in the context of the compassionate treatment, these

cells have not been previously exposed to chemo- and/or radiotherapy. Identifying good responders and non-responders we aim to ascertain which factors determine whether a tumour will be responsive to treatment and which additional pathways need to be targeted to convert non-responders to responders.

Evaluation of preschool examination in Baden-Württemberg

Investigator: Prof. Dr. Harald Bode
Sponsor: Ministry of Social Affairs and Integration (State of Baden-Württemberg)
Partners: 38 local health authorities, public health dept. of Baden-Württemberg
Duration: 2015 - 2017

German federal states conduct preschool examinations of children to assess risks to their success in school. In 2009, step 1 of the preschool examination (ESU) in the German federal State Baden-Württemberg was preponed to the second-to-last year of kindergarten (age 4-5) to gain enough time for developmental interventions. Procedures and practice of ESU by local health authorities in step 1 and step 2 (last year of kindergarten) were analyzed from the data of about 90,000 ESUs and from local experiences to infer strengths, weaknesses and requirements for change in the ESU format. Recommendations for improving diagnostic methods and organization of ESU were given.

Additional Projects in Brief

■ GSC 270: International Graduate School in Molecular Medicine Ulm (IGradU)

Faculty from our lab: Prof. Dr. Christian Beltinger, Prof. Dr. Klaus-Michael Debatin, Prof. Dr. Pamela Fischer-Posovszky, apl. Prof. Dr. Lüder H. Meyer, apl. Prof. Dr. Gudrun Strauß

Coordinator: Prof. Dr. Michael Köhl, Institute of Biochemistry and Molecular Biology
Funding: Excellence Initiative of the German Federal and State Governments
Duration: 2007 - 2019
Partners: Additional Departments and Institutes of Ulm University

■ Else Kröner Research College Ulm – Stem cells, aging and malignant transformation

Fellowship Dr. Julia Zinngrebe: "Evaluation of mechanism of resistance against an IAP-antagonists-based therapy in acute lymphoblastic leukemia in children";

Fellowship Dr. Felix Seyfried: "Identifikation und Charakterisierung genetischer Alterationen in apoptosedefizienten Hochrisiko Leukämien und Evaluierung neuer Therapiestrategien im NOD/SCID huALL Mausmodell";

(Supervisors: Prof. Dr. Klaus-Michael Debatin, apl. Prof. Dr. Lüder H. Meyer)

Fellowship Dr. Julia Würtemberger: "PPP2CA as therapeutic target in neuroblastoma" (Supervisor: Prof. Dr. Christian Beltinger)

Coordinator: Prof. Dr. Stephan Stilgenbauer, Department of Internal Medicine III
Funding: Else Kröner-Fresenius Stiftung
Duration: 2011 - 2018
Partners: Additional Departments and Institutes of Ulm University

■ MPN&MPNr Euronet (COST Action)

apl. Prof. Dr. Holger Cario

Coordinator: Dr. Sylvie Hermouet, University of Nantes
Duration: ongoing (externally funded 2009-2013)
Funding: COST Association
Partners: 128 Members in 28 Countries

■ European Congenital Erythrocytosis Consortium (ECE-C)

apl. Prof. Dr. Holger Cario

Curators: Celeste Bento (Portugal), Holger Cario (Ulm),
 Mary Frances McMullin (UK), François Girodon (France)
Duration: Ongoing since 2004
Partners: 15 Laboratories from Europe

■ International Osteopetrosis Registry

on behalf of the Inborn Error Working Party of the EBMT and the European Society of Immunodeficiencies

Coordinator: apl. Prof. Dr. Ansgar Schulz
Partners: multiple participating centres in Europe

Scientific Events

2018

■ Boehringer Ingelheim Ulm University BioCenter (BIU) – 6th Symposium

Organizer: Prof. Dr. Klaus-Michael Debatin, Dr. Lysann Palkowitsch
Partner: Medical Faculty, Boehringer Ingelheim
Date, Venue: 09.11.2018, Ulm

■ European Consortium of Lipodystrophies (ECLip) Registry Meeting

Organizers: Prof. Dr. Martin Wabitsch, Dr. Julia von Schnurbein
Partners: European Consortium of Lipodystrophies (ECLip)
Date, Venue: 22.10.2018, Ulm

■ Villa Vigoni Meeting – Cell Death and Disease

Organizer: Prof. Dr. Klaus-Michael Debatin
Partners: Profs. Krammer (Heidelberg/D), Simon (Bern/CH), Brancolini (Udine/I)
Date, Venue: 27.-30.06.2018, Loven di Menaggio, Italy

■ 6th Symposium of Hematology Today

Organizer: apl. Prof. Dr. Holger Cario
Partner: Dr. Stephan Lobitz (Köln)
Date, Venue: 19.-21.04.2018, Neu-Ulm

■ **BFM Plenary Meeting**

Organizer: Prof. Dr. Klaus-Michael Debatin, apl. Prof. Dr. Lüder H. Meyer
Partners: BFM Study Centers
Date, Venue: 22.-24.03.2018, Ulm

■ **Training Event “The endocrinologic consultation”**

Organizer: Prof. Dr. Martin Wabitsch
Date, Venue: 23.-24.02.2018, Günzburg

2017■ **European Consortium of Lipodystrophies (ECLip) Registry Meeting**

Organizers: Prof. Dr. Martin Wabitsch, Dr. Julia von Schnurbein
Partner: European Consortium of Lipodystrophies (ECLip)
Date, Venue: 07.-08.07.2017, Ulm

■ **Villa Vigoni Meeting – Cell Death and Disease**

Organizer: Prof. Dr. Klaus-Michael Debatin
Partners: Profs. Krammer (Heidelberg/D), Simon (Bern/CH), Brancolini (Udine/I)
Date, Venue: 14.-17.06.2017, Loven di Menaggio, Italy

■ **Boehringer Ingelheim Ulm University BioCenter (BIU) – 5th Symposium**

Organizer: Prof. Dr. Klaus-Michael Debatin, Dr. Lysann Palkowitsch
Partners: Medical Faculty, Boehringer Ingelheim
Date, Venue: 15.-16.05.2017, Ulm

■ **Rare Disease Day**

Organizer: Prof. Dr. Klaus-Michael Debatin
Partner: Center for Rare Diseases (Zentrum für Seltene Erkrankungen – ZSE)
Date, Venue: 28.02.2017, Ulm

2016■ **1st Pediatric Cardiology Symposium**

Organizer: apl. Prof. Dr. Christian Apitz
Date, Venue: 03.12.2016, Ulm

■ **52nd Workshop for Pediatric Research**

Organizer: Prof. Dr. Klaus-Michael Debatin
Partner: German Society of Pediatrics and Adolescent Medicine (DGKJ)
Date, Venue: 27.-28.10.2016, Frankfurt

■ **Training Event “The endocrinologic consultation”**

Organizer: Prof. Dr. Martin Wabitsch
Date, Venue: 14.-15.10.2016, Günzburg

■ **Advanced Seminar in Developmental Endocrinology, Developmental Biology of Gastrointestinal Hormones**

Organizers: Prof. Dr. Martin Wabitsch, Dr. Anja Moss
Partner: European Society for Paediatric Endocrinology (ESPE)
Date, Venue: 03.-04.06.2016, Ulm

■ **Half-yearly symposium of the South German Pediatric Endocrinologists**

Organizers: PD Dr. Christian Denzer, Prof. Dr. Martin Wabitsch
Date, Venue: 16.04.2016, Ulm

■ **Training Course in Social Pediatrics**

Organizer: Prof. Dr. Harald Bode
Partner: Bezirksärztekammer Südwürttemberg
Date, Venue: 11.03., 12.03., 18.03., 19.03., 23.04.2016; Ulm

2015

■ **Training Course in Social Pediatrics**

Organizer: Prof. Dr. Harald Bode
Partner: Bezirksärztekammer Südwürttemberg
Date, Venue: 13.11., 14.11., 20.11., 21.11.2015, 23.01.2016; Ulm

■ **Training Event “The endocrinologic consultation”**

Organizer: Prof. Dr. Martin Wabitsch
Date, Venue: 03.-04.07.2015, Günzburg

■ **4th Symposium of Hematology Today: Hematology and Friends**

Organizer: apl. Prof. Dr. Holger Cario
Partner: Dr. Stephan Lobitz (Berlin)
Date, Venue: 23.-25.04.2015, Ulm

■ **51st Workshop for Pediatric Research**

Organizer: Prof. Dr. Klaus-Michael Debatin
Partner: German Society of Pediatrics and Adolescent Medicine (DGKJ)
Date, Venue: 16.-17.04.2015, Göttingen

■ **Boehringer Ingelheim Ulm University BioCenter (BIU) – 4th Symposium**


Organizer: Prof. Dr. Klaus-Michael Debatin, Dr. Lysann Palkowitsch
Partners: Medical Faculty, Boehringer Ingelheim
Date, Venue: 14.04.2015, Ulm

■ **8th Workshop in Neuropediatrics**

Organizer: Prof. Dr. Harald Bode
Date, Venue: 18.03.2015, Ulm

■ **Meetings of BMBF Network “Adolescents with Extreme Obesity”, YES-Study**

Organizers: Prof. Dr. Martin Wabitsch, Dr. Julia von Schnurbein
Partner: Federal Ministry for Education and Research (BMBF)
Date, Venue: several meetings 2015-2018, Ulm



Prizes and Awards

2018

- **Dr. Salih Demir**
Best oral contribution
[11th Biennial Childhood Leukemia and Lymphoma Symposium, Helsinki, 2018](#)
- **Dr. Kerstin Felgentreff**
Margarete von Wrangell-Scholarship
(*Habilitationsprogramm für Frauen*)
[State of Baden-Württemberg](#)
- **Dr. Vera Münch**
Franziska-Kolb Prize 2018
[Franziska Kolb Foundation](#)
- **Dr. Melanie Schirmer**
STEPS-Award for “Deletionen auf Chromosom 16p11.2 sind assoziiert mit frühkindlicher Adipositas – 3 Fallberichte”
[German Association for Pediatric Endocrinology and Diabetology \(DGKED\)](#)
- **Dr. Hanna Schmidt**
Hertha-Nathorff Scholarship
[Medical Faculty, Ulm University](#)
- **Felix Stirnweiß**
Experimental Medicine Scholarship 2018
[Medical Faculty, Ulm University](#)
- **Dr. Mike-Andrew Westhoff**
Teaching Award (*Lehrbonus*) 2018 for exceptional teaching qualities
[Ulm University](#)
- **Dr. Julia Zinngrebe**
Margarete von Wrangell-Scholarship
(*Habilitationsprogramm für Frauen*)
[State of Baden-Württemberg](#)
- **Dr. Julia Zinngrebe**
Invited Participation as Young Scientist
[68th Lindau Nobel Laureate Meeting](#)

2017

- **Dr. Stephanie Brandt**
Hertha-Nathorff Scholarship
[Medical Faculty, Ulm University](#)
- **Elena Dorothea Brenner**
Experimental Medicine Scholarship 2017/18
[Medical Faculty, Ulm University](#)
- **PD Dr. Christian Denzer**
AGPD Abstract Award (AAA) for “Insulinsensitivität und Betazellfunktion bei adipösen Kindern und Jugendlichen”, 2017
[Arbeitsgemeinschaft für Pädiatrische Diabetologie \(AGPD\)](#)
- **Prof. Dr. Pamela Fischer-Posovszky**
Heisenberg Professorship, starting 2019
[German Research Foundation \(DFG\)](#)
- **Verena Janina Herbener**
Experimental Medicine Scholarship 2017
[Medical Faculty, Ulm University](#)
- **Dr. Daniel Tews**
STEPS-Award for “Stabile Überexpression von UCP1 in humanen Präadipozyten als ein Modell zur Untersuchung der braunen Fettzellfunktion”
[German Association for Pediatric Endocrinology and Diabetology \(DGKED\)](#)
- **Dr. Julia Zinngrebe**
Doctoral Thesis Award
[Ulmer Universitätsgesellschaft](#)
- **Dr. Julia Zinngrebe**
Hertha-Nathorff Scholarship
[Medical Faculty, Ulm University](#)

2016

- **Maximilian Auerhammer**
Experimental Medicine Scholarship 2016/17
[Medical Faculty, Ulm University](#)

- **Sophie Kiener**
Experimental Medicine Scholarship
2016/17
[Medical Faculty, Ulm University](#)
- **Malena Klingspor**
Experimental Medicine Scholarship
2016/17
[Medical Faculty, Ulm University](#)
- **Dr. Katja Kohlsdorf**
STEPS-Award for “Frühkindlicher BMI-Verlauf bei monogener Adipositas auf Basis einer Mutation im Leptin- oder Leptinrezeptor-Gen”
[German Association for Pediatric Endocrinology and Diabetology \(DGKED\)](#)
- **Dr. Johannes Krämer**
Research Funding 2016
[German Association of Pediatric Cardiology \(DGPK\)](#)
- **Malcom Meyer**
Experimental Medicine Scholarship
2016/17
[Medical Faculty, Ulm University](#)
- **Dr. Felix Seyfried**
2016 ASH Abstract Achievement Award
[American Society of Hematology](#)
- **Ning Wei**
Experimental Medicine Scholarship 2016
[Medical Faculty, Ulm University](#)
- **Prof. Dr. Pamela Fischer-Posovszky**
Mileva-Einstein-Maric Prize 2015
[Ulm University](#)
- **Jan-Bernd Funcke**
Travel Grant DGKED/Merck Serono
[German Association for Pediatric Endocrinology and Diabetology \(DGKED\)](#)
- **Niklas Gäbler**
Experimental Medicine Scholarship 2015
[Medical Faculty, Ulm University](#)
- **Benedikt Haggemüller**
Experimental Medicine Scholarship 2015
[Medical Faculty, Ulm University](#)
- **Sophia Neusser**
Experimental Medicine Scholarship
2014/15
[Medical Faculty, Ulm University](#)
- **PD Dr. Carsten Posovszky**
Ludwig-Demling Research Prize
[German Crohn's and Colitis Association \(DCCV\)](#)
- **PD Dr. Carsten Posovszky**
Research Prize
[German Speaking Society of Pediatric Gastroenterology and Nutrition \(GPGE\)](#)
- **Julian Roos**
Science School “Non-coding RNAs in Paediatric Endocrinology” in Veyrier Le Lac, France
[European Society for Paediatric Endocrinology](#)

2015

- **Dr. Stephanie Brandt**
AGPD Abstract Award (AAA) for “Zusammenhang zwischen dem BMI der Mutter vor der Schwangerschaft und der BMI-Trajektorie des Kindes im Kindesalter - Ergebnisse aus der Ulmer Kinderstudie”, 2015
[Arbeitsgemeinschaft für Pädiatrische Diabetologie \(AGPD\)](#)
- **Julian Roos**
Travel grant “Forum Wachsen” 2015
[German Association for Pediatric Endocrinology and Diabetology \(DGKED\)](#)
- **Dr. Julia von Schnurbein**
Hertha-Nathorff Scholarship
[Medical Faculty, Ulm University](#)

■ **Dr. Daniel Tews**

Travel grant “Forum Wachsen” 2015
German Association for Pediatric Endocrinology and Diabetology (DGKED)

■ **Dr. Daniel Tews**

Klaus-Kruse Stipend 2015
German Association for Pediatric Endocrinology and Diabetology (DGKED)

Guest Scientists

2018

■ **Belinda Lennerz, M.D., Ph.D.**

Boston Children’s Hospital, Division of Endocrinology, USA
regular visits in 2015-2018

2017

■ **Ivana Vorgucin, M.D., Ph.D.**

Institute for child and youth health care of Vojvodina, University of Novi Sad, Serbia
ESPE Clinical Fellowship
March-June 2017

■ **Prof. Dr. Jiwu Wei**

Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, China

2016

■ **Dr. Susanne Trombley**

Uppsala University, Sweden
June 2016

■ **Dr. Agne Kulyte**

Karolinska Institute, Stockholm, Sweden
January 2016

2015

■ **Dr. Maxime Denis**

Montreal Heart Institute, Canada
October 2015

■ **Diya Trust**

Staffordshire University, UK
June-August 2015

■ **Dr. Elena Inzaghi**

University Tor Vergata, Rome, Italy
January-February 2015

■ **Fernando Tavares Fedumenti**

Brazil
October 2014-June 2015

International Cooperation Partners

■ Children’s Cancer Institute Australia and Sydney Children’s Hospital, University of New South Wales, Sydney, Australia

■ Center for Medical Genetics, Ghent University, Belgium

■ Pediatric Stem Cell Transplantation, Willem Alexander Pediatric Hospital, Leiden University, Belgium

■ Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, China

■ Minerva Foundation Institute for Medical Research, Helsinki, Finland

■ Biocenter Oulu, University of Oulu, Finland

■ Pediatric Immunology, Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France

■ Department of Bone Marrow Transplantation and Cancer Immunology, Hadassah Medical Center, Jerusalem, Israel

■ Human Genome Lab, Humanitas Research Hospital, Milan, Italy

■ Department of Women’s and Children’s Health, University of Padova, Italy

- Department of Biology, Nazarbayew University, Astana, Kazakhstan
- Division of Molecular Medicine and Gene Therapy, Lund University, Sweden
- MRC Metabolic Diseases Unit, Metabolic Research Laboratories, University of Cambridge, England, UK
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Scotland, UK
- Laboratory of Clinical Immunology and Microbiology, NIH National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
- Department of Pathology and Cellular Biology, Columbia University Medical Center, New York, USA
- The Children's Hospital of Philadelphia - Research Institute (CHOP), Philadelphia, PA, USA
- Sharp Memorial Hospital, San Diego, CA, USA

Doctorates Conferred

Dr. med. = MD;

Dr. rer. nat. / Dr. biol. hum. = PhD

2018

- **Jan-Bernd Funcke, Dr. rer. nat.**
Diagnosis and characterization of leptin mutation causing severe early-onset obesity
- **Annika Goß, Dr. rer. nat.**
Oncolytic measles virus MV-NIS controls relapsed pediatric ALL patient-derived xenografts
- **Ines Mender, Dr. med.**
Anwendbarkeit und prädiktiver Wert des Thompson Scores bei Kindern mit perinataler Asphyxie im Rahmen der Hypothermietherapie
- **Eva Neuwirth, Dr. med.**
Mortalität und Morbidität bei Ligatur des persistierenden Ductus Arteriosus Botalli bei Frühgeborenen unter 1500g auf einer neonatologischen Intensivstation
- **Lara Riehl, Dr. rer. nat.**
Targeted deep sequencing to identify novel blood biomarkers of neuroblastoma
- **Silke Streiftau, Dr. med.**
Langfristige Entwicklungsprognose nach extremer Frühgeburtlichkeit
- **Franziska Stupp, Dr. med.**
Lebensqualität und Elternzufriedenheit nach Adenotomie und Adenotonsillotomie im Kindesalter - Eine prospektive Studie -
- **Felix Zirngibl, Dr. med.**
Attenuated oncolytic measles virus as a new therapeutic approach against pediatric acute lymphoblastic leukemia: a proof of principle (*summa cum laude*)
- **Verena Zoller, Dr. rer. nat.**
Regulation of adipose tissue homeostasis by the death ligand TRAIL

2017

- **Ina Karen Alberts, Dr. med.**
Leptin- und Adiponektin Gehalt im Nabelschnurblut und die Auswirkungen auf die Körperfettmasse sowie die Körperfettverteilung der Kinder
- **Louise Cypionka, Dr. med.**
Übergewicht und Adipositas nach akuter lymphatischer Leukämie und Morbus Hodgkin im Kindes- und Jugendalter
- **Salih Demir, PhD**
Restoration of mutant TP53 as a therapeutic targeting strategy in pediatric B-cell precursor acute lymphoblastic leukemia

■ **Lioba Doornekamp-Zähr, Dr. med.**

Prävalenz endokrinologischer Spätfolgen nach onkologischen Erkrankungen im Kindes- und Jugendalter - eine unizentrische Fallserienuntersuchung

■ **Stefanie Havers, Dr. med.**

Zerebrale Oxygenierung während der postnatalen Adaption von Neugeborenen in Abhängigkeit des Geburtsmodus und Gestationsalters

■ **Clarissa Klein, Dr. med.**

Verifikation potentieller Interaktionspartner des Zellzyklusregulators p27Kip1

■ **Kathy Kohleis, Dr. biol. hum.**

Seelische Gesundheit von Kindern und Jugendlichen mit infantiler Zerebralparese und Spina bifida

■ **Joanna Meßmann, Dr. rer. nat.**

Myeloid-derived suppressor cells (MDSCs) as modulators of graft-versus-host disease (GVHD)

■ **Vera Münch, Dr. rer. nat.**

VEGF – A Novel Therapeutic Target in Central Nervous System Acute Lymphoblastic Leukaemia

■ **Nicola Roßmann, Dr. med.**

Verlauf und Outcome der Anwendung von permissiver Hyperkapnie bei immun-supprimierten Kindern mit Atemversagen

■ **Kolja Sievert, Dr. med.**

Inpatient Long-Term Therapy for Extremely Obese Adolescents and Young Adults: Reduction of the Visceral Fat and Improvement of Cardiovascular Risk Profile

■ **Sebastian Ulrich, Dr. med.**

The Death-Associated Protein Kinase 1 (DAPK1) - prognostic relevance in pediatric acute lymphoblastic leukemia (ALL) and evaluation as a therapeutic target

■ **Julia Zinngrebe, Dr. med.**

The role of linear ubiquitination in toll-like receptor 3 signalling (summa cum laude)

2016

■ **Richard Blossey, Dr. med.**

Die Bedeutung der Zelltodinduktion bei der in vitro Interaktion von MDSCs und T-Zellen

■ **Amina Hochweber, Dr. med.**

Die Entwicklung von Körpergewicht und Körpergröße von Geburt bis zum Schulalter bei Ulmer Schulkindern

■ **Daniela Holzner, Dr. med.**

Thyreoidale Dysfunktion und Steatosis hepatis bei übergewichtigen Kindern und Jugendlichen

■ **Hannah Kunze, Dr. med.**

Die Bedeutung phosphorylierter Signaltransduktionsproteine in der akuten pädiatrischen lymphoblastischen Leukämie

■ **Verena Panitz, Dr. med.**

Regulation of human granzyme B-producing plasmacytoid dendritic cells by viral stimuli

■ **Matthias Schneider, Dr. med.**

A paired comparison between glioblastoma cancer stem cells and differentiated cells in view of proliferation, resistance to conventional therapies and tumour-initiating capabilities

■ **Felix Seyfried, Dr. med.**

Characterization of aspects of leukemia biology and association with patient prognosis (summa cum laude)

■ **Jana Stursberg, Dr. med.**

Charakterisierung prognostischer Faktoren der pädiatrischen akuten lymphatischen Leukämie auf Genexpressions- und funktioneller Ebene

■ **Ivana Zagotta, PhD**

The Effect of Resveratrol on Obesity Associated Fibrosis in Adipocytes

2015

■ **Eveliina Enlund, PhD**

Role of MicroRNAs in the Pathophysiology of Obesity

■ **Md. Nabiul Hasan, Dr. biol. hum.**

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia as a novel treatment strategy

Habitations Conferred

2018

■ **Christian Denzer, PD Dr. med.**

Körperliche Entwicklung und metabolische Komorbidität bei adipösen Kindern und Jugendlichen

2015

■ **Carsten Posovszky, PD Dr. med.**

Pathophysiologie angeborener Erkrankungen des Intestinums

■ **Catharina Schütz, PD Dr. med.**

Monogenic immunodeficiencies: a spectrum from severe immunodeficiency to mild immune dysregulation with emphasis on RAG deficiencies



Publications in Scientific Journals

IF = Journal impact factor

2018

1. [Point shear wave elastography of the pancreas in patients with cystic fibrosis: a comparison with healthy controls.](#)
Abdom Radiol (NY). 2018; 43(9): 2384-2390 (IF=1.506)
Pfahler MHC, Kratzer W, [Leichsenring M](#), Graeter T, Schmidt SA, Wendlik I, Lormes E, Schmidberger J, [Fabricius D](#)
2. [BARI-AD: Leitlinien-basiertes Interview als Grundlage psychologischer Stellungnahmen vor einem Adipositas-chirurgischen Eingriff bei Adoleszenten](#)
Adipositas. 2018; 12(03): 134-142
Ardelt-Gattinger E, Gattinger E, Andersen B, Miller K, Kreuzer C, Meindl M, Metzger R, Ring-Dimitriou S, Siegfried W, Studtmann L, [Wabitsch M](#), Weiner S, Brix J, Weghuber D
3. [Epidemiologie des Übergewichts und der Adipositas bei Kindern und Jugendlichen anhand von deutschen Schuleingangsdaten](#)
Adipositas. 2018; 12(01): 10-15
[Brandt S](#), [Moß A](#), Klenk J, Kromeyer-Hauschild K, [Wabitsch M](#)
4. [True Colours - Heterogenität des Fettgewebes](#)
Adipositas. 2018; 12(04): 193-197
[Fischer-Posovszky P](#), [Tews D](#)
5. [Monogene Formen der Adipositas beim Menschen](#)
Adipositas. 2018; 12(04): 162-167
[Herrmann G](#), [Wabitsch M](#), [von Schnurbein J](#)
6. [Kongressausgabe zur 34. Jahrestagung der DAG und zur 12. Diabetes Herbsttagung der DDG](#)
Adipositas. 2018; 12(03): 109-109
[Wabitsch W](#)
7. [Distinct Effects of IL-6 Classic and Trans-Signaling in Bone Fracture Healing.](#)
Am J Pathol. 2018; 188(2): 474-490 (IF=4.069)
Prystaz K, Kaiser K, Kovtun A, Haffner-Luntzer M, Fischer V, Rapp AE, Liedert A, [Strauss G](#), Waetzig GH, Rose-John S, Ignatius A
8. [Efficacy and safety of methylene blue in the treatment of malaria: a systematic review.](#)
BMC Med. 2018; 16(1): 59 (IF=9.088)
Lu G, Nagbanshi M, Goldau N, Mendes Jorge M, [Meissner P](#), Jahn A, Mockenhaupt FP, Müller O
9. [IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.](#)
Blood. 2018; 132(15): 1614-1617 (IF=15.132)
Alsadeq A, Lenk L, Vadakumchery A, Cousins A, Vokuhl C, Khadour A, Vogiatzi F, [Seyfried E](#), [Meyer LH](#), [Cario G](#), Hobeika E, [Debatin KM](#), Halsey C, Schrappe M, Schewe DM, Jumaa H
10. [Identification of a new exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.](#)
Blood. 2018; 132(5): 469-483 (IF=15.132)
Lenglet M, Robriquet F, Schwarz K, Camps C, Couturier A, Hoogewijs D, Buffet A, Knight SJL, Gad S, Couvé S, Chesnel F, Pacault M, Lindenbaum P, Job S, Dumont S, Besnard T, Cornec M, Dreau H, Pentony M, Kvikstad E, Deveaux S, Burnichon N, Ferlicot S, Vilaine M, Mazzella JM, Airaud F, Garrec C, Heidet L, Irtan S, Mantadakis E, Bouchireb K, [Debatin KM](#), Redon R, Bezieau S, Bressac-de Paillerets B, Teh BT, Girodon F, Randi ML, Putti MC, Bours V, Van Wijk R, Göthert JR, Kattamis A, Janin N, Bento C, Taylor JC, Arlot-Bonnemains Y, Richard S, Gimenez-Roqueplo AP, [Cario H](#), Gardie B
11. [Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.](#)
Blood. 2018; 131(26): 2929-2942 (IF=15.132)
Wang F, [Demir S](#), Gehringer F, Osswald CD, [Seyfried E](#), [Enzenmüller S](#), [Eckhoff SM](#), Maier T, Holzmann K, [Debatin KM](#), Wirth T, [Meyer LH](#), Ushmorov A
12. [Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.](#)
Blood Adv. 2018; 2(19): 2550-2553
[Schuetz C](#), [Hoenig M](#), Moshous D, Weinstock C, Castelle M, Bendavid M, Shimano K, Tolbert V, [Schulz AS](#), Dvorak CC
13. [Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product \(MSC-FFM\).](#)
Bone Marrow Transplant. 2018; 53(7): 852-862 (IF=4.497)
Bader P, Kuçi Z, Bakhtiar S, Basu O, Bug G, Dennis M, Greil J, Barta A, Kállay KM, Lang P, Lucchini G, Pol R, [Schulz A](#), Sykora KW, von Luetichau I, Herter-Sprie G, Uddin MA, Jenkin P, Alsultan A, Buechner J, Stein J, Kelemen A, Jarisch A, Soerensen J, Salzmann-Manrique E, Hutter M, Schäfer R, Seifried E, Klingebiel T, Bonig H, Kuçi S
14. [Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.](#)
Bone Marrow Transplant. 2018; 53(2): 138-145 (IF=4.497)
Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, Lankester A, Locatelli F, Pagliuca A, Peters C, Richardson PG, [Schulz AS](#), Sedlacek P, Stein J, Sykora KW, Toporski J, Trigos E, Vetteranta K, Wachowiak J, Wallhult E, Wynn R, Yaniv I, Yesilipek A, Mohty M, Bader P
15. [Recent advances in understanding the pathogenesis and management of reticular dysgenesis.](#)
Br J Haematol. 2018; 180(5): 644-653 (IF=5.128)
[Hoenig M](#), Pannicke U, Gaspar HB, Schwarz K

16. [Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trial.](#)
Br J Haematol. 2018; 183(1): 104-109 (IF=5.128)
Kuhlen M, Bader P, Sauer M, Albert MH, Gruhn B, GÜngör T, Kropshofer G, Lang P, Lawitschka A, Metzler M, Pentek F, Rossig C, Schlegel PG, Schrappe M, Schrum J, Schulz A, Schwinger W, von Stackelberg A, Strahm B, Suttrop M, Luettichau IT, Wößmann W, Borkhardt A, Meisel R, Poetschger U, Glogova E, Peters C
17. [Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.](#)
Cell Death Differ. 2018; 25(3): 486-541 (IF=8.000)
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkenkin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G
18. [Cell death-based treatment of childhood cancer.](#)
Cell Death Dis. 2018; 9(2): 116 (IF=5.638)
Westhoff MA, Marschall N, Grunert M, Karpel-Massler G, Burdach S, Debatin KM
19. [LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.](#)
Clin Cancer Res. 2018; 24(22): 5772-5783 (IF=10.199)
Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, de Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C
20. [Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.](#)
Clin Cancer Res. 2018; 24(21): 5392-5406 (IF=10.199)
Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TTT, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD
21. [Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.](#)
Clin Cancer Res. 2018; 24(16): 3941-3954 (IF=10.199)
Zhang Y, Ishida CT, Ishida W, Lo SL, Zhao J, Shu C, Bianchetti E, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Canoll P, Siegelin MD
22. [Targetted inhibition of CD74 attenuates adipose COX-2-MIF-mediated M1 macrophage polarization and retards obesity-related adipose tissue inflammation and insulin resistance.](#)
Clin Sci (Lond). 2018; 132(14): 1581-1596 (IF=5.22)
Chan PC, Wu TN, Chen YC, Lu CH, Wabitsch M, Tian YF, Hsieh PS
23. [Radiation and Brain Tumors: An Overview.](#)
Crit Rev Oncog. 2018; 23(1-2): 119-138
Grunert M, Kassubek R, Danz B, Klemenz B, Hasslacher S, Stroh S, Schneelee L, Langhans J, Ströbele S, Barry SE, Zhou S, Debatin KM, Westhoff MA
24. [Area Deprivation and Regional Disparities in Treatment and Outcome Quality of 29,284 Pediatric Patients With Type 1 Diabetes in Germany: A Cross-sectional Multicenter DPV Analysis.](#)
Diabetes Care. 2018; 41(12): 2517-2525 (IF=13.397)
Auzanneau M, Lanzinger S, Bohn B, Kroschwald P, Kuhnle-Krahl U, Holterhus PM, Placzek K, Hamann J, Bachran R, Rosenbauer J, Maier W, DPV Initiative
25. [Leptin Replacement Reestablishes Brain Insulin Action in the Hypothalamus in Congenital Leptin Deficiency.](#)
Diabetes Care. 2018; 41(4): 907-910 (IF=13.397)
Frank-Podlech S, von Schnurbein J, Veit R, Heni M, Machann J, Heinze JM, Kullmann S, Manzoor J, Mahmood S, Häring HU, Preissl H, Wabitsch M, Fritsche A
26. [Increased Ifi202b/IFI16 expression stimulates adipogenesis in mice and humans.](#)
Diabetologia. 2018; 61(5): 1167-1179 (IF=6.023)
Stadion M, Schwerbel K, Graja A, Baumeier C, Rödiger M, Jonas W, Wolfrum C, Staiger H, Fritsche A, Häring HU, Klötting N, Blüher M, Fischer-Posovszky P, Schulz TJ, Joost HG, Vogel H, Schürmann A

27. [Obesity and Diabetes mellitus](#)
Diabetologie und Stoffwechsel. 2018; 13(2): S192-S197 (IF=0.868)
Hauner H, [Moss A](#), Berg A, Bischoff SC, Colombo-Benkmann M, Ellrott T, Kanthak U, Kunze D, Stefan N, Teufel M, [Wabitsch M](#), Wirth A
28. [Methylenblau-Kombinationstherapie: Wieder eine Schlüsselrolle bei Malaria](#)
Dtsch Arztebl Int. 2018; 115(27-28): S28-29 (IF=3.89)
Müller O, [Meißner P](#)
29. [PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents.](#)
Eur J Cancer. 2018; 103: 227-237 (IF=7.191)
Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Baust K, Bautz A, Beck JD, Berger C, Binder H, Borgmann-Staudt A, Broer L, [Cario H](#), Casagrande L, Clemens E, Deuster D, de Vries A, Dirksen U, Falck Winther J, Fosså S, Font-Gonzalez A, Grandage V, Haupt R, Hecker-Nolting S, Hjorth L, Kaiser M, Kenborg L, Kepak T, Képáková K, Knudsen LE, Krawczuk-Rybak M, Kruseova J, Kuehni CE, Kunstreich M, Kuonen R, Lackner H, Leiper A, Loeffen EAH, Luks A, Modan-Moses D, Mulder R, Parfitt R, Paul NW, Ranft A, Ruud E, Schilling R, Spix C, Stefanowicz J, Strauß G, Uitterlinden AG, van den Berg M, van der Kooi AL, van Dijk M, van Leeuwen F, Zolk O, Zöller D, Kaatsch P, PanCareLIFE consortium
30. [Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.](#)
Eur J Haematol. 2018; 101(6): 791-797 (IF=2.595)
Jarisch A, Salzmann-Manrique E, [Cario H](#), Grosse R, Soerensen J, Fischer R, [Schulz A](#), Hammerstingl R, Wunderlich A, Bader P
31. [Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study.](#)
Front Immunol. 2018; 9: 1841 (IF=5.511)
Salzmann-Manrique E, Bremm M, Huenecke S, Stech M, Orth A, Eylich M, [Schulz A](#), Esser R, Klingebiel T, Bader P, Herrmann E, Koehl U
32. [Successful Resuscitation in a Model of Asphyxia and Hemorrhage to Test Different Volume Resuscitation Strategies. A Study in Newborn Piglets After Transition.](#)
Front Pediatr. 2018; 6: 192 (IF=2.335)
[Mendler MR](#), [Schwarz S](#), [Hechenrieder L](#), [Kurth S](#), Weber B, Höfler S, Kalbitz M, Mayer B, [Hummler HD](#)
33. [Potts Shunt to Be Preferred Above Atrial Septostomy in Pediatric Pulmonary Arterial Hypertension Patients: A Modeling Study.](#)
Front Physiol. 2018; 9: 1252 (IF=3.394)
Delhaas T, Koeken Y, Latus H, [Apitz C](#), Schranz D
34. [Comparison of Fatty Acid and Gene Profiles in Skeletal Muscle in Normal and Obese C57BL/6J Mice before and after Blunt Muscle Injury.](#)
Front Physiol. 2018; 9: 19 (IF=3.394)
Werner JU, Tödter K, Xu P, Lockhart L, Jähnert M, Gottmann P, Schürmann A, Scheja L, [Wabitsch M](#), Knippschild U
35. [Diet-Induced Obesity Affects Muscle Regeneration After Murine Blunt Muscle Trauma-A Broad Spectrum Analysis.](#)
Front Physiol. 2018; 9: 674 (IF=3.394)
Xu P, Werner JU, Milerski S, Hamp CM, Kuzenko T, Jähnert M, Gottmann P, de Roy L, Warnecke D, Abaei A, Palmer A, Huber-Lang M, Dürselen L, Rasche V, Schürmann A, [Wabitsch M](#), Knippschild U
36. [Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM \(S2k-Level, AWMF Registry No. 015/082, November 2017\) - Recommendations and Statements for Girls and Women.](#)
Geburtshilfe Frauenheilkd. 2018; 78(6): 567-584 (IF=1.291)
Dittrich R, Kliesch S, Schüring A, Balcerak M, Baston-Büst DM, Beck R, Beckmann MW, Behringer K, Borgmann-Staudt A, Cremer W, [Denzer C](#), Diemer T, Dorn A, Fehm T, Gaase R, Germeyer A, Geue K, Ghadjar P, Goeckenjan M, Götte M, Guth D, Hauffa BP, Hehr U, Hetzer F, Hirschenhain J, Hoffmann W, Hornemann B, Jantke A, Kantenich H, Kiesel L, Köhn FM, Korell M, Lax S, Liebenthron J, Lux M, Meißner J, Micke O, Nassar N, Nawroth F, Nordhoff V, Ochsendorf F, Oppelt PG, Pelz J, Rau B, Reisch N, Riesenbeck D, Schlatt S, Sender A, Schwab R, Siedentopf F, Thorn P, Wagner S, Wildt L, Wimberger P, Wischmann T, von Wolff M, Lotz L
37. [\[Preschool Examination in Baden-Wuerttemberg: Results of a Survey by Local Health Authorities\].](#)
Gesundheitswesen. 2018; 80(4): 325-331 (IF=0.993)
[Bode H](#)
38. [Variable impairment of platelet functions in patients with severe, genetically linked immune deficiencies.](#)
Haematologica. 2018; 103(3): 540-549 (IF=9.09)
Nagy M, Mastenbroek TG, Mattheij NJA, de Witt S, Clemetson KJ, Kirschner J, [Schulz AS](#), Vraetz T, Speckmann C, Braun A, Cosemans JMEM, Zieger B, Heemskerk JWM
39. [Leukemia reconstitution is driven by cells in early cell cycle and low metabolic state.](#)
Haematologica. 2018; 103(6): 1008-1017 (IF=9.09)
[Trentin L](#), [Queudeville M](#), [Eckhoff SM](#), [Hasan N](#), [Münch V](#), [Boldrin E](#), [Seyfried F](#), [Enzenmüller S](#), [Debatin KM](#), [Meyer LH](#)
40. [Targeting NSG Mice Engrafting Cells with a Clinically Applicable Lentiviral Vector Corrects Osteoclasts in Infantile Malignant Osteopetrosis.](#)
Hum Gene Ther. 2018; 29(8): 938-949 (IF=4.241)
Moscatelli I, Löfvall H, Schneider Thudium C, Rothe M, Montano C, Kertész Z, [Sirin M](#), [Schulz A](#), Schambach A, Henriksen K, Richter J

41. [MYO5B, STX3, and STXBP2 mutations reveal a common disease mechanism that unifies a subset of congenital diarrheal disorders: A mutation update.](#)
Hum Mutat. 2018; 39(3): 333-344 (IF=5.359)
Dhekne HS, Pylypenko O, Overeem AW, Ferreira RJ, van der Velde KJ, Rings EHHM, [Posovszky C](#), Swertz MA, Houdusse A, van IJendoorn SCD
42. [Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.](#)
Int J Cardiol. 2018; 272S: 37-45 (IF=4.034)
Hoepfer MM, [Apitz C](#), Grünig E, Halank M, Ewert R, Kaemmerer H, Kabitz HJ, Kähler C, Klose H, Leuchte H, Ulrich S, Olsson KM, Distler O, Rosenkranz S, Ghofrani HA
43. [Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018.](#)
Int J Cardiol. 2018; 272S: 79-88 (IF=4.034)
Kaemmerer H, [Apitz C](#), Brockmeier K, Eicken A, Gorenflo M, Hager A, de Haan F, Huntgeburth M, Kozlik-Feldmann RG, Miera O, Diller GP
44. [Screen Time, Physical Activity and Self-Esteem in Children: The Ulm Birth Cohort Study.](#)
Int J Environ Res Public Health. 2018; 15(6) (IF=2.145)
Braig S, Genuneit J, Walter V, [Brandt S](#), [Wabitsch M](#), Goldbeck L, Brenner H, Rothenbacher D
45. [Impact of X-ray Exposure on the Proliferation and Differentiation of Human Pre-Adipocytes.](#)
Int J Mol Sci. 2018; 19(9) (IF=3.687)
Shreder K, Rapp F, Tsoukala I, Rzeznik V, [Wabitsch M](#), [Fischer-Posovszky P](#), Fournier C
46. [Early childhood BMI trajectories in monogenic obesity due to leptin, leptin receptor, and melanocortin 4 receptor deficiency.](#)
Int J Obes (Lond). 2018; 42(9): 1602-1609 (IF=5.151)
Kohlsdorf K, Nunziata A, Funcke JB, [Brandt S](#), [von Schnurbein J](#), [Vollbach H](#), Lennerz B, Fritsch M, Greber-Platzer S, Fröhlich-Reiterer E, Luedeke M, Borck G, [Debatin KM](#), [Fischer-Posovszky P](#), [Wabitsch M](#)
47. [Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.](#)
Int J Oncol. 2018; 53(5): 1881-1896 (IF=3.333)
[Hasslacher S](#), [Schneele L](#), Stroh S, [Langhans J](#), [Zeiler K](#), [Kattner P](#), Karpel-Massler G, Siegelin MD, [Schneider M](#), Zhou S, Grunert M, Halatsch ME, [Nonnenmacher L](#), [Debatin KM](#), [Westhoff MA](#)
48. [Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study.](#)
J Allergy Clin Immunol. 2018; 141(3): 1036-1049.e5 (IF=13.258)
Barzaghi F, Amaya Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, Nademi Z, Slatter MA, Ulloa ER, Shcherbina A, Roppelt A, Worth A, Silva J, Aiuti A, Murguia-Favela L, Speckmann C, Carneiro-Sampaio M, Fernandes JF, Baris S, Ozen A, Karakoc-Aydiner E, Kiykim A, [Schulz A](#), [Steinmann S](#), Notarangelo LD, Gambineri E, Lionetti P, Shearer WT, Forbes LR, Martinez C, Moshous D, Blanche S, Fisher A, Ruemmele FM, Tissandier C, Ouachee-Chardin M, Rieux-Laucat F, Cavazzana M, Qasim W, Lucarelli B, Albert MH, Kobayashi I, Alonso L, Diaz De Heredia C, Kanegane H, Lawitschka A, Seo JJ, Gonzalez-Vicent M, Diaz MA, Goyal RK, Sauer MG, Yesilipek A, Kim M, Yilmaz-Demirdag Y, Bhatia M, Khlevner J, Richmond Padilla EJ, Martino S, Montin D, Neth O, Molinos-Quintana A, Valverde-Fernandez J, Broides A, Pinsk V, Ballauf A, Haerynck F, Bordon V, Dhooge C, Garcia-Lloret ML, Bredius RG, Kałwak K, Haddad E, Seidel MG, Duckers G, Pai SY, Dvorak CC, Ehl S, Locatelli F, Goldman F, Gennery AR, Cowan MJ, Roncarolo MG, Bacchetta R, Primary Immune Deficiency Treatment Consortium (PIDTC) and the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT)
49. [Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series.](#)
J Allergy Clin Immunol. 2018; 142(5): 1628-1631.e4 (IF=13.258)
Belderbos ME, Gennery AR, Dvorak CC, Blok HJ, Eikema DJ, Silva JMF, Veys P, Neven B, Buckley R, Cole T, Cowan MJ, Goebel WS, [Hoenig M](#), Kuo CY, Stiehm ER, Wynn R, Bierings M, Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and the Primary Immune Deficiency Treatment Consortium
50. [Prevalence and clinical challenges among adults with primary immunodeficiency and recombination-activating gene deficiency.](#)
J Allergy Clin Immunol. 2018; 141(6): 2303-2306 (IF=13.258)
Lawless D, Geier CB, Farmer JR, Lango Allen H, Thwaites D, Atschekzei F, Brown M, Buchbinder D, Burns SO, Butte MJ, Csomos K, Deevi SVV, Egner W, Ehl S, Eibl MM, Fadugba O, Foldvari Z, Green DM, Henrickson SE, Holland SM, John T, Klemann C, Kuijpers TW, Moreira F, Piller A, Rayner-Matthews P, Romberg ND, Sargur R, Schmidt RE, Schröder C, [Schuetz C](#), Sharapova SO, Smith KGC, Sogkas G, Speckmann C, Stirrups K, Thrasher AJ, Wolf HM, Notarangelo LD, Anwar R, Boyes J, Ujhazi B, NIH Rare Disease Consortium, Thaventhiran J, Walter JE, Savic S

51. [Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.](#)
J Allergy Clin Immunol. 2018; 142(6): 1932-1946 (IF=13.258)
Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevskaya A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiburger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila TA, Geha R, McDermott E, Bunn S, Kurzai M, [Schulz A](#), Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B
52. [Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.](#)
J Allergy Clin Immunol. 2018; 141(1): 322-328.e10 (IF=13.258)
Slack J, Albert MH, Balashov D, Belohradsky BH, Bertaina A, Bleesing J, Booth C, Buechner J, Buckley RH, Ouachée-Charadin M, Deripapa E, Drabko K, Eapen M, Feuchtinger T, Finocchi A, Gaspar HB, Ghosh S, Gillio A, Gonzalez-Granado LI, Grunebaum E, Güngör T, Heilmann C, Helminen M, Higuchi K, Imai K, Kalwak K, Kanazawa N, Karasu G, Kucuk ZY, Laberko A, Lange A, Mahlaoui N, Meisel R, Moshous D, Muramatsu H, Parikh S, Pasic S, Schmid I, [Schuetz C](#), [Schulz A](#), Schultz KR, Shaw PJ, Slatter MA, Sykora KW, Tamura S, Taskinen M, Wawer A, Wolska- Kuśnierz B, Cowan MJ, Fischer A, Gennery AR, Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the European Society for Immunodeficiencies, Stem Cell Transplant for Immunodeficiencies in Europe (SCETIDE), Center for International Blood and Marrow Transplant Research, Primary Immunodeficiency Treatment Consortium
53. [Extra-adrenal glucocorticoids contribute to the postprandial increase of circulating leptin in mice.](#)
J Cell Commun Signal. 2018; 12(2): 433-439 (IF=2.516)
Tomabechi Y, Tsuruta T, Saito S, [Wabitsch M](#), Sonoyama K
54. [RAG Deficiency: Two Genes, Many Diseases.](#)
J Clin Immunol. 2018; 38(6): 646-655 (IF=4.227)
Delmonte OM, [Schuetz C](#), Notarangelo LD
55. [Biallelic mutations in DNA ligase 1 underlie a spectrum of immune deficiencies.](#)
J Clin Invest. 2018; 128(12): 5489-5504 (IF=13.251)
Maffucci P, Chavez J, Jurkiw TJ, O'Brien PJ, Abbott JK, Reynolds PR, Worth A, Notarangelo LD, [Felgentreff K](#), Cortes P, Boisson B, Radigan L, Cobat A, Dinakar C, Ehlayel M, Ben-Omran T, Gelfand EW, Casanova JL, Cunningham-Rundles C
56. [Trajectories of Body Mass Index from Childhood to Young Adulthood among Patients with Type 1 Diabetes-A Longitudinal Group-Based Modeling Approach Based on the DPV Registry.](#)
J Pediatr. 2018; 201: 78-85.e4 (IF=3.667)
Prinz N, Schwandt A, Becker M, [Denzler C](#), Flury M, Fritsch M, Galler A, Lemmer A, Papsch M, Reinehr T, Rosenbauer J, Holl RW
57. [Bilateral Pulmonary Sequestration in a Preterm Infant.](#)
J Pediatr. 2018; 194: 260-260.e1 (IF=3.667)
[von Scheidt E](#), Eicken A, [Wowra T](#), Brunner H, [Apitz C](#)
58. [Glucose-6-phosphate dehydrogenase activity measured by spectrophotometry and associated genetic variants from the Oromiya zone, Ethiopia.](#)
Malar J. 2018; 17(1): 358 (IF=2.845)
Kießling N, [Brintrup J](#), Zeynudin A, Abduselam N, Götz S, Mack M, Pritsch M, Wieser A, [Kohne E](#), Berens-Riha N
59. [Hemoglobinopathies--genetically diverse, clinically complex, and globally relevant](#)
Memo. 2018; 11(3): 235-240
[Cario H](#)
60. [Precision medicine in pediatric oncology.](#)
Mol Cell Pediatr. 2018; 5(1): 6
Burdach SEG, [Westhoff MA](#), Steinhauser MF, [Debatin KM](#)
61. [Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis.](#)
Mol Cell Pediatr. 2018; 5(1): 1
[Schleker T](#), [Jacobsen EM](#), Mayer B, [Strauss G](#), [Debatin KM](#), [Posovszky C](#)
62. [A computational biology approach of a genome-wide screen connected miRNAs to obesity and type 2 diabetes.](#)
Mol Metab. 2018; 11: 145-159 (IF=6.291)
Gottmann P, Ouni M, Saussenthaler S, [Roos J](#), Stirn L, Jähnert M, Kamitz A, Hallahan N, Jonas W, Fritsche A, Häring HU, Staiger H, Blüher M, [Fischer-Posovszky P](#), Vogel H, Schürmann A
63. [Extracellular Vesicles from Hypoxic Adipocytes and Obese Subjects Reduce Insulin-Stimulated Glucose Uptake.](#)
Mol Nutr Food Res. 2018; 62(5) (IF=5.151)
Mleczko J, Ortega FJ, Falcon-Perez JM, [Wabitsch M](#), Fernandez-Real JM, Mora S
64. [Hemoglobinopathies as a challenge of migrant medicine](#)
Monatsschr Kinderheilkd. 2018; 166(11): 968-976 (IF=0.23)
[Cario H](#), Lobitz S
65. [Strategies to combat the obesity epidemic](#)
Monatsschr Kinderheilkd. 2018; 166(5): 386-387 (IF=0.23)
Koletzko B, [Wabitsch M](#)

66. Vitamin D supplementation beyond the second year of life. Joint statement of the Nutrition Committee of the German Society for Pediatric and Adolescent Medicine (DGKJ) and the German Society for Pediatric Endocrinology and Diabetology (DGKED) **Monatsschr Kinderheilkd.** 2018; 166(9): 814-822 (IF=0.23)
Reinehr T, Schnabel D, Wabitsch M, Pozzalla SBD, Buhner C, Heidtmann B, Jochum F, Kauth T, Korner A, Mihatsch W, Prell C, Rudloff S, Tittel B, Wolfle J, Zimmer KP, Koletzko B, Ernährungskommission der Deutschen Gesellschaft für Kinder- und Jugendmedizin
67. Monogenic obesity. New diagnostic and therapeutic options **Monatsschr Kinderheilkd.** 2018; 166(5): 388-394 (IF=0.23)
von Schnurbein J, Borck G, Hinney A, Wabitsch M
68. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. **Mucosal Immunol.** 2018; 11(2): 562-574 (IF=7.36)
Schwerdt T, Bryant RV, Pandey S, Capitani M, Meran L, Cazier JB, Jung J, Mondal K, Parkes M, Mathew CG, Fiedler K, McCarthy DJ, WGS500 Consortium, Oxford IBD cohort study investigators, COLORS in IBD group investigators (including Posovszky C), UK IBD Genetics Consortium, Sullivan PB, Rodrigues A, Travis SPL, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, INTERVAL Study, Russell RK, Wilson DC, Kelsen JR, Cornall R, Denson LA, Kugathasan S, Knaus UG, Serra EG, Anderson CA, Duerr RH, McGovern DP, Cho J, Powrie F, Li VS, Muise AM, Uhlig HH
69. Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma. **Naunyn Schmiedebergs Arch Pharmacol.** 2018; 391(5): 523-536 (IF=2.238)
Kaiser K, Prystaz K, Vikman A, Haffner-Luntzer M, Bergdolt S, Strauss G, Waetzig GH, Rose-John S, Ignatius A
70. Predictive Value of Thompson-Score for Long-Term Neurological and Cognitive Outcome in Term Newborns with Perinatal Asphyxia and Hypoxic-Ischemic Encephalopathy Undergoing Controlled Hypothermia Treatment. **Neonatology.** 2018; 114(4): 341-347 (IF=2.688)
Mendler MR, Mendler I, Hassan MA, Mayer B, Bode H, Hummler HD
71. Influence of PCO2 Control on Clinical and Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants. **Neonatology.** 2018; 113(3): 221-230 (IF=2.688)
Thome UH, Dreyhaupt J, Genzel-Boroviczeny O, Bohnhorst B, Schmid M, Fuchs H, Rohde O, Avenarius S, Topf HG, Zimmermann A, Faas D, Timme K, Kleinlein B, Buxmann H, Schenk W, Segerer H, Teig N, Ackermann B, Hentschel R, Heckmann M, Schlösser R, Peters J, Rossi R, Rascher W, Böttger R, Seidenberg J, Hansen G, Bode H, Zernickel M, Muche R, Hummler HD, PHELBI Study Group
72. Human Milk Oligosaccharides: 2'-Fucosyllactose (2'-FL) and Lacto-N-Neotetraose (LNnT) in Infant Formula. **Nutrients.** 2018; 10(9) (IF=4.196)
Vandenplas Y, Berger B, Carnielli VP, Ksiazek J, Lagström H, Sanchez Luna M, Migacheva N, Mosselmans JM, Picaud JC, Possner M, Singhal A, Wabitsch M
73. Current Guidelines for Obesity Prevention in Childhood and Adolescence. **Obes Facts.** 2018; 11(3): 263-276 (IF=3.108)
Weihrauch-Blüher S, Kromeyer-Hauschild K, Graf C, Widhalm K, Korsten-Reck U, Jödicke B, Markert J, Müller MJ, Moss A, Wabitsch M, Wiegand S
74. Viability of glioblastoma stem cells is effectively reduced by diisothiocyanate-derived mercapturic acids. **Oncol Lett.** 2018; 16(5): 6181-6187 (IF=1.664)
Cwiklowska K, Westhoff MA, Freisinger S, Dwucet A, Halatsch ME, Knippschild U, Debatin KM, Schirmbeck R, Winiarski L, Oleksyszyn J, Wirtz CR, Burster T
75. Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies. **Oncolytic Virother.** 2018; 7: 37-41
Xu C, Goß AV, Dorneburg C, Debatin KM, Wei J, Beltinger C
76. The therapeutic properties of resminostat for hepatocellular carcinoma. **Oncoscience.** 2018; 5(5-6): 196-208
Zhao J, Gray SG, Wabitsch M, Greene CM, Lawless MW
77. [Morphological characteristics of osteopetrosis]. **Pathologe.** 2018; 39(2): 164-171 (IF=0.555)
Zustin J, Amling M, Crazzolara R, Butscheidt S, Schulz A, Oheim R
78. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. **Pediatr Blood Cancer.** 2018; 65(6): e27003 (IF=2.646)
Ruf S, Hebart H, Hjalgrim LL, Kabickova E, Lang P, Steinbach D, Schwabe GC, Woessmann W
79. Impact of the Right Ventricular Sokolow-Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension. **Pediatr Cardiol.** 2018; 39(6): 1115-1122 (IF=1.54)
Krämer J, Kreuzer F, Kaestner M, Bride P, von Scheidt F, Siaplaouras J, Latus H, Schranz D, Apitz C
80. Long-term study of tubeless insulin pump therapy compared to multiple daily injections in youth with type 1 diabetes: Data from the German/Austrian DPV registry. **Pediatr Diabetes.** 2018; 19(5): 979-984 (IF=3.161)
Danne T, Schwandt A, Biester T, Heidtmann B, Rami-Merhar B, Haberland H, Müther S, Khodaverdi S, Haak T, Holl RW, DPV Initiative

81. [Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative.](#)
Pediatr Diabetes. 2018; 19(7): 1271-1275 (IF=3.161)
DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, Lilienthal E, Sherr JL, Tauschmann M, Holl RW, [T1D Exchange and DPV Registries](#)
82. [Metabolic control of type 1 diabetes in youth with autism spectrum disorder: A multicenter Diabetes-Patienten-Verlaufsdocumentation analysis based on 61 749 patients up to 20 years of age.](#)
Pediatr Diabetes. 2018; 19(5): 930-936 (IF=3.161)
Lemay JF, Lanzinger S, Pacaud D, Plener PL, Fürst-Burger A, Biester T, Hilgard D, Lilienthal E, Galler A, Berger G, Holl RW, [German/Austrian DPV Initiative](#)
83. [Risk of recurrent severe hypoglycemia remains associated with a past history of severe hypoglycemia up to 4 years: Results from a large prospective contemporary pediatric cohort of the DPV initiative.](#)
Pediatr Diabetes. 2018; 19(3): 493-500 (IF=3.161)
Pacaud D, Hermann JM, Karges B, Rosenbauer J, Danne T, Dürr R, Herbst A, Lindauer S, Müther S, Pötzsch S, Raile K, Witsch M, Holl RW, [DPV Initiative](#)
84. [Sleep and glycemic control in adolescents with type 1 diabetes.](#)
Pediatr Diabetes. 2018; 19(1): 143-149 (IF=3.161)
[von Schnurbein J](#), Boettcher C, [Brandt S](#), Karges B, Dunstheimer D, Galler A, [Denzer C](#), [Denzer F](#), [Vollbach H](#), [Wabitsch M](#), Roenneberg T, Vetter C
85. [Presentation of pediatric Henoch-Schönlein purpura nephritis changes with age and renal histology depends on biopsy timing.](#)
Pediatr Nephrol. 2018; 33(2): 277-286 (IF=2.627)
Hennies I, Gimpel C, Gellermann J, Möller K, Mayer B, Dittrich K, Büscher AK, Hansen M, Aulbert W, Wühl E, Nissel R, Schalk G, Weber LT, Pohl M, Wygoda S, Beetz R, Klaus G, Fehrenbach H, König S, Staude H, [Beringer O](#), Bald M, Walden U, von Schnakenburg C, Bertram G, Wallot M, Häffner K, Wiech T, Hoyer PF, Pohl M, German Society of Pediatric Nephrology
86. [Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.](#)
Pediatr Nephrol. 2018; 33(12): 2289-2298 (IF=2.627)
Holle J, Berenberg-Goßler L, Wu K, [Beringer O](#), [Kropp E](#), Müller D, Thumfart J
87. [Circulating levels of miR-122 and nonalcoholic fatty liver disease in pre-pubertal obese children.](#)
Pediatr Obes. 2018; 13(3): 175-182 (IF=3.98)
[Brandt S](#), [Roos J](#), Inzaghi E, Kotnik P, Kovac J, Battelino T, Cianfarani S, Nobili V, Colajacomo M, Kratzer W, [Denzer C](#), [Fischer-Posovszky P](#), [Wabitsch M](#)
88. [Creation of a restrictive atrial communication in pulmonary arterial hypertension \(PAH\): effective palliation of syncope and end-stage heart failure.](#)
Pulm Circ. 2018; 8(2): 2045894018776518 (IF=2.283)
Bauer A, Khalil M, Schmidt D, Bauer J, Esmaeili A, [Apitz C](#), Voelkel NF, Schranz D
89. [Sildenafil-Bosentan Drug-Drug Interaction: A Word of Caution Regarding the Most Common Combination Therapy in Children with Advanced Pulmonary Arterial Hypertension.](#)
Respiration. 2018; 96(3): 302 (IF=2.591)
[Apitz C](#), Schranz D
90. [MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.](#)
Sci Rep. 2018; 8(1): 9020 (IF=4.122)
Kleemann M, Schneider H, Unger K, Sander P, Schneider EM, [Fischer-Posovszky P](#), Handrick R, Otte K
91. [Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.](#)
Sci Rep. 2018; 8(1): 5527 (IF=4.122)
[Mettang M](#), [Meyer-Pannwitz V](#), Karpel-Massler G, Zhou S, Carragher NO, Föhr KJ, Baumann B, [Nonnenmacher L](#), [Enzenmüller S](#), [Dahlhaus M](#), Siegelin MD, [Stroh S](#), Mertens D, [Fischer-Posovszky P](#), Schneider EM, Halatsch ME, [Debatin KM](#), [Westhoff MA](#)
92. [DEHP deregulates adipokine levels and impairs fatty acid storage in human SGBS-adipocytes.](#)
Sci Rep. 2018; 8(1): 3447 (IF=4.122)
Schaedlich K, Gebauer S, Hunger L, Beier LS, Koch HM, [Wabitsch M](#), Fischer B, Ernst J
93. [Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.](#)
Sci Rep. 2018; 8(1): 15383 (IF=4.122)
Shang E, Zhang Y, Shu C, Ishida CT, Bianchetti E, [Westhoff MA](#), Karpel-Massler G, Siegelin MD
94. [Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.](#)
Sci Rep. 2018; 8(1): 7373 (IF=4.122)
Zhang Y, Ishida CT, Shu C, Kleiner G, Sanchez-Quintero MJ, Bianchetti E, Quinzii CM, [Westhoff MA](#), Karpel-Massler G, Siegelin MD
95. [Effects of Levetiracetam and Sulthiame on EEG in benign epilepsy with centrotemporal spikes: A randomized controlled trial.](#)
Seizure. 2018; 56: 115-120 (IF=2.839)
Tacke M, Borggraefe I, Gerstl L, Heinen F, Vill K, Bonfert M, Bast T, HEAD Study group, Neubauer BA, Baumeister F, Baethmann M, Bentele K, Blank C, Blank HM, [Bode H](#), Bosch F, Brandl U, Brockmann K, Dahlem P, Ernst JP, Feldmann E, Fiedler A, Gerigk M, Heß S, Hikel C, Hoffmann HG, Kieslich M, Klepper J, Kluger G, Koch H, Koch W, Korinthenberg R, Krois I, Kühne H, Kurlmann G, Mandl M, Mause U, Navratil P, Opp J, Penzien J, Prietsch V, Quattländer A, Rating D, Schara U, Shamdeen MG, Sprinz A, Wendker-Magrabi H, Stephani U, Muhle H, Straßburg HM, Töpke B, Trollmann R, Tuschen-Hofstätter E, Waltz S, Weber G, Wien FU, Wolff M, Polster T, Freitag H, Sönmez Ö, Reinhardt K, Traus M, Hoovey Z
96. [Mini photopheresis for refractory chronic graft-versus-host disease in children and adolescents.](#)
Transfusion. 2018; 58(11): 2495-2500 (IF=3.423)
Verdú-Amorós J, Woessmann W, Maecker-Kolhoff B, [Schulz A](#), Strauss G, Bein G, Hackstein H

97. [IVH Prevention for ELBW Preterm Babies in Two Different Perinatal Centers].
Z Geburtshilfe Neonatol. 2018; 222(6): 245-253 (IF=0.246)
Cipowicz C, Schmid M, Hummler H, Thome U

2017

98. New approach shows no association between maternal milk fatty acid composition and childhood wheeze or asthma.
Allergy. 2017; 72(9): 1374-1383 (IF=6.048)
Logan CA, Brandt S, Wabitsch M, Brenner H, Wiens F, Stahl B, Marosvölgyi T, Decsi T, Rothenbacher D, Genuneit J
99. Toward evidence-based diagnosis of myocarditis in children and adolescents: Rationale, design, and first baseline data of MYKKE, a multicenter registry and study platform.
Am Heart J. 2017; 187: 133-144 (IF=4.171)
Messroghli DR, Pickardt T, Fischer M, Opgen-Rhein B, Papakostas K, Böcker D, Jakob A, Khalil M, Mueller GC, Schmidt F, Kaestner M, Udink Ten Cate FEA, Wagner R, Ruf B, Kiski D, Wiegand G, Degener F, Bauer UMM, Friede T, Schubert S, MYKKE Consortium
100. 4.7 Mb deletion encompassing TGFB2 associated with features of Loeys-Dietz syndrome and osteoporosis in adulthood.
Am J Med Genet A. 2017; 173(8): 2289-2292 (IF=2.264)
Gaspar H, Lutz B, Reicherter K, Lühl S, Taurman R, Gabriel H, Brenner RE, Borck G
101. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.
Am J Med Genet A. 2017; 173(4): 1017-1037 (IF=2.264)
Ripperger T, Biellack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm CM, Kühlen M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren AO, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP
102. Glutaraldehyde Treatment of Allografts and Aortic Outcomes Post-Norwood: Challenging Surgical Decision.
Ann Thorac Surg. 2017; 104(4): 1395-1401 (IF=3.779)
Martin BJ, Kaestner M, Peng M, Ross DB, Urschel S, West LJ, Rebeyka IM
103. Neurodevelopmental outcomes of extremely low birthweight infants randomised to different PCO2 targets: the PHELBI follow-up study.
Arch Dis Child Fetal Neonatal Ed. 2017; 102(5): F376-F382 (IF=3.953)
Thome UH, Genzel-Boroviczeny O, Bohnhorst B, Schmid M, Fuchs H, Rohde O, Avenarius S, Topf HG, Zimmermann A, Faas D, Timme K, Kleinlein B, Buxmann H, Schenk W, Segerer H, Teig N, Bläser A, Hentschel R, Heckmann M, Schlösser R, Peters J, Rossi R, Rascher W, Böttger R, Seidenberg J, Hansen G, Zernickel M, Bode H, Dreyhaupt J, Muche R, Hummler HD, PHELBI Study Group
104. Cell death: From initial concepts to pathways to clinical applications - Personal reflections of a clinical researcher.
Biochem Biophys Res Commun. 2017; 482(3): 445-449 (IF=2.559)
Debatin KM
105. Novel patient missense mutations in the HSD17B10 gene affect dehydrogenase and mitochondrial tRNA modification functions of the encoded protein.
Biochim Biophys Acta. 2017; 1863(12): 3294-3302 (IF=5.108)
Oerum S, Roovers M, Leichsenring M, Acquaviva-Bourdain C, Beermann F, Gemperle-Britschgi C, Fouilhoux A, Korwitz-Reichelt A, Bailey HJ, Droogmans L, Oppermann U, Sass JO, Yue WW
106. HSCT cures ADA2 deficiency.
Blood. 2017; 130(24): 2582-2583 (IF=15.132)
Debatin KM
107. Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome.
Blood. 2017; 129(21): 2928-2938 (IF=15.132)
Hoening M, Lagresle-Peyrou C, Pannicke U, Notarangelo LD, Porta F, Gennery AR, Slatter M, Cowan MJ, Stepensky P, Al-Mousa H, Al-Zahrani D, Pai SY, Al Herz W, Gaspar HB, Veys P, Oshima K, Imai K, Yabe H, Noroski LM, Wulffraat NM, Sykora KW, Soler-Palacin P, Muramatsu H, Al Hilali M, Moshous D, Debatin KM, Schuetz C, Jacobsen EM, Schulz AS, Schwarz K, Fischer A, Friedrich W, Cavazzana M, European Society for Blood and Marrow Transplantation (EBMT) Inborn Errors Working Party
108. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor.
Blood. 2017; 130(5): 643-654 (IF=15.132)
Münch V, Trentin L, Herzig J, Demir S, Seyfried F, Kraus JM, Kestler HA, Köhler R, Barth TFE, Te Kronnie G, Debatin KM, Meyer LH
109. Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin.
Blood. 2017; 130(7): 875-880 (IF=15.132)
Seo A, Ben-Harosh M, Sirin M, Stein J, Dgany O, Kaplulshnik J, Hoening M, Pannicke U, Lorenz M, Schwarz K, Stockklauser C, Walsh T, Gulsuner S, Lee MK, Sendamarai A, Sanchez-Bonilla M, King MC, Cario H, Kulozik AE, Debatin KM, Schulz A, Tamary H, Shimamura A

110. [Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.](#)
Br J Haematol. 2017; 179(2): 272-283 (IF=5.128)
Kuhlen M, Bleckmann K, Möricke A, Schrappe M, Vieth S, Escherich G, Bronsema A, Vonalt A, Queudeville M, Zwaan CM, Ebinger M, Debatin KM, Klingebiel T, Koscielniak E, Rossig C, Burkhardt B, Kolb R, Eckert C, Borkhardt A, von Stackelberg A, Chen-Santel C
111. [Predictors of health-related quality of life in children with chronic heart disease.](#)
Cardiol Young. 2017; 27(8): 1455-1464 (IF=0.978)
Niemitz M, Gunst DCM, Hövels-Gürich HH, Hofbeck M, Kaulitz R, Galm C, Berger F, Nagdyman N, Stiller B, Borth-Bruhns T, Konzag I, Balmer C, Goldbeck L
112. [Pediatric reference intervals for alkaline phosphatase.](#)
Clin Chem Lab Med. 2017; 55(1): 102-110 (IF=3.556)
Zierk J, Arzideh F, Haeckel R, Cario H, Frühwald MC, Groß HJ, Gscheidmeier T, Hoffmann R, Krebs A, Lichthagen R, Neumann M, Ruf HG, Steigerwald U, Streichert T, Rascher W, Metzler M, Rauh M
113. [Newborn screening for severe combined immunodeficiency using a novel and simplified method to measure T-cell excision circles \(TREC\).](#)
Clin Immunol. 2017; 175: 51-55 (IF=3.557)
Tagliaferri L, Kunz JB, Happich M, Esposito S, Bruckner T, Hübschmann D, Okun JG, Hoffmann GF, Schulz A, Kappe J, Speckmann C, Muckenthaler MU, Kulozik AE
114. [Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4.](#)
Clin Infect Dis. 2017; 64(12): 1637-1643 (IF=9.117)
Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau MC, Schild R, Lemke J, Beringer O, Müller D, Härtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper MJ
115. [Risk factors for necrobiosis lipoidica in Type 1 diabetes mellitus.](#)
Diabet Med. 2017; 34(1): 86-92 (IF=3.132)
Hammer E, Lilienthal E, Hofer SE, Schulz S, Bollow E, Holl RW, DPV Initiative and the German BMBF Competence Network for Diabetes Mellitus
116. [Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents.](#)
Diabetes Care. 2017; 40(8): 1034-1040 (IF=13.397)
Craig ME, Prinz N, Boyle CT, Campbell FM, Jones TW, Hofer SE, Simmons JH, Holman N, Tham E, Fröhlich-Reiterer E, DuBose S, Thornton H, King B, Maahs DM, Holl RW, Warner JT, Australasian Diabetes Data Network (ADDN), T1D Exchange Clinic Network (T1DX), National Paediatric Diabetes Audit (NPDA) and the Royal College of Paediatrics and Child Health, Prospective Diabetes Follow-up Registry (DPV) initiative
117. [Response to Comment on Craig et al. Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents.](#)
Diabetes Care. 2017; 40(11): e168-e169 (IF=13.397)
Craig ME, Prinz N, Boyle CT, Campbell FM, Jones TW, Hofer SE, Simmons JH, Holman N, Tham E, Fröhlich-Reiterer E, DuBose S, Thornton H, King B, Maahs DM, Holl RW, Warner JT, Australasian Diabetes Data Network (ADDN), the T1D Exchange Clinic Network (T1DX), the National Paediatric Diabetes Audit (NPDA) and the Royal College
118. [Longitudinal Trajectories of Metabolic Control From Childhood to Young Adulthood in Type 1 Diabetes From a Large German/Austrian Registry: A Group-Based Modeling Approach.](#)
Diabetes Care. 2017; 40(3): 309-316 (IF=13.397)
Schwandt A, Hermann JM, Rosenbauer J, Boettcher C, Dunstheimer D, Grulich-Henn J, Kuss O, Rami-Merhar B, Vogel C, Holl RW, DPV Initiative
119. [Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry.](#)
Diabetes Res Clin Pract. 2017; 129: 52-58 (IF=2.548)
Bohn B, Zimmermann A, Wagner C, Merger S, Dunstheimer D, Kopp F, Gollisch K, Zindel V, Holl RW, DPV Initiative
120. [Development and Anatomy of the Enteroendocrine System in Humans.](#)
Endocr Dev. 2017; 32: 20-37
Posovszky C
121. [Gastrointestinal Hormones Induced the Birth of Endocrinology.](#)
Endocr Dev. 2017; 32: 1-7
Wabitsch M
122. [Gastrointestinal Endocrinology in Bariatric Surgery.](#)
Endocr Dev. 2017; 32: 124-138
Wabitsch M
123. [Measurement of immunofunctional leptin to detect and monitor patients with functional leptin deficiency.](#)
Eur J Endocrinol. 2017; 176(3): 315-322 (IF=4.333)
Wabitsch M, Pridzun L, Ranke MB, von Schnurbein J, Moss A, Brandt S, Kohlsdorf K, Moepps B, Schaab M, Funcke JB, Gierschik P, Fischer-Posovszky P, Flehmig B, Kratzsch J
124. [Coexisting variants in OSTM1 and MANEAL cause a complex neurodegenerative disorder with NBIA-like brain abnormalities.](#)
Eur J Hum Genet. 2017; 25(9): 1092-1095 (IF=3.636)
Herebian D, Alhaddad B, Seibt A, Schwarzmayer T, Danhauser K, Klee D, Harmsen S, Meitinger T, Strom TM, Schulz A, Mayatepek E, Haack TB, Distelmaier F
125. [Diabetes screening in overweight and obese children and adolescents: choosing the right test.](#)
Eur J Pediatr. 2017; 176(1): 89-97 (IF=2.242)
Ehehalt S, Wiegand S, Körner A, Schweizer R, Liesenkötter KP, Partsch CJ, Blumenstock G, Spielau U, Denzer C, Ranke MB, Neu A, Binder G, Wabitsch M, Kiess W, Reinehr T

126. Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.
Expert Opin Drug Discov. 2017; 12(10): 1031-1040 (IF=4.692)
Karpel-Massler G, Ishida CT, Zhang Y, Halatsch ME, Westhoff MA, Siegelin MD
127. Cerebral Microstructural Alterations after Radiation Therapy in High-Grade Glioma: A Diffusion Tensor Imaging-Based Study.
Front Neurol. 2017; 8: 286 (IF=3.508)
Kassubek R, Gorges M, Westhoff MA, Ludolph AC, Kassubek J, Müller HP
128. Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease.
Front Pediatr. 2017; 5: 18 (IF=2.335)
Ebner K, Schaefer F, Liebau MC, ARegPKD Consortium (including Beringer O)
129. Inflammatory Mediators in Tracheal Aspirates of Preterm Infants Participating in a Randomized Trial of Permissive Hypercapnia.
Front Pediatr. 2017; 5: 246 (IF=2.335)
Gentner S, Laube M, Uhlig U, Yang Y, Fuchs HW, Dreyhaupt J, Hummler HD, Uhlig S, Thome UH
130. Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling.
Gut. 2017; 66(3): 473-486 (IF=17.016)
Hohwieler M, Illing A, Hermann PC, Mayer T, Stockmann M, Perkhofer L, Eiseler T, Antony JS, Müller M, Renz S, Kuo CC, Lin Q, Sendler M, Breunig M, Kleiderman SM, Lechel A, Zenker M, Leichsenring M, Rosendahl J, Zenke M, Sainz B, Mayerle J, Costa IG, Seufferlein T, Kormann M, Wagner M, Liebau S, Kleger A
131. Mutations of PTPN23 in developmental and epileptic encephalopathy.
Hum Genet. 2017; 136(11-12): 1455-1461 (IF=3.930)
Sowada N, Hashem MO, Yilmaz R, Hamad M, Kakar N, Thiele H, Arold ST, Bode H, Alkuraya FS, Borck G
132. Prevalence and phenotypic characterization of MC4R variants in a large pediatric cohort.
Int J Obes (Lond). 2017; 41(1): 13-22 (IF=5.151)
Vollbach H, Brandt S, Lahr G, Denzer C, von Schnurbein J, Debatin KM, Wabitsch M
133. Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the "AJET" Working Group of the German Society for Pediatric Oncology and Hematology.
J Adolesc Young Adult Oncol. 2017; 6(2): 194-199 (IF=2.167)
Escherich G, Bielack S, Maier S, Braungart R, Brümmendorf TH, Freund M, Grosse R, Hoferer A, Kampschulte R, Koch B, Lauten M, Milani V, Ross H, Schilling F, Wöhrle D, Cario H, Dirksen U
134. Severe glucose-6-phosphate dehydrogenase deficiency leads to susceptibility to infection and absent NETosis.
J Allergy Clin Immunol. 2017; 139(1): 212-219.e3 (IF=13.258)
Siler U, Romao S, Tejera E, Pastukhov O, Kuzmenko E, Valencia RG, Meda Spaccamela V, Belohradsky BH, Speer O, Schmugge M, Kohne E, Hoenig M, Freiherst J, Schulz AS, Reichenbach J
135. A prospective study on the natural history of patients with profound combined immunodeficiency: An interim analysis.
J Allergy Clin Immunol. 2017; 139(4): 1302-1310.e4 (IF=13.258)
Speckmann C, Doerken S, Aiuti A, Albert MH, Al-Herz W, Allende LM, Scarselli A, Avcin T, Perez-Becker R, Cancrini C, Cant A, Di Cesare S, Finocchi A, Fischer A, Gaspar HB, Ghosh S, Gennery A, Gilmour K, González-Granado LI, Martinez-Gallo M, Hambleton S, Hauck F, Hoenig M, Moshous D, Neven B, Niehues T, Notarangelo L, Picard C, Rieber N, Schulz A, Schwarz K, Seidel MG, Soler-Palacin P, Stepsensky P, Strahm B, Vraetz T, Warnatz K, Winterhalter C, Worth A, Fuchs S, Uhlmann A, Ehl S, P-CID study of the Inborn Errors Working Party of the EBMT
136. Mast Cells Are Critical Regulators of Bone Fracture-Induced Inflammation and Osteoclast Formation and Activity.
J Bone Miner Res. 2017; 32(12): 2431-2444 (IF=6.314)
Kroner J, Kovtun A, Kemmler J, Messmann JJ, Strauss G, Seitz S, Schinke T, Amling M, Kotrba J, Froebel J, Dudeck J, Dudeck A, Ignatius A
137. MicroRNA-221-3p Regulates Angiopoietin-Like 8 (ANGPTL8) Expression in Adipocytes.
J Clin Endocrinol Metab. 2017; 102(11): 4001-4012 (IF=5.789)
Mysore R, Ortega FJ, Latorre J, Ahonen M, Savolainen-Peltonen H, Fischer-Posovszky P, Wabitsch M, Olkkonen VM, Fernández-Real JM, Haridas PAN
138. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
J Crohns Colitis. 2017; 11(10): 1230-1237 (IF=6.637)
Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D
139. Quantitative, Phenotypic, and Functional Characterization of Cellular Immunity in Children and Adolescents With Down Syndrome.
J Infect Dis. 2017; 215(10): 1619-1628 (IF=5.186)
Schoch J, Rohrer TR, Kaestner M, Abdul-Khalik H, Gortner L, Sester U, Sester M, Schmidt T
140. Cerebral oxygenation and desaturations in preterm infants - a longitudinal data analysis.
J Neonatal Perinatal Med. 2017; 10(3): 267-273
Mayer B, Pohl M, Hummler HD, Schmid MB

141. **Disrupted apical exocytosis of cargo vesicles causes enteropathy in FHL5 patients with Munc18-2 mutations.**
JCI Insight. 2017; 2(14): e94564
Vogel GF, van Rijn JM, Krainer IM, Janecke AR, Posovszky C, Cohen M, Searle C, Jantchou P, Escher JC, Patey N, Cutz E, Müller T, Middendorp S, Hess MW, Huber LA
142. **Pulmonale und pulmonalarterielle Hypertonie bei Erwachsenen mit angeborenen Herzfehlern**
Journal für angeborene Herzfehler. 2017; 2017(06)
Kaemmerer H, Apitz C, Brockmeier K, Eicken A, Gorenflo M, Hager A, deHaan F, Huntgeburth M, Kozlik-Feldmann R, Miera O, Neidenbach R, Ewert P, Rosenkranz S, Diller GP
143. **„Migrantenanämien“ oder „Migrationsanämie“. Neue Worte für alte Erkrankungen**
Kinder- und Jugendmedizin. 2017; 17(2): 75-80
Cario H
144. **Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia - first findings of the OPAL trial.**
Leuk Lymphoma. 2017; 58(10): 2363-2369 (IF=2.644)
Krull K, Kunstreich M, Klasen-Sansone J, Kloetgen A, Gruener F, Escherich G, Bleckmann K, Moericke A, Schrappe M, Jorch N, Steinbach D, Classen CF, Guggemos A, Kolb R, Klee D, Borkhardt A, Kuhlen M
145. **The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.**
Leukemia. 2017; 31(11): 2365-2375 (IF=10.023)
Savino AM, Sarno J, Trentin L, Vieri M, Fazio G, Bardini M, Bugarin C, Fossati G, Davis KL, Gaipa G, Izraeli S, Meyer LH, Nolan GP, Biondi A, Te Kronnie G, Palmi C, Cazzaniga G
146. **Frühkindlicher BMI-Verlauf bei monogener Adipositas**
Med Genet. 2017; 29(4): 360-364 (IF=0.213)
Kohlsdorf K, Nunziata A, Funcke JB, Brandt S, von Schnurbein J, Vollbach H, Lennerz B, Fritsch M, Greber-Platzer S, Fröhlich-Reiterer E, Borck G, Fischer-Posovszky P, Wabitsch M
147. **Lipodystrophie-Erkrankungen**
Med Genet. 2017; 29(4): 374-388 (IF=0.213)
Miehle K, von Schnurbein J, Fasshauer M, Stumvoll M, Borck G, Wabitsch M
148. **Zu viel Fett – zu wenig Fett**
Med Genet. 2017; 29(4): 347-347 (IF=0.213)
Wabitsch M, Borck G
149. **Monogene Adipositas**
Med Genet. 2017; 29(4): 348-359 (IF=0.213)
von Schnurbein J, Wabitsch M
150. **Teneurin-2 (TENM2) deficiency induces UCP1 expression in differentiating human fat cells.**
Mol Cell Endocrinol. 2017; 443: 106-113 (IF=3.563)
Tews D, Fromme T, Keuper M, Hofmann SM, Debatin KM, Klingenspor M, Wabitsch M, Fischer-Posovszky P
151. **Estimated prevalence of potentially damaging variants in the leptin gene.**
Mol Cell Pediatr. 2017; 4(1): 10
Nunziata A, Borck G, Funcke JB, Kohlsdorf K, Brandt S, Hinney A, Moepps B, Gierschik P, Debatin KM, Fischer-Posovszky P, Wabitsch M
152. **Differential expression of serpins may selectively licence distinct granzyme B functions including antigen cross-presentation.**
Mol Immunol. 2017; 87: 325-326 (IF=3.188)
Fabricius D, Trzaska T, Fecher T, Dimitriou E, Jahrsdörfer B
153. **Activated macrophages control human adipocyte mitochondrial bioenergetics via secreted factors.**
Mol Metab. 2017; 6(10): 1226-1239 (IF=6.291)
Keuper M, Sachs S, Walheim E, Berti L, Raedle B, Tews D, Fischer-Posovszky P, Wabitsch M, Hrabě de Angelis M, Kastenmüller G, Tschöp MH, Jastroch M, Staiger H, Hofmann SM
154. **Treatment of pulmonary hypertension associated with congenital heart disease**
Monatsschr Kinderheilkd. 2017; 165(11): 972-981 (IF=0.230)
Apitz C
155. **Physiological relevance of brown adipose tissue in humans**
Monatsschr Kinderheilkd. 2017; 165(6): 502-509 (IF=0.230)
Tews D, Fischer-Posovszky P, Debatin KM, Beer AJ, Wabitsch M
156. **Transcription factor Hlx controls a systematic switch from white to brown fat through Prdm16-mediated co-activation.**
Nat Commun. 2017; 8(1): 68 (IF=12.353)
Huang L, Pan D, Chen Q, Zhu LJ, Ou J, Wabitsch M, Wang YX
157. **Reliability of Pulse Oximetry during Progressive Hypoxia, Cardiopulmonary Resuscitation, and Recovery in a Piglet Model of Neonatal Hypoxic Cardiac Arrest.**
Neonatology. 2017; 112(1): 40-46 (IF=2.688)
Hassan MA, Weber C, Waitz M, Huang L, Hummler HD, Mendler MR
158. **Tidal Volume Delivery and Endotracheal Tube Leak during Cardiopulmonary Resuscitation in Intubated Newborn Piglets with Hypoxic Cardiac Arrest Exposed to Different Modes of Ventilatory Support.**
Neonatology. 2017; 111(2): 100-106 (IF=2.688)
Mendler MR, Weber C, Hassan MA, Huang L, Mayer B, Hummler HD
159. **Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.**
Neurochem Res. 2017; 42(12): 3382-3389 (IF=2.772)
Karpel-Massler G, Kast RE, Siegelin MD, Dwucet A, Schneider E, Westhoff MA, Wirtz CR, Chen XY, Halatsch ME, Bolm C

160. Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro. **Neurochem Res.** 2017; 42(5): 1543-1554 (IF=2.772) Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Karpel-Massler S, Nonnenmacher L, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME
161. Single-stranded DNA library preparation from highly degraded DNA using T4 DNA ligase. **Nucleic Acids Res.** 2017; 45(10): e79 (IF=11.561) Gansauge MT, Gerber T, Glocke I, Korlevic P, Lippik L, Nagel S, Riehl LM, Schmidt A, Meyer M
162. Changing Characteristics of Obese Children and Adolescents Entering Pediatric Lifestyle Intervention Programs in Germany over the Last 11 Years: An Adiposity Patients Registry Multicenter Analysis of 65,453 Children and Adolescents. **Obes Facts.** 2017; 10(5): 517-530 (IF=3.108) Bohn B, Wiegand S, Kiess W, Reinehr T, Stachow R, Oepen J, Langhof H, Hermann T, Widhalm K, Wabitsch M, Gellhaus I, Holl R, APV Initiative and the German Competence Network Obesity
163. A Structured, Manual-Based Low-Level Intervention vs. Treatment as Usual Evaluated in a Randomized Controlled Trial for Adolescents with Extreme Obesity - the STEREO Trial. **Obes Facts.** 2017; 10(4): 341-352 (IF=3.108) Mühlhig Y, Scherag A, Bickenbach A, Giesen U, Holl R, Holle R, Kiess W, Lennerz B, Lütke Brintrup D, Moss A, Neef M, Ose C, Reinehr T, Teuner CM, Wiegand S, Wolters B, Wabitsch M, Hebebrand J
164. The effects of PI3K-mediated signalling on glioblastoma cell behaviour. **Oncogenesis.** 2017; 6(11): 4 (IF=4.722) Langhans J, Schneele L, Trenkler N, von Bandemer H, Nonnenmacher L, Karpel-Massler G, Siegelin MD, Zhou S, Halatsch ME, Debatin KM, Westhoff MA
165. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. **Oncotarget.** 2017; 8(18): 29558-29573 Ishida CT, Bianchetti E, Shu C, Halatsch ME, Westhoff MA, Karpel-Massler G, Siegelin MD
166. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. **Oncotarget.** 2017; 8(23): 37140-37153 Ishida CT, Shu C, Halatsch ME, Westhoff MA, Altieri DC, Karpel-Massler G, Siegelin MD
167. Prediction of BMI at age 11 in a longitudinal sample of the Ulm Birth Cohort Study. **PLoS ONE.** 2017; 12(8): e0182338 (IF=2.766) Christiansen H, Brandt S, Walter V, Wabitsch M, Rothenbacher D, Brenner H, Schimmelmann BG, Hirsch O
168. Permissive hypercapnia for severe acute respiratory distress syndrome in immunocompromised children: A single center experience. **PLoS ONE.** 2017; 12(6): e0179974 (IF=2.766) Fuchs H, Rossmann N, Schmid MB, Hoenig M, Thome U, Mayer B, Klotz D, Hummler HD
169. Metabolomics reveals an entanglement of fasting leptin concentrations with fatty acid oxidation and gluconeogenesis in healthy children. **PLoS ONE.** 2017; 12(8): e0183185 (IF=2.766) Kirchberg FF, Brandt S, Moß A, Peissner W, Koenig W, Rothenbacher D, Brenner H, Koletzko B, Hellmuth C, Wabitsch M
170. Inflammatory Mediators in Tracheal Aspirates of Preterm Infants Participating in a Randomized Trial of Inhaled Nitric Oxide. **PLoS ONE.** 2017; 12(1): e0169352 (IF=2.766) Laube M, Amann E, Uhlig U, Yang Y, Fuchs HW, Zemlin M, Mercier JC, Maier RF, Hummler HD, Uhlig S, Thome UH
171. Diagnostics in Children and Adolescents with Suspected or Confirmed Pulmonary Hypertension. **Paediatr Respir Rev.** 2017; 23: 3-15 (IF=2.354) Koestenberger M, Hansmann G, Apitz C, Latus H, Lammers A
172. The epidemiology of sickle cell disease in Germany following recent large-scale immigration. **Pediatr Blood Cancer.** 2017; 64(7) (IF=2.646) Kunz JB, Cario H, Grosse R, Jarisch A, Lobitz S, Kulozik AE
173. Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease. **Pediatr Cardiol.** 2017; 38(7): 1342-1349 (IF=1.540) Latus H, Wagner I, Ostermayer S, Kerst G, Kreuder J, Schranz D, Apitz C
174. Home Exercise Training in Children and Adolescents with Pulmonary Arterial Hypertension: A Pilot Study. **Pediatr Cardiol.** 2017; 38(1): 191-198 (IF=1.540) Zöller D, Siaplaouras J, Apitz A, Bride P, Kaestner M, Latus H, Schranz D, Apitz C
175. Blood pressure regulation determined by ambulatory blood pressure profiles in children and adolescents with type 1 diabetes mellitus: Impact on diabetic complications. **Pediatr Diabetes.** 2017; 18(8): 874-882 (IF=3.161) Dost A, Bechtold-Dalla Pozza S, Bollow E, Kovacic R, Vogel P, Feldhahn L, Schwab KO, Holl RW, Initiative DPV
176. Low association between fasting and OGTT stimulated glucose levels with HbA1c in overweight children and adolescents. **Pediatr Diabetes.** 2017; 18(8): 734-741 (IF=3.161) Eehalt S, Wiegand S, Körner A, Schweizer R, Liesenkötter KP, Partsch CJ, Blumenstock G, Spielau U, Denzer C, Ranke MB, Neu A, Binder G, Wabitsch M, Kiess W, Reinehr T
177. PLA2R-positive (primary) membranous nephropathy in a child with IPEX syndrome **Pediatr Nephrol.** 2017; 32(9): 1621-1624 (IF=2.627) Chuva T, Pfister F, Beringer O, Felgentreff K, Büttner-Herold M, Amann K
178. Thyroid dysfunction and hepatic steatosis in overweight children and adolescents. **Pediatr Obes.** 2017; 12(1): 67-74 (IF=3.980) Kaltenbach TE, Graeter T, Oetzuerk S, Holzner D, Kratzer W, Wabitsch M, Denzer C

179. [Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.](#)
Sci Rep. 2017; 7(1): 5170 (IF=4.122)
Chen A, Zhang Y, Meng G, Jiang D, Zhang H, Zheng M, Xia M, Jiang A, Wu J, [Beltinger C](#), Wei J
180. [Splenic glucocorticoid resistance following psychosocial stress requires physical injury.](#)
Sci Rep. 2017; 7(1): 15730 (IF=4.122)
Foertsch S, Füchsl AM, Faller SD, Hölzer H, Langgartner D, [Messmann J](#), [Strauß G](#), Reber SO
181. [MDSCs are induced after experimental blunt chest trauma and subsequently alter antigen-specific T cell responses.](#)
Sci Rep. 2017; 7(1): 12808 (IF=4.122)
[Hüsecken Y](#), [Muche S](#), [Kustermann M](#), [Klingspor M](#), Palmer A, Braumüller S, Huber-Lang M, [Debatin KM](#), [Strauss G](#)
182. [Cardiac Depression in Pigs after Multiple Trauma - Characterization of Posttraumatic Structural and Functional Alterations.](#)
Sci Rep. 2017; 7(1): 17861 (IF=4.122)
Kalbitz M, Schwarz S, Weber B, Bosch B, Pressmar J, Hoenes FM, Braun CK, Horst K, Simon TP, Pfeifer R, Störmann P, [Hummler H](#), Gebhard F, Pape HC, Huber-Lang M, Hildebrand F, TREAT Research Group, Auner B, Relja B, Marzi I, Marx G, Haug A, Egerer L, Griensven MV, Tolba R, Reiss K, Uhlig S, Teuben M, Almahmoud K, Kalbas Y, Lüken H, Almahmoud K
183. [Subcutaneous white adipocytes express a light sensitive signaling pathway mediated via a melanopsin/TRPC channel axis.](#)
Sci Rep. 2017; 7(1): 16332 (IF=4.122)
Ondrusova K, Fatehi M, Barr A, Czarnecka Z, Long W, Suzuki K, Campbell S, Philippaert K, Hubert M, Tredget E, Kwan P, Touret N, [Wabitsch M](#), Lee KY, Light PE
184. [Trail \(TNF-related apoptosis-inducing ligand\) induces an inflammatory response in human adipocytes.](#)
Sci Rep. 2017; 7(1): 5691 (IF=4.122)
[Zoller V](#), [Funcke JB](#), [Roos J](#), [Dahlhaus M](#), [Abd El Hay M](#), Holzmann K, Marienfeld R, Kietzmann T, [Debatin KM](#), [Wabitsch M](#), [Fischer-Posovszky P](#)
185. [Sport mit angeborenem Herzfehler - Wo stehen wir 2017?](#)
Swiss Sports & Exercise Medicine. 2017; 65(3): 60-64
[Siaplaouras J](#), Albrecht C, [Apitz C](#)
186. [A case of anti-Rd causing fetal anemia.](#)
Transfusion. 2017; 57(6): 1485-1487 (IF=3.423)
Rauch S, Ritgen J, Wißkirchen M, Bauerfeind U, [Kohne E](#), Weinstock C
187. [Hämoglobinopathien - vielgestaltiges Krankheitsbild und Methodenspektrum](#)
Trillium Diagnostik. 2017; 15(1): 62
Frömmel C, [Kohne E](#)
188. [TLRs Go Linear - On the Ubiquitin Edge.](#)
Trends Mol Med. 2017; 23(4): 296-309 (IF=11.021)
[Zinngrebe J](#), Walczak H
189. [Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells.](#)
Tumor Biol. 2017; 39(3): 1010428317692227
Bischof J, [Westhoff MA](#), Wagner JE, Halatsch ME, Trentmann S, Knippschild U, Wirtz CR, Burster T
190. [\[EXIT - A Possible Intervention for New- and Earlyborn Babies with Severe Hydrops Fetalis and Hydrothoraces on Both Sides\].](#)
Z Geburtshilfe Neonatol. 2017; 221(6): 286-290 (IF=0.246)
[Koch S](#), [Essers J](#), [Beringer O](#), Reister F, [Hummler H](#), Moewes A
191. [Mild Hypothermia in a Child with Low-Dose Risperidone.](#)
Z Kinder Jugendpsychiatr Psychother. 2017; 45(4): 335-337 (IF=1.206)
Grau K, Plener PL, Gahr M, [Denzer C](#), Freudenmann RW

2016

192. [Novel Approaches to Apoptosis-Inducing Therapies.](#)
Adv Exp Med Biol. 2016; 930: 173-204 (IF=1.881)
[Westhoff MA](#), [Marschall N](#), [Debatin KM](#)
193. [LNK mutations and myeloproliferative disorders.](#)
Am J Hematol. 2016; 91(2): 248-51 (IF=5.275)
McMullin MF, [Cario H](#)
194. [Prehepatic secretion and disposal of insulin in obese adolescents as estimated by three-hour, eight-sample oral glucose tolerance tests.](#)
Am J Physiol Endocrinol Metab. 2016; 311(1): E82-94 (IF=4.142)
Vogt JA, [Domzig C](#), [Wabitsch M](#), [Denzer C](#)
195. [Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway.](#)
Am J Physiol Regul Integr Comp Physiol. 2016; 311(1): R104-14 (IF=2.982)
[Bordicchia M](#), [Ceresiani M](#), [Pavani M](#), [Minardi D](#), [Polito M](#), [Wabitsch M](#), [Cannone V](#), [Burnett JC](#), [Dessi-Fulgheri P](#), [Sarzan R](#)
196. [Development and psychometric validation of the 'Parent Perspective University of Rhode Island Change Assessment-Short' \(PURICA-S\) Questionnaire for the application in parents of children with overweight and obesity.](#)
BMJ Open. 2016; 6(11): e012711 (IF=2.369)
Junne F, Ziser K, Mander J, Martus P, [Denzer C](#), Reinehr T, [Wabitsch M](#), Wiegand S, Renner T, Giel KE, Teufel M, Zipfel S, Eehalt S
197. [Congenital intestinal diarrhoeal diseases: A diagnostic and therapeutic challenge.](#)
Best Pract Res Clin Gastroenterol. 2016; 30(2): 187-211 (IF=3.762)
[Posovszky C](#)
198. [Resveratrol inhibits lipogenesis of 3T3-L1 and SGBS cells by inhibition of insulin signaling and mitochondrial mass increase.](#)
Biochim Biophys Acta. 2016; 1857(6): 643-52 (IF=4.702)
Li S, Bouzar C, Cottet-Rousselle C, [Zagotta I](#), Lamarche F, [Wabitsch M](#), Tokarska-Schlattner M, [Fischer-Posovszky P](#), Schlattner U, Rousseau D

199. [MicroRNA-192* impairs adipocyte triglyceride storage.](#)
Biochim Biophys Acta. 2016; 1861(4): 342-351 (IF=4.702)
Mysore R, Zhou Y, Sädevirta S, Savolainen-Peltonen H, Nidhina Haridas PA, Soronen J, Leivonen M, Sarin AP, [Fischer-Posovszky P](#), [Wabitsch M](#), Yki-Järvinen H, Olkkonen VM
200. [Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis.](#)
Biol Blood Marrow Transplant. 2016; 22(11): 1997-2002 (IF=4.704)
Chiesa R, Ruggeri A, Paviglianiti A, Zecca M, González-Vicent M, Bordon V, Stein J, Lawson S, Dupont S, Lanino E, Abecasis M, Al-Seraihy A, Kenzey C, Bierings M, Locatelli F, Gluckman E, [Schulz A](#), Gennery A, Page K, Kurtzberg J, Rocha V, Eurocord, Inborn Errors Working Party, Cell Therapy, Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
201. [Impact of genotype on endocrinal complications in \$\beta\$ -thalassemia patients.](#)
Biomed Rep. 2016; 4(6): 728-736
Al-Akhras A, Badr M, El-Safy U, [Kohne E](#), Hassan T, Abdelrahman H, Mourad M, [Brintrup J](#), Zakaria M
202. [Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome.](#)
Blood. 2016; 127(8): 997-1006 (IF=13.164)
Ammann S, [Schulz A](#), Krägeloh-Mann I, Dieckmann NM, Niethammer K, Fuchs S, Eckl KM, Plank R, Werner R, Altmüller J, Thiele H, Nürnberg P, Bank J, [Strauss A](#), von Bernuth H, Zur Stadt U, Grieve S, Griffiths GM, Lehmborg K, Hennies HC, Ehl S
203. [The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis.](#)
Blood. 2016; 127(25): 3281-90 (IF=13.164)
Hartz B, Marsh R, Rao K, Henter JI, Jordan M, Filipovich L, Bader P, Beier R, Burkhardt B, Meisel R, [Schulz A](#), Winkler B, Albert MH, Greil J, Karasu G, Woessmann W, Corbacioglu S, Gruhn B, Holter W, Kühl JS, Lang P, Seidel MG, Veys P, Löfstedt A, Ammann S, Ehl S, Janka G, Müller I, Lehmborg K
204. [Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.](#)
Blood. 2016; 128(3): 440-8 (IF=13.164)
Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, [Schulz A](#), Ewins AM, Gibson B, Sedlacek P, Krol L, Strahm B, Zaidman I, Kalwak K, Talano JA, Woolfrey A, Fraser C, Meyts I, Müller I, Wachowiak J, Bernardo ME, Veys P, Sykora KW, Gennery AR, Slatter M
205. [Regulation and Function of Lentiviral Vector-Mediated TCIRG1 Expression in Osteoclasts from Patients with Infantile Malignant Osteopetrosis: Implications for Gene Therapy.](#)
Calcif Tissue Int. 2016; 99(6): 638-648 (IF=3.124)
Thudium CS, Moscatelli I, Löfvall H, Kertész Z, Montano C, Bjurström CF, Karsdal MA, [Schulz A](#), Richter J, Henriksen K
206. [Cathepsin G-mediated proteolytic degradation of MHC class I molecules to facilitate immune detection of human glioblastoma cells.](#)
Cancer Immunol Immunother. 2016; 65(3): 283-91 (IF=4.711)
Palesch D, Wagner J, Meid A, Molenda N, Sienczyk M, Burkhardt J, Münch J, Prokop L, Stevanovic S, [Westhoff MA](#), Halatsch ME, Wirtz CR, Zimecki M, Burster T
207. [Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.](#)
Cancer Lett. 2016; 371(1): 79-89 (IF=6.375)
[Dahlhaus M](#), Burkovski A, Hertwig F, Mussel C, Volland R, Fischer M, [Debatin KM](#), Kestler HA, [Beltinger C](#)
208. [Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia.](#)
Cell Death Dis. 2016; 7: e2052 (IF=5.965)
[Schirmer M](#), Trentin L, [Queudeville M](#), Seyfried F, Demir S, Tausch E, Stilgenbauer S, [Eckhoff SM](#), [Meyer LH](#), [Debatin KM](#)
209. [TRAIL \(TNF-related apoptosis-inducing ligand\) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors.](#)
Cell Death Dis. 2016; 7(10): e2412 (IF=5.965)
[Zoller V](#), [Funcke JB](#), [Keuper M](#), [Abd El Hay M](#), [Debatin KM](#), [Wabitsch M](#), [Fischer-Posovszky P](#)
210. [Cell Death Induction in Cancer Therapy - Past, Present, and Future.](#)
Crit Rev Oncog. 2016; 21(3-4): 253-267
[Nonnenmacher L](#), [Hasslacher S](#), [Zimmermann J](#), Karpel-Massler G, La Ferla-Brühl K, Barry SE, Burster T, Siegelin MD, Brühl O, Halatsch ME, [Debatin KM](#), [Westhoff MA](#)
211. [Zerebraler Krampfanfall – Ein Leitfaden zur prähospitalen Diagnosefindung und Therapie](#)
Der Notarzt. 2016; 32(01): 40-45 (IF=0.318)
Harth A, [Winter B](#), Kulla M
212. [International Comparison of Smoking and Metabolic Control in Patients With Type 1 Diabetes.](#)
Diabetes Care. 2016; 39(10): e177-8 (IF=11.857)
Hofer SE, Miller K, Hermann JM, DeSalvo DJ, Riedl M, Hirsch IB, Karges W, Beck RW, Holl RW, Maahs DM, [DPV Initiative](#), T1D Exchange Clinic Network
213. [Does \$\beta\$ -Cell Autoimmunity Play a Role in Cystic Fibrosis-Related Diabetes? Analysis Based on the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry.](#)
Diabetes Care. 2016; 39(8): 1338-44 (IF=11.857)
Konrad K, Kapellen T, Lilienthal E, Prinz N, Bauer M, Thon A, Rietschel E, Wiemann D, Holl RW, [DPV Initiative](#) and the Competence Network Diabetes Mellitus
214. [Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria.](#)
Diabetes Res Clin Pract. 2016; 115: 31-8 (IF=3.639)
Bohn B, Kerner W, Seufert J, Kempe HP, Jehle PM, Best F, Füchtenbusch M, Knauerhase A, Hofer M, Rosenbauer J, Holl RW, [DPV-initiative](#)

215. [Prevalence and comorbidities of double diabetes.](#)
Diabetes Res Clin Pract. 2016; 119: 48-56 (IF=3.639)
Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, Müller-Korbsch M, Holl RW, [DPV Initiative](#), German BMBF Competence Network Diabetes mellitus
216. [Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries.](#)
Diabetes Res Clin Pract. 2016; 122: 28-37 (IF=3.639)
Weinstock RS, Schütz-Fuhrmann I, Connor CG, Hermann JM, Maahs DM, Schütt M, Agarwal S, Hofer SE, Beck RW, Holl RW, T1D Exchange Clinic Network, [DPV Initiative](#)
217. [Insulin Pumps in Type 1 Diabetes with Mental Disorders: Real-Life Clinical Data Indicate Discrepancies to Recommendations.](#)
Diabetes Technol Ther. 2016; 18(1): 34-8 (IF=2.698)
Prinz N, Bächle C, Becker M, Berger G, Galler A, Haberland H, Meusers M, Mirza J, Plener PL, von Sengbusch S, Thienelt M, Holl RW, [DPV Initiative](#)
218. [Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries.](#)
Diabetologia. 2016; 59(1): 87-91 (IF=6.08)
Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, Maahs DM, Kapellen TM, Holman N, Tamborlane WV, Holl RW, Beck RW, Warner JT, [T1D Exchange Clinic Network](#), the [DPV Initiative](#), and the [National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries](#)
219. [Redundant roles of the phosphatidate phosphatase family in triacylglycerol synthesis in human adipocytes.](#)
Diabetologia. 2016; 59(9): 1985-94 (IF=6.08)
Temprano A, Sembongi H, Han GS, Sebastián D, Capellades J, Moreno C, Guardiola J, [Wabitsch M](#), Richart C, Yanes O, Zorzano A, Carman GM, Siniossoglou S, Miranda M
220. [Prevention and Therapy of Obesity](#)
Diabetologie und Stoffwechsel. 2016; 11(S02): S130-S135 (IF=0.429)
Hauner H, [Moss A](#), Berg A, Bischoff SC, Colombo-Benkmann M, Ellrott T, Kanthak U, Kunze D, Stefan N, Teufel M, [Wabitsch M](#), Wirth A
221. [The role of enterocyte defects in the pathogenesis of congenital diarrheal disorders.](#)
Dis Model Mech. 2016; 9(1): 1-12 (IF=4.691)
Overeem AW, [Posovszky C](#), Rings EH, Giepmans BN, van IJendoorn SC
222. [\[Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016\].](#)
Dtsch Med Wochenschr. 2016; 141(S 01): S33-S41 (IF=0.552)
Hoepfer MM, [Apitz C](#), Grünig E, Halank M, Ewert R, Kaemmerer H, Kabitz HJ, Kähler C, Klose H, Leuchte H, Ulrich S, Olsson KM, Distler O, Rosenkranz S, Ghofrani HA
223. [\[Pulmonary hypertension in grown-ups with congenital heart disease: Recommendations of the Cologne Consensus Conference 2016\].](#)
Dtsch Med Wochenschr. 2016; 141(S 01): S70-S79 (IF=0.552)
Kaemmerer H, [Apitz C](#), Brockmeier K, Eicken A, Gorenflo M, Hager A, deHaan F, Huntgeburth M, Kozlik-Feldmann R, Miera O, Diller GP
224. [Bowel preparation in pediatric colonoscopy: results of an open observational study.](#)
Endosc Int Open. 2016; 4(7): E820-7
Berger T, Classen M, Engelhardt H, Keller KM, Laass MW, Melchior R, [Posovszky C](#), Rodeck B, Schaper K, Behrens R
225. [Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prostaglandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance.](#)
FASEB J. 2016; 30(6): 2282-97 (IF=5.498)
Chan PC, Hsiao FC, Chang HM, [Wabitsch M](#), Hsieh PS
226. [Functional characterization of retromer in GLUT4 storage vesicle formation and adipocyte differentiation.](#)
FASEB J. 2016; 30(3): 1037-50 (IF=5.498)
Yang Z, Hong LK, Follett J, [Wabitsch M](#), Hamilton NA, Collins BM, Bugarcic A, Teasdale RD
227. [Mortality and Major Morbidity of Very-Low-Birth-Weight Infants in Germany 2008-2012: A Report Based on Administrative Data.](#)
Front Pediatr. 2016; 4: 23 (IF=2.172)
Jeschke E, Biermann A, Günster C, Böhler T, Heller G, [Hummeler HD](#), Bühner C, Routine Data-Based Quality Improvement Panel
228. [Primary Familial and Congenital Polycythemia](#)
GeneReviews. 2016: NBK395975
Bento C, McMullin MF, Percy M, [Cario H](#)
229. [Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations.](#)
Haematologica. 2016; 101(11): 1306-1318 (IF=7.702)
Camps C, Petousi N, Bento C, [Cario H](#), Copley RR, McMullin MF, van Wijk R, Ratcliffe PJ, Robbins PA, Taylor JC, WGS500 Consortium
230. [Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.](#)
Haematologica. 2016; 101(8): 985-94 (IF=7.702)
Kuçi Z, Böni H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, Škifić M, Michel K, Eising B, Lucchini G, Bakhtiar S, Greil J, Lang P, Basu O, von Lüttichau I, [Schulz A](#), Sykora KW, Jarisch A, Soerensen J, Salzmann-Manrique E, Seifried E, Klingebiel T, Bader P, Kuçi S

231. Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia.
Haematologica. 2016; 101(6): 741-6 (IF=7.702)
Preuner S, Peters C, Pötschger U, Daxberger H, Fritsch G, Geyeregger R, Schrauder A, von Stackelberg A, Schrappe M, Bader P, Ebell W, Eckert C, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Lawitschka A, Mann G, Panzer-Grümayer R, Güngör T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Lion T
232. Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.
Haematologica. 2016; 101(4): e153-6 (IF=7.702)
Rettinger E, Huenecke S, Böinig H, Merker M, Jarisch A, Soerensen J, Willasch A, Bug G, Schulz A, Klingebiel T, Bader P
233. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmon
Heart. 2016; 102 Suppl: ii23-9 (IF=6.059)
Apitz C, Hansmann G, Schranz D
234. Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
Heart. 2016; 102 Suppl: ii86-100 (IF=6.059)
Hansmann G, Apitz C, Abdul-Khaliq H, Alastalo TP, Beerbaum P, Bonnet D, Dubowy KO, Gorenflo M, Hager A, Hilgendorff A, Kaestner M, Koestenberger M, Koskenvuo JW, Kozlik-Feldmann R, Kuehne T, Lammers AE, Latus H, Michel-Behnke I, Miera O, Moledina S, Muthurangu V, Pattathu J, Schranz D, Warnecke G, Zartner P
235. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
Heart. 2016; 102 Suppl: ii67-85 (IF=6.059)
Hansmann G, Apitz C
236. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
Heart. 2016; 102 Suppl: ii49-56 (IF=6.059)
Hilgendorff A, Apitz C, Bonnet D, Hansmann G
237. Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
Heart. 2016; 102 Suppl: ii57-66 (IF=6.059)
Kaestner M, Schranz D, Warnecke G, Apitz C, Hansmann G, Miera O
238. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by
Heart. 2016; 102 Suppl: ii42-8 (IF=6.059)
Kozlik-Feldmann R, Hansmann G, Bonnet D, Schranz D, Apitz C, Michel-Behnke I
239. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European
Heart. 2016; 102 Suppl: ii1-13 (IF=6.059)
Lammers AE, Apitz C, Zartner P, Hager A, Dubowy KO, Hansmann G
240. Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmo
Heart. 2016; 102 Suppl: ii30-5 (IF=6.059)
Latus H, Kuehne T, Beerbaum P, Apitz C, Hansmann G, Muthurangu V, Moledina S
241. Clinical and prognostic value of endothelin-1 and big endothelin-1 expression in children with pulmonary hypertension.
Heart. 2016; 102(13): 1052-8 (IF=6.059)
Latus H, Karanatsios G, Basan U, Salser K, Müller S, Khalil M, Kreuder J, Schranz D, Apitz C
242. Towards a proposal for a universal diagnostic definition of protein-losing enteropathy in Fontan patients: a systematic review.
Heart. 2016; 102(14): 1115-9 (IF=6.059)
Udink Ten Cate FE, Hannes T, Germund I, Khalil M, Huntgeburth M, Apitz C, Brockmeier K, Sreeram N
243. Functional Significance and Predictive Value of MicroRNAs in Pediatric Obesity: Tiny Molecules with Huge Impact?
Horm Res Paediatr. 2016; 86(1): 3-10 (IF=1.844)
Fischer-Posovszky P, Roos J, Kotnik P, Battelino T, Inzaghi E, Nobili V, Cianfarani S, Wabitsch M
244. MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child.
Hum Mutat. 2016; 37(3): 257-68 (IF=4.601)
Gatz SA, Salles D, Jacobsen EM, Dörk T, Rausch T, Aydin S, Surowy H, Volcic M, Vogel W, Debatin KM, Stütz AM, Schwarz K, Pannicke U, Hess T, Korbel JO, Schulz AS, Schumacher J, Wiesmüller L
245. A paired comparison between glioblastoma “stem cells” and differentiated cells.
Int J Cancer. 2016; 138(7): 1709-18 (IF=6.513)
Schneider M, Ströbele S, Nonnenmacher L, Siegelin MD, Tepper M, Stroh S, Hasslacher S, Enzenmüller S, Strauss G, Baumann B, Karpel-Massler G, Westhoff MA, Debatin KM, Halatsch ME

246. Anti-inflammatory properties of bone morphogenetic protein 4 in human adipocytes.
Int J Obes (Lond). 2016; 40(2): 319-27 (IF=5.487)
Baraban E, Chavakis T, Hamilton BS, Sales S, Wabitsch M, Bornstein SR, Ehrhart-Bornstein M
247. Granzyme B produced by Plasmacytoid Dendritic Cells Promotes Antigen uptake While Suppressing Premature T cell Activation
Int J Vaccine Res. 2016; 1(2): 3
Fabricius D, Trzaska T, Jahrsdörfer B
248. The Need for Comprehensive Cardiac Catheterization in Children With Pulmonary Hypertension.
J Am Coll Cardiol. 2016; 67(8): 1009-10 (IF=19.896)
Hansmann G, Apitz C
249. Pediatric Head Injury: The Incidence of Multiple Injuries
J Behav Brain Sci. 2016; 6(6): 254-267
Kapapa T, Kapapa M, Posovszky C, Gülke J, König R, Woischneck D, Wirtz CR, Pala A
250. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
J Clin Endocrinol Metab. 2016; 101(12): 4500-4511 (IF=5.455)
Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T
251. Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency.
J Clin Immunol. 2016; 36(7): 725-32 (IF=3.253)
John T, Walter JE, Schuetz C, Chen K, Abraham RS, Bonfim C, Boyce TG, Joshi AY, Kang E, Carvalho BT, Mahajerin A, Nugent D, Puthenveetil G, Soni A, Su H, Cowan MJ, Notarangelo L, Buchbinder D
252. LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation.
J Exp Med. 2016; 213(12): 2671-2689 (IF=11.991)
Zinngrebe J, Rieser E, Taraborrelli L, Peltzer N, Hartwig T, Ren H, Kovács I, Endres C, Draber P, Darding M, von Karstedt S, Lemke J, Dome B, Bergmann M, Ferguson BJ, Walczak H
253. Immune phenotypes predict survival in patients with glioblastoma multiforme.
J Hematol Oncol. 2016; 9(1): 77 (IF=6.35)
Mostafa H, Pala A, Högel J, Hlavac M, Dietrich E, Westhoff MA, Nonnenmacher L, Burster T, Georgieff M, Wirtz CR, Schneider EM
254. Human Immunodeficiency Virus Arrests Plasmacytoid Dendritic Cells in a Granzyme Bhigh Tolerogenic State
J Vaccines Vaccin. 2016; 7: 337
Jahrsdörfer B, Panitz V, Fabricius D
255. Assessment of RV function with pressure-volume loops - impact on treatment indication for a volume-loaded RV
Journal für angeborene Herzfehler. 2016; 05(Apr): 16-17
Apitz C
256. [Current Guidelines to Prevent Obesity in Childhood and Adolescence].
Klin Padiatr. 2016; 228(1): 1-10 (IF=0.731)
Blüher S, Kromeyer-Hauschild K, Graf C, Grünewald-Funk D, Widhalm K, Korsten-Reck U, Markert J, Güssfeld C, Müller MJ, Moss A, Wabitsch M, Wiegand S
257. Risk Factors Associated with Intraventricular Hemorrhage in Preterm Infants with <=28 Weeks Gestational Age.
Klin Padiatr. 2016; 228(5): 245-50 (IF=0.731)
Waitz M, Nusser S, Schmid MB, Dreyhaupt J, Reister F, Hummler H
258. Diabetes in Patients with β -thalassemia or other Hemoglobinopathies - Analysis from the DPV Database.
Klin Padiatr. 2016; 228(6-07): 307-312 (IF=0.731)
Warncke K, Konrad K, Köhne E, Hammer E, Ohlenschläger U, Herrlinger S, Jäger A, Holl RW
259. Growth impairment in children with pulmonary hypertension.
Lancet Respir Med. 2016; 4(4): 245-7 (IF=19.287)
Latus H, Schranz D, Apitz C
260. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Leukemia. 2016; 30(6): 1246-54 (IF=11.702)
Köhler S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA
261. [Case series: BMI long courses in patients with extreme juvenile obesity. Short- and long-term success of long-term inpatient treatment].
MMW Fortschr Med. 2016; 158 Suppl: 1-7
Brandt S, König D, Lennerz B, Schoosleitner C, Schäfer A, Siegfried A, Siegfried W, Wabitsch M
262. Rechter Ventrikel im Fokus der Kinderkardiologie Management und Krankenhaus. 2016; 2016(9): 12
Apitz C
263. SREBP-1c/MicroRNA 33b Genomic Loci Control Adipocyte Differentiation.
Mol Cell Biol. 2016; 36(7): 1180-93 (IF=4.398)
Price NL, Holtrup B, Kwei SL, Wabitsch M, Rodeheffer M, Bianchini L, Suárez Y, Fernández-Hernando C
264. Adipocyte-specific Hypoxia-inducible gene 2 promotes fat deposition and diet-induced insulin resistance.
Mol Metab. 2016; 5(12): 1149-1161 (IF=6.799)
DiStefano MT, Roth Flach RJ, Senol-Cosar O, Danai LV, Virbasius JV, Nicoloso SM, Straubhaar J, Dagdeviren S, Wabitsch M, Gupta OT, Kim JK, Czech MP
265. miR-125b affects mitochondrial biogenesis and impairs brite adipocyte formation and function.
Mol Metab. 2016; 5(8): 615-25 (IF=6.799)
Giroud M, Pisani DF, Karbiener M, Barquissau V, Ghandour RA, Tews D, Fischer-Posovszky P, Chambard JC, Knippschild U, Niemi T, Taittonen M, Nuutila P, Wabitsch M, Herzig S, Virtanen KA, Langin D, Scheideler M, Amri EZ

266. Microbiological screening in preterm infants. Results and consequences for hygiene management
Monatsschr Kinderheilkd. 2016; 164(9): 805-812 (IF=0.31)
Lindner W, Essig A, Hummler HD, Reister F, von Baum H
267. Tenomodulin promotes human adipocyte differentiation and beneficial visceral adipose tissue expansion.
Nat Commun. 2016; 7: 10686 (IF=12.124)
Senol-Cosar O, Flach RJ, DiStefano M, Chawla A, Nicoloso S, Straubhaar J, Hardy OT, Noh HL, Kim JK, Wabitsch M, Scherer PE, Czech MP
268. Effect of Different Respiratory Modes on Return of Spontaneous Circulation in a Newborn Piglet Model of Hypoxic Cardiac Arrest.
Neonatology. 2016; 109(1): 22-30 (IF=2.598)
Mendler MR, Weber C, Hassan MA, Huang L, Waitz M, Mayer B, Hummler HD
269. Sonographically Assessed Intra-Abdominal Fat And Cardiometabolic Risk Factors in Adolescents with Extreme Obesity.
Obes Facts. 2016; 9(2): 121-37 (IF=2.25)
Moss A, Sievert K, Siegfried W, Siegfried A, Brandt S, Koenig W, Wabitsch M
270. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
Oncotarget. 2016; 7(20): 28914-9 (IF=5.168)
Bresolin S, De Filippi P, Vendemini F, D'Alia M, Zecca M, Meyer LH, Danesino C, Locatelli F, Masetti R, Basso G, Te Kronnie G
271. γ -secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.
Oncotarget. 2016; 7(39): 62799-62813 (IF=5.168)
Dorneburg C, Goß AV, Fischer M, Roels F, Barth TF, Berthold F, Kappler R, Oswald F, Siveke JT, Molenaar JJ, Debatin KM, Beltinger C
272. Exogenous cathepsin G upregulates cell surface MHC class I molecules on immune and glioblastoma cells.
Oncotarget. 2016; 7(46): 74602-74611 (IF=5.168)
Giese M, Turiello N, Molenda N, Palesch D, Meid A, Schroeder R, Basílico P, Benarafa C, Halatsch ME, Zimecki M, Westhoff MA, Wirtz CR, Burster T
273. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
Oncotarget. 2016; 7(23): 33512-28 (IF=5.168)
Karpel-Massler G, Ramani D, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD
274. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.
Oncotarget. 2016; 7(11): 12791-805 (IF=5.168)
Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD
275. The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.
Oncotarget. 2016; 7(6): 6620-5 (IF=5.168)
Riehl LM, Schulte JH, Mulaw MA, Dahlhaus M, Fischer M, Schramm A, Eggert A, Debatin KM, Beltinger C
276. Novel homozygous RARS2 mutation in two siblings without pontocerebellar hypoplasia - further expansion of the phenotypic spectrum.
Orphanet J Rare Dis. 2016; 11(1): 140 (IF=3.507)
Lühl S, Bode H, Schlötzer W, Bartsakoulia M, Horvath R, Abicht A, Stenzel M, Kirschner J, Grünert SC
277. 20 Years of Pediatric Benchmarking in Germany and Austria: Age-Dependent Analysis of Longitudinal Follow-Up in 63,967 Children and Adolescents with Type 1 Diabetes.
PLoS ONE. 2016; 11(8): e0160971 (IF=2.806)
Bohn B, Karges B, Vogel C, Otto KP, Marg W, Hofer SE, Fröhlich-Reiterer E, Holder M, Plamper M, Wabitsch M, Kerner W, Holl RW, DPV Initiative
278. A Recurrent Germline Mutation in the 5'UTR of the Androgen Receptor Causes Complete Androgen Insensitivity by Activating Aberrant uORF Translation.
PLoS ONE. 2016; 11(4): e0154158 (IF=2.806)
Hornig NC, de Beaufort C, Denzer F, Cools M, Wabitsch M, Ukat M, Kulle AE, Schweikert HU, Werner R, Hiort O, Audi L, Siebert R, Ammerpohl O, Holterhus PM
279. The Effects of Lung Protective Ventilation or Hypercapnic Acidosis on Gas Exchange and Lung Injury in Surfactant Deficient Rabbits.
PLoS ONE. 2016; 11(2): e0147807 (IF=2.806)
Hummler HD, Banke K, Wolfson MR, Buonocore G, Ebsen M, Bernhard W, Tsikas D, Fuchs H
280. Adipocytes as a Link Between Gut Microbiota-Derived Flagellin and Hepatocyte Fat Accumulation.
PLoS ONE. 2016; 11(4): e0152786 (IF=2.806)
Munukka E, Wiklund P, Partanen T, Välimäki S, Laakkonen EK, Lehti M, Fischer-Posovzsky P, Wabitsch M, Cheng S, Huovinen P, Pekkala S
281. Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children.
Pediatr Allergy Immunol. 2016; 27(2): 177-84 (IF=3.775)
Hagl B, Heinz V, Schlesinger A, Spielberger BD, Sawalle-Belohradsky J, Senn-Rauh M, Magg T, Boos AC, Hönig M, Schwarz K, Dückers G, von Bernuth H, Pache C, Karitnig-Weiss C, Belohradsky BH, Frank J, Niehues T, Wahn V, Albert MH, Wollenberg A, Jansson AF, Renner ED
282. Coexpression of Multiple ABC-Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia.
Pediatr Blood Cancer. 2016; 63(2): 242-7 (IF=2.513)
Bartholomae S, Gruhn B, Debatin KM, Zimmermann M, Creutzig U, Reinhardt D, Steinbach D
283. Current practice of diabetes education in children and adolescents with type 1 diabetes in Germany and Austria: analysis based on the German/Austrian DPV database.
Pediatr Diabetes. 2016; 17(7): 483-491 (IF=4.267)
Konrad K, Vogel C, Bollow E, Fritsch M, Lange K, Bartus B, Holl RW, German/Austrian DPV Initiative and the competence network of diabetes

284. [Therapeutic potential of the dual peroxisome proliferator activated receptor \(PPAR\) \$\alpha/\gamma\$ agonist aleglitazar in attenuating TNF- \$\alpha\$ -mediated inflammation and insulin resistance in human adipocytes.](#)
Pharmacol Res. 2016; 107: 125-36 (IF=4.48)
Massaro M, Scoditti E, Pellegrino M, Carluccio MA, Calabriso N, [Wabitsch M](#), Storelli C, Wright M, De Caterina R
285. [Synkopen im Kindesalter](#)
Päd Praktische Pädiatrie. 2016; 2016(5): 276-282
[Kaestner M](#), [Bride P](#), [Apitz C](#)
286. [Vaccination of immunosuppressed children and adolescents](#)
Pädiatr Prax. 2016; 85(3): 363-384
[Schleker T](#), [Speth F](#), [Posovszky C](#)
287. [Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.](#)
Rheumatology (Oxford). 2016; 55(4): 689-96 (IF=4.818)
Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weißbarth-Riedel E, [Schuetz C](#), Kallinich T, Krause K, Rietschel C, Horneff G, Benseler SM
288. [MRI-Based Liver Iron Content Determination at 3T in Regularly Transfused Patients by Signal Intensity Ratio Using an Alternative Analysis Approach Based on R2* Theory.](#)
Rofo. 2016; 188(9): 846-52 (IF=1.418)
Wunderlich AP, [Cario H](#), Bommer M, Beer M, Schmidt SA, Juchems MS
289. [Noninvasive MRI-Based Liver Iron Quantification: Methodic Approaches, Practical Applicability and Significance.](#)
Rofo. 2016; 188(11): 1031-1036 (IF=1.418)
Wunderlich AP, [Cario H](#), Juchems MS, Beer M, Schmidt SA
290. [miR-146a-mediated suppression of the inflammatory response in human adipocytes.](#)
Sci Rep. 2016; 6: 38339 (IF=4.259)
[Roos J](#), [Enlund E](#), [Funcke JB](#), [Tews D](#), [Holzmann K](#), [Debatin KM](#), [Wabitsch M](#), [Fischer-Posovszky P](#)
291. [Ancillary therapies to enhance success of non-invasive modes of respiratory support - Approaches to delivery room use of surfactant and caffeine?](#)
Semin Fetal Neonatal Med. 2016; 21(3): 212-8 (IF=3.33)
[Kribs A](#), [Hummler H](#)
292. [Erythrozytenaustausch bei Sichelzellerkrankung](#)
Transfusionsmedizin. 2016; 6(01): 13-18
Anyanwu A, [Cario H](#), Dürken M
293. [Clozapine modifies the differentiation program of human adipocytes inducing browning.](#)
Transl Psychiatry. 2016; 6(11): e963 (IF=4.73)
Kristóf E, Doan-Xuan QM, Sárvari AK, Klusóczy Á, [Fischer-Posovszky P](#), [Wabitsch M](#), Bacso Z, Bai P, Balajthy Z, Fésüs L
294. [\[The Wolf-Hirschhorn Syndrome\].](#)
Z Geburtshilfe Neonatol. 2016; 220(5): 195-199 (IF=0.476)
[Friebe-Hoffmann U](#), [Reister F](#), [Gaspar H](#), [Hummler H](#), [Lindner W](#), Lato K
- 2015
295. [Hepatitis B Postexposure Prophylaxis in Preterm and Low-Birth-Weight Infants.](#)
AJP Rep. 2015; 5(1): e67-72
[Waitz M](#), [Hopfner R](#), [Hummler HD](#), [Heininger U](#)
296. [Ambulante, multidisziplinäre Adipositas therapie für Kinder und Jugendliche in der Regelversorgung. Die Ulmer Erfahrung](#)
Adipositas. 2015; 9(1): 26-33
[Denzer C](#), [Weyhreter H](#), [Wabitsch M](#)
297. [Leptin – Neuigkeiten von einem alten Bekannten](#)
Adipositas. 2015; 9(3): 140-145
[Funcke J-B](#), [Wabitsch M](#), [Fischer-Posovszky P](#)
298. [Gegen Diskriminierung und für die Förderung von Kindern und Jugendlichen mit Adipositas – die Geschichte der AGA](#)
Aktuell Ernährungsmed. 2015; 40(01): 50-53
[Wabitsch M](#)
299. [Blood pressure in 57,915 pediatric patients who are overweight or obese based on five reference systems.](#)
Am J Cardiol. 2015; 115(11): 1587-94 (IF=3.154)
[Flechtner-Mors M](#), [Neuhauser H](#), [Reinehr T](#), [Roost HP](#), [Wiegand S](#), [Siegfried W](#), [Zwiauer K](#), [Molz E](#), [Holl RW](#), [APV initiative and the BMBF Competence Network Obesity](#)
300. [Intrafamilial associations of cardiometabolic risk factors--results of the Ulm Birth Cohort Study.](#)
Atherosclerosis. 2015; 240(1): 174-83 (IF=3.942)
[Brandt S](#), [Moß A](#), [Koenig W](#), [Rothenbacher D](#), [Brenner H](#), [Wabitsch M](#)
301. [Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years.](#)
BMC Endocr Disord. 2015; 15: 41 (IF=1.739)
[Ludwig U](#), [Holzner D](#), [Denzer C](#), [Greiner A](#), [Haenle MM](#), [Oeztuerk S](#), [Koenig W](#), [Boehm BO](#), [Mason RA](#), [Kratzer W](#), [Graeter T](#), [EMIL-Study](#), [Adler G](#), [Armsen A](#), [Banzhaf H](#), [Bauerdick M](#), [Bertling U](#), [Boehm BO](#), [Brandner BO](#), [Brockmann SO](#), [Deckert M](#), [Dingler C](#), [Eggink S](#), [Fuchs M](#), [Gaus W](#), [Goussis H](#), [Gruenert A](#), [Haenle MM](#), [Hampel W](#), [Haug C](#), [Hay B](#), [Huetter ML](#), [Imhof A](#), [Kern P](#), [Kimmig P](#), [Kirch A](#), [Klass D](#), [Koenig W](#), [Kratzer W](#), [Kron M](#), [Manfras B](#), [Meitinger K](#), [Mertens T](#), [Oehme R](#), [Pfaff G](#), [Piechotowski I](#), [Reuter S](#), [Romig T](#), [von Schmiesing AF](#), [Steinbach G](#), [Toubier M](#), [Voegtler A](#), [Walcher T](#), [Wolff S](#)
302. [Intestinal epithelial cells promote secretion of leptin and adiponectin in adipocytes.](#)
Biochem Biophys Res Commun. 2015; 458(2): 362-8 (IF=2.371)
[Ishihara R](#), [Mizuno Y](#), [Miwa A](#), [Hamada A](#), [Tsuruta T](#), [Wabitsch M](#), [Sonoyama K](#)
303. [Central nervous system acute lymphoblastic leukemia: role of natural killer cells.](#)
Blood. 2015; 125(22): 3420-31 (IF=11.847)
[Frishman-Levy L](#), [Shemesh A](#), [Bar-Sinai A](#), [Ma C](#), [Ni Z](#), [Frenkel S](#), [Muench V](#), [Bruckmueller H](#), [Vokuhl C](#), [Debatin KM](#), [Eckert C](#), [Stanulla M](#), [Schrapppe M](#), [Campbell KS](#), [Loewenthal R](#), [Schewe DM](#), [Hochman J](#), [Meyer LH](#), [Kaufman D](#), [Cario G](#), [Porgador A](#), [Israeli S](#)

304. [In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity.](#)
Blood. 2015; 126(9): 1138-48 (IF=11.847)
Messmann JJ, Reisser T, Leithäuser F, Lutz MB, Debatin KM, Strauss G
305. [First characterization of platelet secretion defect in patients with familial hemophagocytic lymphohistiocytosis type 3 \(FHL-3\).](#)
Blood. 2015; 125(2): 412-4 (IF=11.847)
Nakamura L, Bertling A, Brodde MF, Zur Stadt U, Schulz AS, Ammann S, Sandrock-Lang K, Beutel K, Zieger B, Kehrel BE
306. [Outcomes of pregnancy in patients with congenital erythrocytosis.](#)
Br J Haematol. 2015; 170(4): 586-8 (IF=5.812)
McMullin MF, Bento C, Rossi C, Rainey MG, Girodon F, Cario H
307. [Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.](#)
Cell Death Differ. 2015; 22(1): 58-73 (IF=8.218)
Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G
308. [Bariatrisch-chirurgische Eingriffe bei Jugendlichen mit extremer Adipositas](#)
Chir Allg. 2015; 2015(7/8): 417-420
Arbeitsgemeinschaft Adipositas im Kindes- und Jugendalter (AGA) Berlin
309. [Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.](#)
Clin Cancer Res. 2015; 21(6): 1353-9 (IF=8.738)
Steinbach D, Bader P, Willasch A, Bartholomae S, Debatin KM, Zimmermann M, Creutzig U, Reinhardt D, Gruhn B
310. [Treatment of young patients with HNF1A mutations \(HNF1A-MODY\).](#)
Diabet Med. 2015; 32(4): 526-30 (IF=3.152)
Raile K, Schober E, Konrad K, Thon A, Grulich-Henn J, Meissner T, Wölflle J, Scheuing N, Holl RW, DPV Initiative the German BMBF Competence Network Diabetes Mellitus
311. [Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients.](#)
Diabetes Care. 2015; 38(8): 1536-43 (IF=8.934)
Bohn B, Herbst A, Pfeifer M, Krakow D, Zimny S, Kopp F, Melmer A, Steinacker JM, Holl RW, DPV Initiative
312. [Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany.](#)
Diabetes Care. 2015; 38(10): 1876-82 (IF=8.934)
Maahs DM, Hermann JM, Holman N, Foster NC, Kapellen TM, Allgrove J, Schatz DA, Hofer SE, Campbell F, Steigleder-Schweiger C, Beck RW, Warner JT, Holl RW, National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health, the DPV Initiative, and the T1D Exchange Clinic Network
313. [Accuracy of blood glucose meters for self-monitoring affects glucose control and hypoglycemia rate in children and adolescents with type 1 diabetes.](#)
Diabetes Technol Ther. 2015; 17(4): 275-82 (IF=2.198)
Boettcher C, Dost A, Wudy SA, Flechtner-Mors M, Borkenstein M, Schiel R, Weitzel D, Bechtold-Dalla Pozza S, Wolf J, Holl RW, German/Austrian Diabetes Prospective Documentation Initiative
314. [Prävention und Therapie der Adipositas](#)
Diabetologie und Stoffwechsel. 2015; 10(S 02): S152-S157 (IF=0.466)
Hauner H, Moss A, Berg A, Bischoff SC, Colombo-Benkmann M, Ellrott T, Kanthak U, Kunze D, Stefan N, Teufel M, Wabitsch M, Wirth A
315. [Clinical Practice Guideline: The Prevention and Treatment of Obesity \[author reply to comments\].](#)
Dtsch Arztebl Int. 2015; 112(14): 250 (IF=3.738)
Wirth A, Wabitsch M, Hauner H
316. [Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.](#)
Eur J Clin Microbiol Infect Dis. 2015; 34(6): 1189-200 (IF=2.857)
Döring M, Eikemeier M, Cabanillas Stanchi KM, Hartmann U, Ebinger M, Schwarze CP, Schulz A, Handgretinger R, Müller I
317. [TNF-related apoptosis-inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation.](#)
FASEB J. 2015; 29(7): 3065-75 (IF=5.299)
Funcke JB, Zoller V, El Hay MA, Debatin KM, Wabitsch M, Fischer-Posovszky P
318. [Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension.](#)
Front Pediatr. 2015; 3: 63
Latus H, Bandorski D, Rink F, Tiede H, Siaplaouras J, Ghofrani A, Seeger W, Schranz D, Apitz C

319. Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue.
Front Pharmacol. 2015; 6: 79 (IF=4.418)
Zagotta I, Dimova EY, Debatin KM, Wabitsch M, Kietzmann T, Fischer-Posovszky P
320. Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes.
Growth Horm IGF Res. 2015; 25(3): 115-20 (IF=1.448)
Wilhelm F, Kässner F, Schmid G, Kratzsch J, Laner A, Wabitsch M, Körner A, Kiess W, Garten A
321. Levothyroxine Treatment of Euthyroid Children with Autoimmune Hashimoto Thyroiditis: Results of a Multicenter, Randomized, Controlled Trial.
Horm Res Paediatr. 2015; 84(4): 266-74 (IF=1.661)
Dörr HG, Bettendorf M, Binder G, Karges B, Kneppo C, Schmidt H, Voss E, Wabitsch M, Dötsch J
322. Regulation of appetite, satiation, and body weight by enteroendocrine cells. Part 1: characteristics of enteroendocrine cells and their capability of weight regulation.
Horm Res Paediatr. 2015; 83(1): 1-10 (IF=1.661)
Posovszky C, Wabitsch M
323. Regulation of appetite, satiation, and body weight by enteroendocrine cells. Part 2: therapeutic potential of enteroendocrine cells in the treatment of obesity.
Horm Res Paediatr. 2015; 83(1): 11-8 (IF=1.661)
Posovszky C, Wabitsch M
324. RIST: A potent new combination therapy for glioblastoma.
Int J Cancer. 2015; 136(4): E173-87 (IF=5.531)
Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM
325. Ethnicity and cardiovascular risk factors: evaluation of 40 921 normal-weight, overweight or obese children and adolescents living in Central Europe.
Int J Obes (Lond). 2015; 39(1): 45-51 (IF=5.337)
Martin L, Oepen J, Reinehr T, Wabitsch M, Claussnitzer G, Waldeck E, Ingrisch S, Stachow R, Oelert M, Wiegand S, Holl R
326. PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity.
J Allergy Clin Immunol. 2015; 135(6): 1578-88.e5 (IF=12.485)
Mathieu AL, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD, Butte MJ, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zabot MT, Balme B, Viel S, Bienvenu J, Cochat P, van der Burg M, Caux C, Kemp EH, Rouvet I, Malcus C, Méritet JF, Lim A, Crow YJ, Fabien N, Ménétrier-Caux C, De Villartay JP, Walzer T, Belot A
327. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency.
J Allergy Clin Immunol. 2015; 135(4): 988-997.e6 (IF=12.485)
Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, Recher M, Gruhn B, Holbro A, Heijnen I, Meyer D, Grigoleit G, Einsele H, Baumann U, Witte T, Sykora KW, Goldacker S, Regairaz L, Aksoylar S, Ardeniz Ö, Zecca M, Zdziarski P, Meyts I, Matthes-Martin S, Imai K, Kamae C, Fielding A, Seneviratne S, Mahlaoui N, Slatter MA, Güngör T, Arkwright PD, van Montfrans J, Sullivan KE, Grimbacher B, Cant A, Peter HH, Finke J, Gaspar HB, Warnatz K, Rizzi M, Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the European Society for Immunodeficiency
328. Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation.
J Cancer Res Clin Oncol. 2015; 141(6): 1089-94 (IF=3.141)
Weiss M, Steinbach D, Zintl F, Beck J, Gruhn B
329. Head Injury in Children: Has a Change in Circumstances Caused an Increase in Treatment Numbers?
J Child Neurol. 2015; 30(9): 1153-8 (IF=1.434)
Pal'a A, Kapapa M, Posovszky C, Röderer G, König R, Woischneck D, Wirtz CR, Kapapa T
330. Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin.
J Clin Endocrinol Metab. 2015; 100(10): E1299-307 (IF=5.531)
Nidhina Haridas PA, Soronen J, Sädevirta S, Mysore R, Quagliarini F, Pasternack A, Metso J, Perttilä J, Leivonen M, Smas CM, Fischer-Posovszky P, Wabitsch M, Ehnholm C, Ritvos O, Jauhainen M, Olkonen VM, Yki-Järvinen H
331. A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma.
J Clin Endocrinol Metab. 2015; 100(10): 3603-6 (IF=5.531)
Patni N, Alves C, von Schnurbein J, Wabitsch M, Tannin G, Rakheja D, Garg A
332. Severe Early-Onset Obesity Due to Bioinactive Leptin Caused by a p.N103K Mutation in the Leptin Gene.
J Clin Endocrinol Metab. 2015; 100(9): 3227-30 (IF=5.531)
Wabitsch M, Funcke JB, von Schnurbein J, Denzer F, Lahr G, Mazen I, El-Gammal M, Denzer C, Moss A, Debatin KM, Gierschik P, Mistry V, Keogh JM, Farooqi IS, Moepps B, Fischer-Posovszky P

333. [Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency.](#)
J Clin Invest. 2015; 125(11): 4135-48 (IF=12.575)
 Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, Ujhazi B, Chen K, Lee YN, Tirosh I, Dobbs K, Al-Herz W, Cowan MJ, Puck J, Bleesing JJ, Grimley MS, Malech H, De Ravin SS, Gennery AR, Abraham RS, Joshi AY, Boyce TG, Butte MJ, Nadeau KC, Balboni I, Sullivan KE, Akhter J, Adeli M, El-Feky RA, El-Ghoneimy DH, Dbaiho G, Wakim R, Azzari C, Palma P, Cancrini C, Capuder K, Condino-Neto A, Costa-Carvalho BT, Oliveira JB, Roifman C, Buchbinder D, Kumanovics A, Franco JL, Niehues T, [Schuetz C](#), Kuijpers T, Yee C, Chou J, Masaad MJ, Geha R, Uzel G, Gelman R, Holland SM, Recher M, Utz PJ, Browne SK, Notarangelo LD
334. [Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial.](#)
J Clin Oncol. 2015; 33(11): 1275-84 (IF=20.982)
 Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, [Schulz A](#), Lang P, Müller I, Albert MH, Willasch AM, Klingebiel TE, Peters C
335. [Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors-The ALL-SCT-BFM-2003 Trial.](#)
J Clin Oncol. 2015; 33(11): 1265-74 (IF=20.982)
 Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, [Schulz A](#), Woessmann W, Poetschger U, Zimmermann M, Klingebiel T
336. [Kindlin-3-mediated integrin adhesion is dispensable for quiescent but essential for activated hematopoietic stem cells.](#)
J Exp Med. 2015; 212(9): 1415-32 (IF=11.24)
 Ruppert R, Moser M, Sperandio M, Rognoni E, Orban M, Liu WH, [Schulz AS](#), Oostendorp RA, Massberg S, Fässler R
337. [CD4+ T cell-derived IL-21 and deprivation of CD40 signaling favor the in vivo development of granzyme B-expressing regulatory B cells in HIV patients.](#)
J Immunol. 2015; 194(8): 3768-77 (IF=4.985)
 Kaltenmeier C, Gawanbacht A, Beyer T, Lindner S, Trzaska T, van der Merwe JA, Härter G, Grüner B, [Fabricius D](#), Lotfi R, Schwarz K, [Schütz C](#), [Hönig M](#), [Schulz A](#), Kern P, Bommer M, Schrezenmeier H, Kirchhoff F, Jahrsdörfer B
338. [Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in burkina faso.](#)
J Infect Dis. 2015; 211(5): 689-97 (IF=6.344)
 Coulibaly B, Pritsch M, Bountogo M, Meissner PE, Nebié E, Klose C, Kieser M, Berens-Riha N, Wieser A, Sirima SB, Breitschütz J, Schirmer RH, Sié A, Mockenhaupt FP, Drakeley C, Bousema T, Müller O
339. [Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.](#)
J Neurooncol. 2015; 122(1): 21-33 (IF=2.754)
 Karpel-Massler G, Kast RE, [Westhoff M](#), Dwucet A, Welscher N, [Nonnenmacher L](#), Hlavac M, Siegelin MD, Wirtz CR, [Debatin K](#), Halatsch M
340. [Lutein Leads to a Decrease of Factor D Secretion by Cultured Mature Human Adipocytes.](#)
J Ophthalmol. 2015; 2015: 430741 (IF=1.463)
 Tian Y, Kijlstra A, Renes J, [Wabitsch M](#), Webers CA, Berendschot TT
341. [Glucocorticoids attenuate acute graft-versus-host disease by suppressing the cytotoxic capacity of CD8\(+\) T cells.](#)
J Pathol. 2015; 235(4): 646-55 (IF=7.381)
 Theiss-Suennemann J, Jörß K, [Messmann JJ](#), Reichardt SD, Montes-Cobos E, Lühder F, Tuckermann JP, AWOlf H, Dressel R, Gröne HJ, [Strauß G](#), Reichardt HM
342. [Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States.](#)
J Pediatr. 2015; 167(3): 627-32.e1-4 (IF=3.89)
 DuBose SN, Hermann JM, Tamborlane WV, Beck RW, Dost A, DiMeglio LA, Schwab KO, Holl RW, Hofer SE, Maahs DM, [Type 1 Diabetes Exchange Clinic Network and Diabetes Prospective Follow-up Registry](#)
343. [Comorbidity of type 1 diabetes and juvenile idiopathic arthritis.](#)
J Pediatr. 2015; 166(4): 930-5.e1-3 (IF=3.89)
 Hermann G, Thon A, Mönkemöller K, Lilienthal E, Klinkert C, Holder M, Hörtenhuber T, Vogel-Gerlicher P, Haberland H, Schebek M, Holl RW, [Diabetes Patienten Verlaufsdokumentation-initiative](#), Federal Ministry of Education and Research Competence Network Diabetes Mellitus
344. [Unmistakable Morphology? Infantile Malignant Osteopetrosis Resembling Juvenile Myelomonocytic Leukemia in Infants.](#)
J Pediatr. 2015; 167(2): 486-8 (IF=3.89)
 Strauss A, [Furlan J](#), [Steinmann S](#), Buchholz B, Kremens B, Rossig C, Corbacioglu S, Rajagopal R, [Lahr G](#), Yoshimi A, Strahm B, Niemeyer CM, [Schulz A](#)
345. [Effects of Automated Adjustment of the Inspired Oxygen on Fluctuations of Arterial and Regional Cerebral Tissue Oxygenation in Preterm Infants with Frequent Desaturations.](#)
J Pediatr. 2015; 166(2): 240-244.e1 (IF=3.89)
[Waitz M](#), [Schmid MB](#), [Fuchs H](#), [Mendler MR](#), Dreyhaupt J, [Hummeler HD](#)

346. [Automated versus Manual Oxygen Control with Different Saturation Targets and Modes of Respiratory Support in Preterm Infants.](#)
J Pediatr. 2015; 167(3): 545-50.e1-2 (IF=3.89)
van Kaam AH, Hummler HD, Wilinska M, Swietlinski J, Lal MK, te Pas AB, Lista G, Gupta S, Fajardo CA, Onland W, Waitz M, Warakomska M, Cavigioli F, Bancalari E, Claure N, Bachman TE
347. [Bosentan-induced Reduction in Cyclosporine-A Levels: A Rare Interaction in an Infant With Osteopetrosis and Severe Pulmonary Hypertension.](#)
J Pediatr Hematol Oncol. 2015; 37(7): 573-4 (IF=1.146)
Masarwa R, Shamriz O, Zilkha A, Braun J, Kleid DM, Weintraub M, Schulz A, Stepensky P
348. [Comprehensive molecular characterization of human adipocytes reveals a transient brown phenotype.](#)
J Transl Med. 2015; 13: 135 (IF=3.694)
Guenoun A, Kazantzis M, Thomas R, Wabitsch M, Tews D, Seetharama Sastry K, Abdelkarim M, Zilberfarb V, Strosberg AD, Chouchane L
349. [Consensus of German transplant centers on hematopoietic stem cell transplantation in Fanconi anemia.](#)
Klin Padiatr. 2015; 227(3): 157-65 (IF=0.98)
Chao MM, Ebell W, Bader P, Beier R, Burkhardt B, Feuchtinger T, Handgretinger R, Hanenberg H, Koehl U, Kratz C, Kremens B, Lang P, Meisel R, Mueller I, Roessig C, Sauer M, Schlegel PG, Schulz A, Strahm B, Thol F, Sykora KW
350. [The Cause of Acute Respiratory Failure Predicts the Outcome of Noninvasive Ventilation in Immunocompromised Children.](#)
Klin Padiatr. 2015; 227(6-07): 322-328 (IF=0.98)
Fuchs H, Schoss J, Mendler MR, Lindner W, Hopfner R, Schulz A, Hoening M, Steinbach D, Debatin KM, Hummler HD, Schmid M
351. [Permissive hypercapnia in extremely low birthweight infants \(PHELBI\): a randomised controlled multicentre trial.](#)
Lancet Respir Med. 2015; 3(7): 534-43 (IF=15.328)
Thome UH, Genzel-Boroviczeny O, Bohnhorst B, Schmid M, Fuchs H, Rohde O, Avenarius S, Topf HG, Zimmermann A, Faas D, Timme K, Kleinlein B, Buxmann H, Schenk W, Segerer H, Teig N, Gebauer C, Hentschel R, Heckmann M, Schlösser R, Peters J, Rossi R, Rascher W, Böttger R, Seidenberg J, Hansen G, Zernickel M, Alzen G, Dreyhaupt J, Muche R, Hummler HD, PHELBI Study Group
352. [Inaktives Leptin und extremes Übergewicht: Einer seltenen Erkrankung auf der Spur](#)
MDK Forum. 2015; 2015(3): 30-31
Wabitsch M
353. [Safety of insecticide-treated mosquito nets for infants and their mothers: randomized controlled community trial in Burkina Faso.](#)
Malar J. 2015; 14(1): 527 (IF=3.079)
Lu G, Traoré C, Meissner P, Kouyaté B, Kynast-Wolf G, Beiersmann C, Coulibaly B, Becher H, Müller O
354. [Fructose Alters Intermediary Metabolism of Glucose in Human Adipocytes and Diverts Glucose to Serine Oxidation in the One-Carbon Cycle Energy Producing Pathway.](#)
Metabolites. 2015; 5(2): 364-85
Varma V, Boros LG, Nolen GT, Chang CW, Wabitsch M, Beger RD, Kaput J
355. [Metabolic fate of fructose in human adipocytes: a targeted \(13\)C tracer fate association study.](#)
Metabolomics. 2015; 11(3): 529-544 (IF=3.661)
Varma V, Boros LG, Nolen GT, Chang CW, Wabitsch M, Beger RD, Kaput J
356. [The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.](#)
Mol Cancer Ther. 2015; 14(4): 889-98 (IF=5.579)
Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Di Rorà AG, Martinelli G, Meyer LH, Debatin KM, Orecchioni S, Bertolini F, Pelicci PG
357. [Angiotensin II directly impairs adipogenic differentiation of human preadipose cells.](#)
Mol Cell Biochem. 2015; 408(1-2): 115-22 (IF=2.613)
Palominos MM, Dünner NH, Wabitsch M, Rojas CV
358. [Inhibition of adipogenic differentiation of human SGBS preadipocytes by androgen-regulated microRNA miR-375.](#)
Mol Cell Endocrinol. 2015; 414: 177-85 (IF=3.859)
Kraus M, Greither T, Wenzel C, Bräuer-Hartmann D, Wabitsch M, Behre HM
359. [Gene expression levels of Casein kinase 1 \(CK1\) isoforms are correlated to adiponectin levels in adipose tissue of morbid obese patients and site-specific phosphorylation mediated by CK1 influences multimerization of adiponectin.](#)
Mol Cell Endocrinol. 2015; 406: 87-101 (IF=3.859)
Xu P, Fischer-Posovszky P, Bischof J, Radermacher P, Wabitsch M, Henne-Bruns D, Wolf AM, Hillenbrand A, Knippschild U
360. [Taking the next step forward - Diagnosing inherited infantile cholestatic disorders with next generation sequencing.](#)
Mol Cell Probes. 2015; 29(5): 291-8 (IF=1.565)
Herbst SM, Schirmer S, Posovszky C, Jochum F, Rödl T, Schroeder JA, Barth TF, Hehr U, Melter M, Vermehren J
361. [Surveillance after oncological Diseases in Childhood- and Adolescence](#)
Monatsschr Kinderheilkd. 2015; 163(2): 108-109 (IF=0.341)
Debatin KM
362. [Endocrinological Follow-up after oncological Diseases in Childhood- and Adolescence](#)
Monatsschr Kinderheilkd. 2015; 163(2): 110-111 (IF=0.341)
Denzer C, Wabitsch M
363. [Disorders in pubertal development and fertility. Late effects of antineoplastic therapy in childhood and adolescence](#)
Monatsschr Kinderheilkd. 2015; 163(2): 126-134 (IF=0.341)
Denzer C, Hauffa BP, Rohrer T, Bramswig HJ, Dorr HG

364. Neonatal health. Major global health topic for the future
Monatsschr Kinderheilkd. 2015; 163(11): 1117-1124 (IF=0.341)
Meissner PE, Klinkott R, Xylander SV, Kruger C
365. Global situation of child health. Current situation and view into the future
Monatsschr Kinderheilkd. 2015; 163(11): 1110-1116 (IF=0.341)
Weber MW, Schultz A, Meissner P, Carai S, Kruger C
366. Biologically inactive leptin and early-onset extreme obesity [author reply to comments].
N Engl J Med. 2015; 372(13): 1266-7 (IF=59.558)
Fischer-Posovszky P, Funcke JB, Wabitsch M
367. Biologically inactive leptin and early-onset extreme obesity.
N Engl J Med. 2015; 372(1): 48-54 (IF=59.558)
Wabitsch M, Funcke JB, Lennerz B, Kuhnle-Krahl U, Lahr G, Debatin KM, Vatter P, Gierschik P, Moepf B, Fischer-Posovszky P
368. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.
Nat Genet. 2015; 47(7): 717-26 (IF=31.616)
Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Luner G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lambie S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G
369. Reliability of pulse oximetry during cardiopulmonary resuscitation in a piglet model of neonatal cardiac arrest.
Neonatology. 2015; 107(2): 113-9 (IF=2.754)
Hassan MA, Mendler M, Maurer M, Waitz M, Huang L, Hummler HD
370. Effects of Synchronization during Noninvasive Intermittent Mandatory Ventilation in Preterm Infants with Respiratory Distress Syndrome Immediately after Extubation.
Neonatology. 2015; 108(2): 108-14 (IF=2.754)
Huang L, Mendler MR, Waitz M, Schmid M, Hassan MA, Hummler HD
371. Risk Indicators for Air Leaks in Preterm Infants Exposed to Restrictive Use of Endotracheal Intubation.
Neonatology. 2015; 108(1): 1-7 (IF=2.754)
Hummler HD, Parys E, Mayer B, Essers J, Fuchs H, Schmid M
372. Different Techniques of Respiratory Support Do Not Significantly Affect Gas Exchange during Cardiopulmonary Resuscitation in a Newborn Piglet Model.
Neonatology. 2015; 108(1): 73-80 (IF=2.754)
Mendler MR, Maurer M, Hassan MA, Huang L, Waitz M, Mayer B, Hummler HD
373. Cerebral Oxygenation during Intermittent Hypoxemia and Bradycardia in Preterm Infants.
Neonatology. 2015; 107(2): 137-146 (IF=2.754)
Schmid MB, Hopfner RJ, Lenhof S, Hummler HD, Fuchs H
374. The functional anatomy of motor imagery after sub-acute stroke.
NeuroRehabilitation. 2015; 36(3): 329-37 (IF=1.453)
Kraft E, Schaal MC, Lule D, König E, Scheidtman K
375. Toll-like receptor 5 in obesity: The role of gut microbiota and adipose tissue inflammation.
Obesity (Silver Spring). 2015; 23(3): 581-90 (IF=3.614)
Pekkala S, Munukka E, Kong L, Pöllänen E, Autio R, Roos C, Wiklund P, Fischer-Posovszky P, Wabitsch M, Alen M, Huovinen P, Cheng S
376. MFAP5 is related to obesity-associated adipose tissue and extracellular matrix remodeling and inflammation.
Obesity (Silver Spring). 2015; 23(7): 1371-8 (IF=3.614)
Vaithinen M, Kolehmainen M, Rydén M, Eskelinen M, Wabitsch M, Pihlajamäki J, Uusitupa M, Pulkkinen L
377. Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model.
Oncotarget. 2015; 6(3): 1382-95 (IF=5.008)
Hasan MN, Queudeville M, Trentin L, Eckhoff SM, Bronzini I, Palmi C, Barth T, Cazzaniga G, te Kronnie G, Debatin KM, Meyer LH
378. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.
Oncotarget. 2015; 6(16): 14507-21 (IF=5.008)
Karpel-Massler G, Shu C, Chau L, Banu M, Halatsch ME, Westhoff MA, Ramirez Y, Ross AH, Bruce JN, Canoll P, Siegelin MD
379. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Oncotarget. 2015; 6(34): 36456-71 (IF=5.008)
Karpel-Massler G, Bâ M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD
380. Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic Acid and hydroxytyrosol in human adipocytes.
PLoS ONE. 2015; 10(6): e0128218 (IF=3.057)
Scoditti E, Massaro M, Carluccio MA, Pellegrino M, Wabitsch M, Calabriso N, Storelli C, De Caterina R

381. [A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.](#)
PLoS ONE. 2015; 10(6): e0131670 (IF=3.057)
Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Karpel-Massle G, Westhoff MA, Halatsch ME, Debatin KM
382. [A new mutation in the KINDLIN-3 gene ablates integrin-dependent leukocyte, platelet, and osteoclast function in a patient with leukocyte adhesion deficiency-III.](#)
Pediatr Blood Cancer. 2015; 62(9): 1677-9 (IF=2.634)
Crazzolaro R, Maurer K, Schulze H, Zieger B, Zustin J, Schulz AS
383. [Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.](#)
Pediatr Diabetes. 2015; 16(7): 529-37 (IF=3.488)
Konrad K, Datz N, Engelsberger I, Grulich-Henn J, Hoertenhuber T, Knauth B, Meissner T, Wiegand S, Woelfle J, Holl RW, German/Austrian DPV Initiative
384. [Depression, metabolic control, and antidepressant medication in young patients with type 1 diabetes.](#)
Pediatr Diabetes. 2015; 16(1): 58-66 (IF=3.488)
Plener PL, Molz E, Berger G, Schober E, Mönkemöller K, Denzer C, Goldbeck L, Holl RW
385. [Sonographically measured suprailiac adipose tissue is a useful predictor of non-alcoholic fatty liver disease in obese children and adolescents.](#)
Pediatr Obes. 2015; 10(4): 260-6 (IF=3.488)
Schlieske C, Denzer C, Wabitsch M, Oetzuerk S, Mason RA, Thiere D, Kratzer W
386. [Schwindel in der Pädiatrie](#)
Päd Praktische Pädiatrie. 2015; 21: 193-196
Bode H
387. [Uniparental Disomy in Somatic Mosaicism 45,X/46,XY/46,XX Associated with Ambiguous Genitalia.](#)
Sex Dev. 2015; 9(3): 136-43 (IF=2.164)
Serra A, Denzer F, Hiort O, Barth TF, Henne-Bruns D, Barbi G, Rettenberger G, Wabitsch M, Just W, Lerliche C
388. [Sustained Aeration of Infant Lungs \(SAIL\) trial: study protocol for a randomized controlled trial.](#)
Trials. 2015; 16: 95 (IF=1.859)
Foglia EE, Owen LS, Thio M, Ratcliffe SJ, Lista G, Te Pas A, Hummeler H, Nadkarni V, Ades A, Posenche M, Keszler M, Davis P, Kirpalani H
389. [Endocrine and Metabolic Effects of Adipose Tissue in Children and Adolescents](#)
Zdr Varst. 2015; 54(2): 131-138 (IF=0.203)
Kotnik P, Fischer-Posovszky P, Wabitsch M



Sources of Funding

Without financial support from external sources, our research would not be possible.

We cordially thank all organizations and individuals supporting us, in particular:

- German Research Foundation (DFG), including the Excellence Initiative of the German Federal and State Governments
- German Federal Ministry for Education and Research (BMBF)
- Ministry of Science, Research and the Arts Baden-Württemberg
- European Union
- Helmholtz Association
- Arbeitsgemeinschaft industrieller Forschungsvereinigungen „Otto von Guericke“ (AiF)
- Local charities, among others *Förderkreis für tumor- und leukämiekrankte Kinder Ulm e.V.*
- Medical Faculty of Ulm University (intramural programs)
- Boehringer Ingelheim Ulm University BioCenter (BIU)
- Innovationsfonds des gemeinsamen Bundesausschusses (G/BA)
- Deutsche Krebshilfe (German Cancer Aid)
- Else Kröner-Fresenius Stiftung
- German José Carreras Leukaemia Foundation
- Baden-Württemberg Stiftung
- Dr.-Herbert-Schiffers-Stiftung
- Deutsche Kinderkrebsstiftung e.V.
- Brunhilde von Hornstein Stiftung
- Stiftung Valentina
- Stiftung Kinderherz
- W.R. Pitzer Stiftung
- Projektfonds: Das zuckerkrankte Kind (Deutsche Diabetes Stiftung)
- Fördergemeinschaft Deutsche Kinderherzzentren e.V.
- COST Association
- German Adiposity Society
- German Paediatric Diabetes Association (AGPD)
- German Association of Pediatric Cardiology (DGPK)
- Individual Donors
- Industry

